<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.8.25">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Tilabo Williamson, Caitlin Buenk &amp; Jürgen Becker (Project Lead) - AX Consult Group">
<meta name="dcterms.date" content="2026-02-17">

<title>Bone Health - Treatment Outcomes - Phase 2</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
/* CSS for syntax highlighting */
html { -webkit-text-size-adjust: 100%; }
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
  }
pre.numberSource { margin-left: 3em;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<script src="site_libs/quarto-html/quarto.js" type="module"></script>
<script src="site_libs/quarto-html/tabsets/tabsets.js" type="module"></script>
<script src="site_libs/quarto-html/axe/axe-check.js" type="module"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting-7b89279ff1a6dce999919e0e67d4d9ec.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap-e31584831b205ffbb2d98406f31c2a5b.min.css" rel="stylesheet" append-hash="true" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "sidebar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "start",
  "type": "textbox",
  "limit": 50,
  "keyboard-shortcut": [
    "f",
    "/",
    "s"
  ],
  "show-item-context": false,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-text-placeholder": "",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit",
    "search-label": "Search"
  }
}</script>
<script src="site_libs/kePrint-0.0.1/kePrint.js"></script>

<link href="site_libs/lightable-0.0.1/lightable.css" rel="stylesheet">



</head>

<body class="quarto-light">

<div id="quarto-search-results"></div>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">On this page</h2>
   
  <ul>
  <li><a href="#background" id="toc-background" class="nav-link active" data-scroll-target="#background">Background</a></li>
  <li><a href="#osteoguard-efficacy" id="toc-osteoguard-efficacy" class="nav-link" data-scroll-target="#osteoguard-efficacy">OsteoGuard Efficacy</a></li>
  <li><a href="#commercial-analytics" id="toc-commercial-analytics" class="nav-link" data-scroll-target="#commercial-analytics">Commercial Analytics</a></li>
  <li><a href="#conclusion" id="toc-conclusion" class="nav-link" data-scroll-target="#conclusion">Conclusion</a></li>
  <li><a href="#references" id="toc-references" class="nav-link" data-scroll-target="#references">References</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<div class="quarto-title-block"><div><h1 class="title">Bone Health - Treatment Outcomes - Phase 2</h1><button type="button" class="btn code-tools-button dropdown-toggle" id="quarto-code-tools-menu" data-bs-toggle="dropdown" aria-expanded="false"><i class="bi"></i> Code</button><ul class="dropdown-menu dropdown-menu-end" aria-labelelledby="quarto-code-tools-menu"><li><a id="quarto-show-all-code" class="dropdown-item" href="javascript:void(0)" role="button">Show All Code</a></li><li><a id="quarto-hide-all-code" class="dropdown-item" href="javascript:void(0)" role="button">Hide All Code</a></li><li><hr class="dropdown-divider"></li><li><a id="quarto-view-source" class="dropdown-item" href="javascript:void(0)" role="button">View Source</a></li></ul></div></div>
</div>



<div class="quarto-title-meta">

    <div>
    <div class="quarto-title-meta-heading">Author</div>
    <div class="quarto-title-meta-contents">
             <p>Tilabo Williamson, Caitlin Buenk &amp; Jürgen Becker (Project Lead) - AX Consult Group </p>
          </div>
  </div>
    
    <div>
    <div class="quarto-title-meta-heading">Published</div>
    <div class="quarto-title-meta-contents">
      <p class="date">2026-02-17</p>
    </div>
  </div>
  
    
  </div>
  


</header>


<div class="text-center">
<p><img src="image/company_logo.png" class="img-fluid" width="180"></p>
</div>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb1"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(pacman)</span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a><span class="fu">p_load</span>(magrittr, tidyverse, psych, dplyr, ggplot2, haven, janitor, readxl, writexl, knitr, kableExtra, scales, tibble, tidyr, patchwork, ggrepel)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
<section id="background" class="level3">
<h3 class="anchored" data-anchor-id="background">Background</h3>
<p>Osteoporosis is a progressive condition characterised by reduced bone mineral density (BMD) and deterioration of bone structure, leading to increased fracture risk. Many individuals at high risk of fracture remain unidentified under current age-based screening guidelines, particularly those who present with clinical or lifestyle risk factors but do not meet standard screening age thresholds.</p>
<p>Phase 1 of this project used secondary population data (smoking, physical activity, body measurements, prior fracture history) to identify individuals at elevated bone-health risk and to quantify the proportion of high-risk individuals who are not captured by current screening criteria. This revealed a substantial “missed high-risk” population who may benefit from earlier identification and intervention.</p>
<p>Phase 2 builds on these findings by simulating the clinical and commercial impact of a hypothetical osteoporosis treatment if this missed high-risk population were successfully identified and treated. The purpose of this phase is to demonstrate how screening improvements could translate into improved clinical outcomes and potential commercial value in a realistic biopharmaceutical analytics context.</p>
<section id="phase-1-summary" class="level4">
<h4 class="anchored" data-anchor-id="phase-1-summary">Phase 1 summary</h4>
<p>Individuals were classified as high bone risk in Phase 1 using a lumbar spine T-score–led definition. Participants with a lumbar spine T-score in the osteoporosis range (≤ −2.5) were classified as high risk regardless of other factors. Participants with a lumbar spine T-score in the osteopenia range (between −1.0 and −2.5) were classified as high risk only if at least one additional risk indicator was present. Risk indicators included low body mass index, current or former smoking, a history of fracture at the hip, wrist, or spine, or low levels of physical activity. This approach recognizes that moderately reduced bone density becomes more important when combined with other risk factors.</p>
<p>The Phase 1 analysis was conducted using data from <strong>3,107 individuals</strong> in the NHANES 2005–2006 cohort, all aged 20 years or older. Among this study population, <strong>540 individuals were classified as high-risk</strong> for osteoporosis based on bone mineral density (BMD) and additional clinical or lifestyle risk factors. Importantly, <strong>508 of these high-risk individuals were not identified</strong> under current age- and guideline-based screening criteria. This represents approximately <strong>16.35% of the total study population</strong>, highlighting a substantial “missed high-risk” group.</p>
<p>NHANES employs a complex, multistage probability sampling design, meaning raw sample proportions cannot be interpreted as nationally representative without adjustment. Therefore, survey weights (WTMEC2YR), strata (SDMVSTRA), and primary sampling units (SDMVPSU) were applied to account for oversampling and clustering within the National Health and Nutrition Examination Survey framework. After incorporating these design elements, the weighted prevalence of missed high-risk adults was 15.22%. This survey-adjusted estimate provides a nationally representative prevalence that can be used to project the number of U.S. adults aged ≥20 who may fall into this under-identified high-risk category today.</p>
<p>Applying the weighted prevalence estimate of 15.22% to the current U.S. adult population aged ≥20 (approximately 250 million individuals based on recent Census age distributions) suggests that roughly:</p>
<p>250,000,000 × 0.1522 = 38,050,000</p>
<p>≈ 38 million U.S. adults may fall into this expanded high-risk category yet remain unidentified under current age-based screening criteria.</p>
<p>From a public health and commercial perspective, these individuals represent a potentially addressable market for osteoporosis screening and treatment interventions. By targeting this missed population, there is an opportunity to improve early detection, initiate timely therapy, and potentially reduce fracture risk, while also quantifying the market potential for a treatment like OsteoGuard.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb2"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Reading in data from phase 1</span></span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>phase_1 <span class="ot">&lt;-</span> <span class="fu">read_xpt</span>(<span class="st">"data/poe_bone_health_phase1 - 2026.02.12.xpt"</span>)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb3"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Pie chart</span></span>
<span id="cb3-2"><a href="#cb3-2" aria-hidden="true" tabindex="-1"></a><span class="co"># Counts</span></span>
<span id="cb3-3"><a href="#cb3-3" aria-hidden="true" tabindex="-1"></a>total_count <span class="ot">&lt;-</span> <span class="fu">nrow</span>(phase_1) </span>
<span id="cb3-4"><a href="#cb3-4" aria-hidden="true" tabindex="-1"></a>high_risk_count <span class="ot">&lt;-</span> <span class="fu">sum</span>(phase_1<span class="sc">$</span>high_bone_risk <span class="sc">==</span> <span class="dv">1</span>)</span>
<span id="cb3-5"><a href="#cb3-5" aria-hidden="true" tabindex="-1"></a>missed_high_risk_count <span class="ot">&lt;-</span> <span class="fu">sum</span>(phase_1<span class="sc">$</span>missed_high_risk <span class="sc">==</span> <span class="dv">1</span>)</span>
<span id="cb3-6"><a href="#cb3-6" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb3-7"><a href="#cb3-7" aria-hidden="true" tabindex="-1"></a><span class="co"># Preparing df</span></span>
<span id="cb3-8"><a href="#cb3-8" aria-hidden="true" tabindex="-1"></a>pie_data <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(</span>
<span id="cb3-9"><a href="#cb3-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">group =</span> <span class="fu">c</span>( <span class="st">"High Risk and Screened"</span>, <span class="st">"Missed High Risk"</span>, <span class="st">"Not at Risk"</span>),</span>
<span id="cb3-10"><a href="#cb3-10" aria-hidden="true" tabindex="-1"></a>  <span class="at">count =</span> <span class="fu">c</span>(high_risk_count <span class="sc">-</span> missed_high_risk_count,</span>
<span id="cb3-11"><a href="#cb3-11" aria-hidden="true" tabindex="-1"></a>            missed_high_risk_count,</span>
<span id="cb3-12"><a href="#cb3-12" aria-hidden="true" tabindex="-1"></a>            total_count <span class="sc">-</span> high_risk_count)</span>
<span id="cb3-13"><a href="#cb3-13" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb3-14"><a href="#cb3-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb3-15"><a href="#cb3-15" aria-hidden="true" tabindex="-1"></a>    <span class="at">percent =</span> <span class="fu">round</span>(count <span class="sc">/</span> <span class="fu">sum</span>(count) <span class="sc">*</span> <span class="dv">100</span>, <span class="dv">1</span>),</span>
<span id="cb3-16"><a href="#cb3-16" aria-hidden="true" tabindex="-1"></a>    <span class="at">label =</span> <span class="fu">paste0</span>(group, <span class="st">": "</span>, count, <span class="st">" ("</span>, percent, <span class="st">"%)"</span>),</span>
<span id="cb3-17"><a href="#cb3-17" aria-hidden="true" tabindex="-1"></a>    <span class="at">ymax =</span> <span class="fu">cumsum</span>(count),</span>
<span id="cb3-18"><a href="#cb3-18" aria-hidden="true" tabindex="-1"></a>    <span class="at">ymin =</span> <span class="fu">c</span>(<span class="dv">0</span>, <span class="fu">head</span>(ymax, <span class="at">n =</span> <span class="sc">-</span><span class="dv">1</span>)),</span>
<span id="cb3-19"><a href="#cb3-19" aria-hidden="true" tabindex="-1"></a>    <span class="at">mid =</span> (ymax <span class="sc">+</span> ymin) <span class="sc">/</span> <span class="dv">2</span></span>
<span id="cb3-20"><a href="#cb3-20" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb3-21"><a href="#cb3-21" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb3-22"><a href="#cb3-22" aria-hidden="true" tabindex="-1"></a><span class="co"># Rendering plot</span></span>
<span id="cb3-23"><a href="#cb3-23" aria-hidden="true" tabindex="-1"></a>pie_data  <span class="sc">%&lt;&gt;%</span></span>
<span id="cb3-24"><a href="#cb3-24" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb3-25"><a href="#cb3-25" aria-hidden="true" tabindex="-1"></a>    <span class="at">label_y =</span> <span class="fu">case_when</span>(</span>
<span id="cb3-26"><a href="#cb3-26" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"High Risk and Screened"</span>        <span class="sc">~</span> mid,   <span class="co"># middle of wedge</span></span>
<span id="cb3-27"><a href="#cb3-27" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Missed High Risk"</span> <span class="sc">~</span> ymax,  <span class="co"># top of wedge</span></span>
<span id="cb3-28"><a href="#cb3-28" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Not at Risk"</span>      <span class="sc">~</span> mid    <span class="co"># middle of wedge</span></span>
<span id="cb3-29"><a href="#cb3-29" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb3-30"><a href="#cb3-30" aria-hidden="true" tabindex="-1"></a>    <span class="at">label_x =</span> <span class="fu">case_when</span>(</span>
<span id="cb3-31"><a href="#cb3-31" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Missed High Risk"</span> <span class="sc">~</span> <span class="fl">5.4</span>,   <span class="co"># push to the right</span></span>
<span id="cb3-32"><a href="#cb3-32" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span>                        <span class="sc">~</span> <span class="fl">4.5</span>    <span class="co"># default for others</span></span>
<span id="cb3-33"><a href="#cb3-33" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb3-34"><a href="#cb3-34" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb3-35"><a href="#cb3-35" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb3-36"><a href="#cb3-36" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb3-37"><a href="#cb3-37" aria-hidden="true" tabindex="-1"></a><span class="fu">ggplot</span>(pie_data, <span class="fu">aes</span>(<span class="at">ymax =</span> ymax, <span class="at">ymin =</span> ymin, <span class="at">xmax =</span> <span class="dv">4</span>, <span class="at">xmin =</span> <span class="dv">3</span>, <span class="at">fill =</span> group)) <span class="sc">+</span></span>
<span id="cb3-38"><a href="#cb3-38" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_rect</span>(<span class="at">color =</span> <span class="st">"white"</span>) <span class="sc">+</span></span>
<span id="cb3-39"><a href="#cb3-39" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_label</span>(</span>
<span id="cb3-40"><a href="#cb3-40" aria-hidden="true" tabindex="-1"></a>    <span class="fu">aes</span>(<span class="at">x =</span> label_x, <span class="at">y =</span> label_y, <span class="at">label =</span> label, <span class="at">fill =</span> group),</span>
<span id="cb3-41"><a href="#cb3-41" aria-hidden="true" tabindex="-1"></a>    <span class="at">color =</span> <span class="st">"white"</span>,</span>
<span id="cb3-42"><a href="#cb3-42" aria-hidden="true" tabindex="-1"></a>    <span class="at">show.legend =</span> <span class="cn">FALSE</span>,</span>
<span id="cb3-43"><a href="#cb3-43" aria-hidden="true" tabindex="-1"></a>    <span class="at">label.size =</span> <span class="fl">0.2</span></span>
<span id="cb3-44"><a href="#cb3-44" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">+</span></span>
<span id="cb3-45"><a href="#cb3-45" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_fill_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"#E0B6E4"</span>, <span class="st">"#9A4EAE"</span>, <span class="st">"#7E3285"</span>)) <span class="sc">+</span></span>
<span id="cb3-46"><a href="#cb3-46" aria-hidden="true" tabindex="-1"></a>  <span class="fu">coord_polar</span>(<span class="at">theta =</span> <span class="st">"y"</span>, <span class="at">clip =</span> <span class="st">"off"</span>)<span class="sc">+</span></span>
<span id="cb3-47"><a href="#cb3-47" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_void</span>() <span class="sc">+</span></span>
<span id="cb3-48"><a href="#cb3-48" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(</span>
<span id="cb3-49"><a href="#cb3-49" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Phase 1 Study Population Breakdown: Osteoporosis Risk (N = 3107)"</span>,</span>
<span id="cb3-50"><a href="#cb3-50" aria-hidden="true" tabindex="-1"></a>    <span class="at">fill =</span> <span class="st">"Group"</span></span>
<span id="cb3-51"><a href="#cb3-51" aria-hidden="true" tabindex="-1"></a>  )<span class="sc">+</span> </span>
<span id="cb3-52"><a href="#cb3-52" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme</span>(</span>
<span id="cb3-53"><a href="#cb3-53" aria-hidden="true" tabindex="-1"></a>    <span class="at">legend.position =</span> <span class="st">"bottom"</span>,</span>
<span id="cb3-54"><a href="#cb3-54" aria-hidden="true" tabindex="-1"></a>    <span class="at">plot.margin =</span> <span class="fu">margin</span>(<span class="at">t =</span> <span class="dv">10</span>, <span class="at">r =</span> <span class="dv">80</span>, <span class="at">b =</span> <span class="dv">10</span>, <span class="at">l =</span> <span class="dv">10</span>)</span>
<span id="cb3-55"><a href="#cb3-55" aria-hidden="true" tabindex="-1"></a>  )</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<div>
<figure class="figure">
<p><img src="poe_bone_health_phase_2_files/figure-html/unnamed-chunk-3-1.png" class="img-fluid figure-img" style="width:100.0%"></p>
</figure>
</div>
</div>
</div>
</section>
<section id="osteoguard" class="level4">
<h4 class="anchored" data-anchor-id="osteoguard">OsteoGuard</h4>
<p>For the purposes of this analysis, a hypothetical osteoporosis therapy, OsteoGuard, is introduced. OsteoGuard is modelled as a bisphosphonate-like treatment designed to improve bone mineral density and reduce fracture risk in high-risk individuals.</p>
<p>The simulated treatment is assumed to behave similarly to established bisphosphonates used in clinical practice. These therapies are known to increase lumbar spine bone mineral density, reduce fracture risk, and slow the progression from osteopenia to osteoporosis when adherence is maintained. OsteoGuard is assumed to be prescribed to individuals classified as high bone-health risk in Phase 1, with particular focus on those who would otherwise be missed under current screening guidelines.</p>
<p>All clinical and commercial data used in this phase are simulated but grounded in published literature and typical real-world treatment patterns to ensure plausibility.</p>
</section>
</section>
<section id="osteoguard-efficacy" class="level3">
<h3 class="anchored" data-anchor-id="osteoguard-efficacy">OsteoGuard Efficacy</h3>
<p>The simulation of OsteoGuard treatment outcomes was informed by established clinical norms, Phase 1 study population parameters, published bisphosphonate efficacy studies, and pragmatic assumptions regarding adherence, safety, and commercial context.</p>
<p>The table below summarises all key modelling assumptions and their sources to ensure transparency, reproducibility, and interpretability of the simulated clinical and economic outcomes.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb4"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Assumptions table</span></span>
<span id="cb4-2"><a href="#cb4-2" aria-hidden="true" tabindex="-1"></a>assumptions_tbl <span class="ot">&lt;-</span> <span class="fu">tribble</span>(</span>
<span id="cb4-3"><a href="#cb4-3" aria-hidden="true" tabindex="-1"></a>  <span class="sc">~</span>Section, <span class="sc">~</span>Parameter, <span class="sc">~</span>Assumption, <span class="sc">~</span>Reference, <span class="sc">~</span><span class="st">`</span><span class="at">Why it's reasonable</span><span class="st">`</span>,</span>
<span id="cb4-4"><a href="#cb4-4" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-5"><a href="#cb4-5" aria-hidden="true" tabindex="-1"></a>  <span class="co">#Baseline clinical norms</span></span>
<span id="cb4-6"><a href="#cb4-6" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Normal"</span>, <span class="st">"&gt;= -1.0"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb4-7"><a href="#cb4-7" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Standard clinical threshold used in DXA reporting."</span>,</span>
<span id="cb4-8"><a href="#cb4-8" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Osteopenia"</span>, <span class="st">"-1.0 to -2.5"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb4-9"><a href="#cb4-9" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Widely accepted range indicating low bone mass and higher future fracture risk."</span>,</span>
<span id="cb4-10"><a href="#cb4-10" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Osteoporosis"</span>, <span class="st">"&lt;= -2.5"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb4-11"><a href="#cb4-11" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Standard diagnostic threshold used across guidelines and trials."</span>,</span>
<span id="cb4-12"><a href="#cb4-12" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-13"><a href="#cb4-13" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Phase 1 study population baselines</span></span>
<span id="cb4-14"><a href="#cb4-14" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"Mean lumbar T-score (high risk)"</span>, <span class="st">"-1.73"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb4-15"><a href="#cb4-15" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical mean from the Phase 1 high-risk cohort; anchors simulation to observed baseline distribution."</span>,</span>
<span id="cb4-16"><a href="#cb4-16" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"SD lumbar T-score (high risk)"</span>, <span class="st">"0.57"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb4-17"><a href="#cb4-17" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical variability from Phase 1; aligns with typical dispersion in osteopenic/osteoporotic samples."</span>,</span>
<span id="cb4-18"><a href="#cb4-18" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"Mean lumbar T-score (total sample)"</span>, <span class="st">"-0.09"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb4-19"><a href="#cb4-19" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical mean from the Phase 1 full analytic sample; represents general population baseline."</span>,</span>
<span id="cb4-20"><a href="#cb4-20" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"SD lumbar T-score (total sample)"</span>, <span class="st">"1.31"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb4-21"><a href="#cb4-21" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical variability from Phase 1; reflects broad mix of low-to-normal bone density in the sample."</span>,</span>
<span id="cb4-22"><a href="#cb4-22" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-23"><a href="#cb4-23" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Treatment efficacy </span></span>
<span id="cb4-24"><a href="#cb4-24" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (ideal adherence)"</span>, <span class="st">"+4.6%"</span>, <span class="st">"Haderslev et al., 2000"</span>,</span>
<span id="cb4-25"><a href="#cb4-25" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Anchored to published trial evidence for spine BMD response over 12 months."</span>,</span>
<span id="cb4-26"><a href="#cb4-26" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (average adherence)"</span>, <span class="st">"+2.8%"</span>, <span class="st">"Scaled from Haderslev et al., 2000"</span>,</span>
<span id="cb4-27"><a href="#cb4-27" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents partial effectiveness under less-than-ideal adherence, consistent with real-world attenuation."</span>,</span>
<span id="cb4-28"><a href="#cb4-28" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (poor adherence)"</span>, <span class="st">"+1.2%"</span>, <span class="st">"Scaled from Haderslev et al., 2000"</span>,</span>
<span id="cb4-29"><a href="#cb4-29" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Conservative partial benefit reflecting low exposure/persistence with therapy."</span>,</span>
<span id="cb4-30"><a href="#cb4-30" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (control)"</span>, <span class="st">"-0.9%"</span>, <span class="st">"Haderslev et al., 2000"</span>,</span>
<span id="cb4-31"><a href="#cb4-31" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Published untreated trajectory provides a realistic counterfactual baseline."</span>,</span>
<span id="cb4-32"><a href="#cb4-32" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (high adherence)"</span>, <span class="st">"~5.4%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb4-33"><a href="#cb4-33" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Year-2 gains are typically smaller than year-1; projection maintains plausible 2-year cumulative improvement."</span>,</span>
<span id="cb4-34"><a href="#cb4-34" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (moderate adherence)"</span>, <span class="st">"~3.3%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb4-35"><a href="#cb4-35" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived by scaling the high-adherence projection to reflect reduced exposure/persistence."</span>,</span>
<span id="cb4-36"><a href="#cb4-36" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (poor adherence)"</span>, <span class="st">"~1.4%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb4-37"><a href="#cb4-37" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Conservative assumption: small incremental gain beyond 12 months under poor adherence."</span>,</span>
<span id="cb4-38"><a href="#cb4-38" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-39"><a href="#cb4-39" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Fracture assumptions</span></span>
<span id="cb4-40"><a href="#cb4-40" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Control cumulative fracture incidence"</span>, <span class="st">"12.6%"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb4-41"><a href="#cb4-41" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Anchors fracture risk to multi-year bisphosphonate trial evidence for high-risk populations."</span>,</span>
<span id="cb4-42"><a href="#cb4-42" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Treatment cumulative fracture incidence"</span>, <span class="st">"9.0%"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb4-43"><a href="#cb4-43" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents clinically meaningful fracture reduction consistent with trial findings."</span>,</span>
<span id="cb4-44"><a href="#cb4-44" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Relative risk"</span>, <span class="st">"0.71"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb4-45"><a href="#cb4-45" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Directly implied by published incidence values; simple and interpretable for simulation."</span>,</span>
<span id="cb4-46"><a href="#cb4-46" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Simulation horizon"</span>, <span class="st">"2-year proxy using multi-year trial evidence"</span>, <span class="st">"Portfolio modelling assumption"</span>,</span>
<span id="cb4-47"><a href="#cb4-47" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Pragmatic approximation for a prototype: uses published cumulative incidence as a 2-year proxy with sensitivity checks planned."</span>,</span>
<span id="cb4-48"><a href="#cb4-48" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-49"><a href="#cb4-49" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Adherence</span></span>
<span id="cb4-50"><a href="#cb4-50" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"High adherence proportion"</span>, <span class="st">"40%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-51"><a href="#cb4-51" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Consistent with real-world persistence patterns where a minority maintain high adherence long-term."</span>,</span>
<span id="cb4-52"><a href="#cb4-52" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Moderate adherence proportion"</span>, <span class="st">"35%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-53"><a href="#cb4-53" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents partial adherence/persistence typical in observational settings."</span>,</span>
<span id="cb4-54"><a href="#cb4-54" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Poor adherence proportion"</span>, <span class="st">"25%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-55"><a href="#cb4-55" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects drop-off and low persistence commonly reported for oral therapies."</span>,</span>
<span id="cb4-56"><a href="#cb4-56" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (high)"</span>, <span class="st">"10%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-57"><a href="#cb4-57" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Low discontinuation expected among high-adherence patients."</span>,</span>
<span id="cb4-58"><a href="#cb4-58" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (moderate)"</span>, <span class="st">"30%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-59"><a href="#cb4-59" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Moderate discontinuation aligns with partial persistence across the first year."</span>,</span>
<span id="cb4-60"><a href="#cb4-60" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (poor)"</span>, <span class="st">"60%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb4-61"><a href="#cb4-61" aria-hidden="true" tabindex="-1"></a>  <span class="st">"High discontinuation is typical for poor adherence groups and supports conservative effectiveness."</span>,</span>
<span id="cb4-62"><a href="#cb4-62" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-63"><a href="#cb4-63" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb4-64"><a href="#cb4-64" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-65"><a href="#cb4-65" aria-hidden="true" tabindex="-1"></a><span class="co"># Rendering table</span></span>
<span id="cb4-66"><a href="#cb4-66" aria-hidden="true" tabindex="-1"></a><span class="co"># Create display version that blanks repeated sections</span></span>
<span id="cb4-67"><a href="#cb4-67" aria-hidden="true" tabindex="-1"></a>assumptions_display <span class="ot">&lt;-</span> assumptions_tbl <span class="sc">%&gt;%</span></span>
<span id="cb4-68"><a href="#cb4-68" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(Section) <span class="sc">%&gt;%</span></span>
<span id="cb4-69"><a href="#cb4-69" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb4-70"><a href="#cb4-70" aria-hidden="true" tabindex="-1"></a>    <span class="at">Section =</span> <span class="fu">ifelse</span>(<span class="fu">row_number</span>() <span class="sc">==</span> <span class="dv">1</span>, Section, <span class="st">""</span>)</span>
<span id="cb4-71"><a href="#cb4-71" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb4-72"><a href="#cb4-72" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ungroup</span>()</span>
<span id="cb4-73"><a href="#cb4-73" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb4-74"><a href="#cb4-74" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(</span>
<span id="cb4-75"><a href="#cb4-75" aria-hidden="true" tabindex="-1"></a>  assumptions_display,</span>
<span id="cb4-76"><a href="#cb4-76" aria-hidden="true" tabindex="-1"></a>  <span class="at">format =</span> <span class="st">"html"</span>,</span>
<span id="cb4-77"><a href="#cb4-77" aria-hidden="true" tabindex="-1"></a>  <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Section"</span>, <span class="st">"Parameter"</span>, <span class="st">"Assumption"</span>,</span>
<span id="cb4-78"><a href="#cb4-78" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Reference"</span>, <span class="st">"Why it's reasonable"</span>),</span>
<span id="cb4-79"><a href="#cb4-79" aria-hidden="true" tabindex="-1"></a>  <span class="at">align =</span> <span class="st">"l"</span>,</span>
<span id="cb4-80"><a href="#cb4-80" aria-hidden="true" tabindex="-1"></a>  <span class="at">caption =</span> <span class="st">"Simulation assumptions for OsteoGuard treatment modelling"</span></span>
<span id="cb4-81"><a href="#cb4-81" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb4-82"><a href="#cb4-82" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb4-83"><a href="#cb4-83" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb4-84"><a href="#cb4-84" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="st">"condensed"</span>,   <span class="co"># no striped</span></span>
<span id="cb4-85"><a href="#cb4-85" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb4-86"><a href="#cb4-86" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb4-87"><a href="#cb4-87" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb4-88"><a href="#cb4-88" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb4-89"><a href="#cb4-89" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"22em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb4-90"><a href="#cb4-90" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">3</span>, <span class="at">width =</span> <span class="st">"14em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb4-91"><a href="#cb4-91" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">4</span>, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb4-92"><a href="#cb4-92" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">5</span>, <span class="at">width =</span> <span class="st">"26em"</span>)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="table table-condensed caption-top table-sm table-striped small">
<caption>Simulation assumptions for OsteoGuard treatment modelling</caption>
<thead>
<tr class="header">
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Section</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Parameter</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Assumption</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Reference</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Why it's reasonable</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;">Baseline clinical norms</td>
<td style="text-align: left; width: 22em;">T-score interpretation: Normal</td>
<td style="text-align: left; width: 14em;">&gt;= -1.0</td>
<td style="text-align: left; width: 18em;">Clinical DXA conventions</td>
<td style="text-align: left; width: 26em;">Standard clinical threshold used in DXA reporting.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">T-score interpretation: Osteopenia</td>
<td style="text-align: left; width: 14em;">-1.0 to -2.5</td>
<td style="text-align: left; width: 18em;">Clinical DXA conventions</td>
<td style="text-align: left; width: 26em;">Widely accepted range indicating low bone mass and higher future fracture risk.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">T-score interpretation: Osteoporosis</td>
<td style="text-align: left; width: 14em;">&lt;= -2.5</td>
<td style="text-align: left; width: 18em;">Clinical DXA conventions</td>
<td style="text-align: left; width: 26em;">Standard diagnostic threshold used across guidelines and trials.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;">Phase 1 study population parameters</td>
<td style="text-align: left; width: 22em;">Mean lumbar T-score (high risk)</td>
<td style="text-align: left; width: 14em;">-1.73</td>
<td style="text-align: left; width: 18em;">Phase 1 analytic dataset</td>
<td style="text-align: left; width: 26em;">Empirical mean from the Phase 1 high-risk cohort; anchors simulation to observed baseline distribution.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">SD lumbar T-score (high risk)</td>
<td style="text-align: left; width: 14em;">0.57</td>
<td style="text-align: left; width: 18em;">Phase 1 analytic dataset</td>
<td style="text-align: left; width: 26em;">Empirical variability from Phase 1; aligns with typical dispersion in osteopenic/osteoporotic samples.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Mean lumbar T-score (total sample)</td>
<td style="text-align: left; width: 14em;">-0.09</td>
<td style="text-align: left; width: 18em;">Phase 1 analytic dataset</td>
<td style="text-align: left; width: 26em;">Empirical mean from the Phase 1 full analytic sample; represents general population baseline.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">SD lumbar T-score (total sample)</td>
<td style="text-align: left; width: 14em;">1.31</td>
<td style="text-align: left; width: 18em;">Phase 1 analytic dataset</td>
<td style="text-align: left; width: 26em;">Empirical variability from Phase 1; reflects broad mix of low-to-normal bone density in the sample.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;">Treatment efficacy</td>
<td style="text-align: left; width: 22em;">12m BMD change (ideal adherence)</td>
<td style="text-align: left; width: 14em;">+4.6%</td>
<td style="text-align: left; width: 18em;">Haderslev et al., 2000</td>
<td style="text-align: left; width: 26em;">Anchored to published trial evidence for spine BMD response over 12 months.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">12m BMD change (average adherence)</td>
<td style="text-align: left; width: 14em;">+2.8%</td>
<td style="text-align: left; width: 18em;">Scaled from Haderslev et al., 2000</td>
<td style="text-align: left; width: 26em;">Represents partial effectiveness under less-than-ideal adherence, consistent with real-world attenuation.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">12m BMD change (poor adherence)</td>
<td style="text-align: left; width: 14em;">+1.2%</td>
<td style="text-align: left; width: 18em;">Scaled from Haderslev et al., 2000</td>
<td style="text-align: left; width: 26em;">Conservative partial benefit reflecting low exposure/persistence with therapy.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">12m BMD change (control)</td>
<td style="text-align: left; width: 14em;">-0.9%</td>
<td style="text-align: left; width: 18em;">Haderslev et al., 2000</td>
<td style="text-align: left; width: 26em;">Published untreated trajectory provides a realistic counterfactual baseline.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">24m projected change (high adherence)</td>
<td style="text-align: left; width: 14em;">~5.4%</td>
<td style="text-align: left; width: 18em;">Interpolated from 12m &amp; IOF evidence</td>
<td style="text-align: left; width: 26em;">Year-2 gains are typically smaller than year-1; projection maintains plausible 2-year cumulative improvement.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">24m projected change (moderate adherence)</td>
<td style="text-align: left; width: 14em;">~3.3%</td>
<td style="text-align: left; width: 18em;">Interpolated from 12m &amp; IOF evidence</td>
<td style="text-align: left; width: 26em;">Derived by scaling the high-adherence projection to reflect reduced exposure/persistence.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">24m projected change (poor adherence)</td>
<td style="text-align: left; width: 14em;">~1.4%</td>
<td style="text-align: left; width: 18em;">Interpolated from 12m &amp; IOF evidence</td>
<td style="text-align: left; width: 26em;">Conservative assumption: small incremental gain beyond 12 months under poor adherence.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;">Fracture risk</td>
<td style="text-align: left; width: 22em;">Control cumulative fracture incidence</td>
<td style="text-align: left; width: 14em;">12.6%</td>
<td style="text-align: left; width: 18em;">Karpf et al., 1997</td>
<td style="text-align: left; width: 26em;">Anchors fracture risk to multi-year bisphosphonate trial evidence for high-risk populations.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Treatment cumulative fracture incidence</td>
<td style="text-align: left; width: 14em;">9.0%</td>
<td style="text-align: left; width: 18em;">Karpf et al., 1997</td>
<td style="text-align: left; width: 26em;">Represents clinically meaningful fracture reduction consistent with trial findings.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Relative risk</td>
<td style="text-align: left; width: 14em;">0.71</td>
<td style="text-align: left; width: 18em;">Karpf et al., 1997</td>
<td style="text-align: left; width: 26em;">Directly implied by published incidence values; simple and interpretable for simulation.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Simulation horizon</td>
<td style="text-align: left; width: 14em;">2-year proxy using multi-year trial evidence</td>
<td style="text-align: left; width: 18em;">Portfolio modelling assumption</td>
<td style="text-align: left; width: 26em;">Pragmatic approximation for a prototype: uses published cumulative incidence as a 2-year proxy with sensitivity checks planned.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;">Adherence</td>
<td style="text-align: left; width: 22em;">High adherence proportion</td>
<td style="text-align: left; width: 14em;">40%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">Consistent with real-world persistence patterns where a minority maintain high adherence long-term.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Moderate adherence proportion</td>
<td style="text-align: left; width: 14em;">35%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">Represents partial adherence/persistence typical in observational settings.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Poor adherence proportion</td>
<td style="text-align: left; width: 14em;">25%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">Reflects drop-off and low persistence commonly reported for oral therapies.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Discontinue by year 1 (high)</td>
<td style="text-align: left; width: 14em;">10%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">Low discontinuation expected among high-adherence patients.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Discontinue by year 1 (moderate)</td>
<td style="text-align: left; width: 14em;">30%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">Moderate discontinuation aligns with partial persistence across the first year.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em; font-weight: bold;"></td>
<td style="text-align: left; width: 22em;">Discontinue by year 1 (poor)</td>
<td style="text-align: left; width: 14em;">60%</td>
<td style="text-align: left; width: 18em;">Hui et al., 2017; Fatoye et al., 2019</td>
<td style="text-align: left; width: 26em;">High discontinuation is typical for poor adherence groups and supports conservative effectiveness.</td>
</tr>
</tbody>
</table>
</div>
</div>
<section id="cleaning-phase-1-data" class="level4">
<h4 class="anchored" data-anchor-id="cleaning-phase-1-data">Cleaning Phase 1 data</h4>
<p>Phase 1 included all 3,107 individuals in the analytic sample, encompassing both those classified as at risk and not at risk under the revised screening logic.</p>
<p>For Phase 2, the dataset was restricted to the missed high-risk subgroup (n = 508) - individuals who met high-risk clinical criteria but were not captured under current screening guidelines.</p>
<p>Missed high-risk individuals were defined as those with either:</p>
<ul>
<li><p>Osteoporosis-range DXA T-scores (≤ -2.5), or</p></li>
<li><p>Osteopenia-range T-scores (-1.0 to -2.5) plus at least one additional risk factor (prior fracture, smoking history, low BMI, or low physical activity),</p></li>
</ul>
<p>and who would not have been eligible for screening under age-based criteria.</p>
<p>This subgroup represents a clinically meaningful and commercially untapped population.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb5"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Filtering for missed high risk individuals only</span></span>
<span id="cb5-2"><a href="#cb5-2" aria-hidden="true" tabindex="-1"></a>data <span class="ot">&lt;-</span> phase_1 <span class="sc">%&gt;%</span></span>
<span id="cb5-3"><a href="#cb5-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(missed_high_risk <span class="sc">==</span> <span class="dv">1</span>)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
</section>
<section id="simulating-osteoguard-data" class="level4">
<h4 class="anchored" data-anchor-id="simulating-osteoguard-data">Simulating OsteoGuard data</h4>
<p>Using the Phase 1 dataset, which included baseline DXA measurements and risk factor data, we simulated follow-up data at 12- and 24-months. This included:</p>
<p>-&gt; Longitudinal BMD values for the lumbar spine</p>
<p>-&gt; Corresponding T-scores calculated from the simulated BMDs</p>
<p>-&gt; Fracture risk profiles</p>
<p>-&gt; Discontinuation</p>
<p>The simulated dataset reflects expected clinical trajectories and allows evaluation of OsteoGuard screening logic and bisphosphonate eligibility over a 2-year follow-up period.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb6"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulating treatment data</span></span>
<span id="cb6-2"><a href="#cb6-2" aria-hidden="true" tabindex="-1"></a><span class="co"># 1) 50/50 randomization</span></span>
<span id="cb6-3"><a href="#cb6-3" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">123</span>)</span>
<span id="cb6-4"><a href="#cb6-4" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-5"><a href="#cb6-5" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-6"><a href="#cb6-6" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(missed_high_risk) <span class="sc">%&gt;%</span></span>
<span id="cb6-7"><a href="#cb6-7" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">treatment_group =</span> <span class="fu">sample</span>(<span class="fu">rep</span>(<span class="fu">c</span>(<span class="st">"Treatment"</span>, <span class="st">"Control"</span>), <span class="at">length.out =</span> <span class="fu">n</span>()))) <span class="sc">%&gt;%</span></span>
<span id="cb6-8"><a href="#cb6-8" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ungroup</span>() <span class="sc">%&gt;%</span></span>
<span id="cb6-9"><a href="#cb6-9" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">treatment_group =</span> <span class="fu">factor</span>(treatment_group, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"Control"</span>, <span class="st">"Treatment"</span>)))</span>
<span id="cb6-10"><a href="#cb6-10" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-11"><a href="#cb6-11" aria-hidden="true" tabindex="-1"></a><span class="co"># 2) Assigning adherence</span></span>
<span id="cb6-12"><a href="#cb6-12" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">125</span>)</span>
<span id="cb6-13"><a href="#cb6-13" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-14"><a href="#cb6-14" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-15"><a href="#cb6-15" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-16"><a href="#cb6-16" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-17"><a href="#cb6-17" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">~</span> <span class="fu">sample</span>(</span>
<span id="cb6-18"><a href="#cb6-18" aria-hidden="true" tabindex="-1"></a>        <span class="at">x =</span> <span class="fu">c</span>(<span class="st">"High"</span>, <span class="st">"Moderate"</span>, <span class="st">"Poor"</span>),</span>
<span id="cb6-19"><a href="#cb6-19" aria-hidden="true" tabindex="-1"></a>        <span class="at">size =</span> <span class="fu">n</span>(),</span>
<span id="cb6-20"><a href="#cb6-20" aria-hidden="true" tabindex="-1"></a>        <span class="at">replace =</span> <span class="cn">TRUE</span>,</span>
<span id="cb6-21"><a href="#cb6-21" aria-hidden="true" tabindex="-1"></a>        <span class="at">prob =</span> <span class="fu">c</span>(<span class="fl">0.40</span>, <span class="fl">0.35</span>, <span class="fl">0.25</span>)</span>
<span id="cb6-22"><a href="#cb6-22" aria-hidden="true" tabindex="-1"></a>      ),</span>
<span id="cb6-23"><a href="#cb6-23" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb6-24"><a href="#cb6-24" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb6-25"><a href="#cb6-25" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group =</span> <span class="fu">factor</span>(adherence_group, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"High"</span>, <span class="st">"Moderate"</span>, <span class="st">"Poor"</span>))</span>
<span id="cb6-26"><a href="#cb6-26" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-27"><a href="#cb6-27" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-28"><a href="#cb6-28" aria-hidden="true" tabindex="-1"></a><span class="co"># 3) Simulate BMD % change (12m) + incremental gain (12→24m)</span></span>
<span id="cb6-29"><a href="#cb6-29" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-30"><a href="#cb6-30" aria-hidden="true" tabindex="-1"></a><span class="co"># SD for 12-month % change</span></span>
<span id="cb6-31"><a href="#cb6-31" aria-hidden="true" tabindex="-1"></a>sd_bmd_12 <span class="ot">&lt;-</span> <span class="fl">0.8</span></span>
<span id="cb6-32"><a href="#cb6-32" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-33"><a href="#cb6-33" aria-hidden="true" tabindex="-1"></a><span class="co"># 12-month means </span></span>
<span id="cb6-34"><a href="#cb6-34" aria-hidden="true" tabindex="-1"></a>mu_12_ideal <span class="ot">&lt;-</span> <span class="fl">4.6</span></span>
<span id="cb6-35"><a href="#cb6-35" aria-hidden="true" tabindex="-1"></a>mu_12_avg   <span class="ot">&lt;-</span> <span class="fl">2.8</span></span>
<span id="cb6-36"><a href="#cb6-36" aria-hidden="true" tabindex="-1"></a>mu_12_poor  <span class="ot">&lt;-</span> <span class="fl">1.2</span></span>
<span id="cb6-37"><a href="#cb6-37" aria-hidden="true" tabindex="-1"></a>mu_12_ctrl  <span class="ot">&lt;-</span> <span class="sc">-</span><span class="fl">0.9</span></span>
<span id="cb6-38"><a href="#cb6-38" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-39"><a href="#cb6-39" aria-hidden="true" tabindex="-1"></a><span class="co"># Incremental change from 12m to 24m (percentage points)</span></span>
<span id="cb6-40"><a href="#cb6-40" aria-hidden="true" tabindex="-1"></a><span class="co"># (Year-2 gains are smaller than Year-1; control continues to decline)</span></span>
<span id="cb6-41"><a href="#cb6-41" aria-hidden="true" tabindex="-1"></a>sd_inc <span class="ot">&lt;-</span> <span class="fl">0.4</span></span>
<span id="cb6-42"><a href="#cb6-42" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-43"><a href="#cb6-43" aria-hidden="true" tabindex="-1"></a>inc_ideal <span class="ot">&lt;-</span> <span class="fl">0.8</span>   <span class="co"># additional gain (High adherence)</span></span>
<span id="cb6-44"><a href="#cb6-44" aria-hidden="true" tabindex="-1"></a>inc_avg   <span class="ot">&lt;-</span> <span class="fl">0.5</span>   <span class="co"># additional gain (Moderate adherence)</span></span>
<span id="cb6-45"><a href="#cb6-45" aria-hidden="true" tabindex="-1"></a>inc_poor  <span class="ot">&lt;-</span> <span class="fl">0.2</span>   <span class="co"># additional gain (Poor adherence)</span></span>
<span id="cb6-46"><a href="#cb6-46" aria-hidden="true" tabindex="-1"></a>inc_ctrl  <span class="ot">&lt;-</span> <span class="sc">-</span><span class="fl">0.6</span>  <span class="co"># additional decline in control arm</span></span>
<span id="cb6-47"><a href="#cb6-47" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-48"><a href="#cb6-48" aria-hidden="true" tabindex="-1"></a><span class="co"># Assigning BMD</span></span>
<span id="cb6-49"><a href="#cb6-49" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">125</span>)</span>
<span id="cb6-50"><a href="#cb6-50" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-51"><a href="#cb6-51" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-52"><a href="#cb6-52" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-53"><a href="#cb6-53" aria-hidden="true" tabindex="-1"></a>    <span class="co"># 12-month % change</span></span>
<span id="cb6-54"><a href="#cb6-54" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_12m_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-55"><a href="#cb6-55" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ctrl, <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb6-56"><a href="#cb6-56" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span>     <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ideal, <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb6-57"><a href="#cb6-57" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_avg,   <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb6-58"><a href="#cb6-58" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span>     <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_poor,  <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb6-59"><a href="#cb6-59" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb6-60"><a href="#cb6-60" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb6-61"><a href="#cb6-61" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-62"><a href="#cb6-62" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-63"><a href="#cb6-63" aria-hidden="true" tabindex="-1"></a>  <span class="co"># incremental 12→24m % change </span></span>
<span id="cb6-64"><a href="#cb6-64" aria-hidden="true" tabindex="-1"></a>  <span class="at">bmd_inc_12to24_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-65"><a href="#cb6-65" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_ctrl, <span class="at">sd =</span> sd_inc),</span>
<span id="cb6-66"><a href="#cb6-66" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_ideal, <span class="at">sd =</span> sd_inc), <span class="fl">0.2</span>),   <span class="co"># min 0.2%</span></span>
<span id="cb6-67"><a href="#cb6-67" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_avg, <span class="at">sd =</span> sd_inc), <span class="fl">0.1</span>), <span class="co"># min 0.1%</span></span>
<span id="cb6-68"><a href="#cb6-68" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_poor, <span class="at">sd =</span> sd_inc), <span class="dv">0</span>),  <span class="co"># allow 0 or small gains</span></span>
<span id="cb6-69"><a href="#cb6-69" aria-hidden="true" tabindex="-1"></a>   <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb6-70"><a href="#cb6-70" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb6-71"><a href="#cb6-71" aria-hidden="true" tabindex="-1"></a>,</span>
<span id="cb6-72"><a href="#cb6-72" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-73"><a href="#cb6-73" aria-hidden="true" tabindex="-1"></a>    <span class="co"># 24-month % change = 12-month + increment</span></span>
<span id="cb6-74"><a href="#cb6-74" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_24m_pct =</span> bmd_change_12m_pct <span class="sc">+</span> bmd_inc_12to24_pct</span>
<span id="cb6-75"><a href="#cb6-75" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-76"><a href="#cb6-76" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-77"><a href="#cb6-77" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-78"><a href="#cb6-78" aria-hidden="true" tabindex="-1"></a><span class="co"># 4) Convert % change → post-treatment BMD and T-score</span></span>
<span id="cb6-79"><a href="#cb6-79" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-80"><a href="#cb6-80" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-81"><a href="#cb6-81" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_12m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_12m_pct <span class="sc">/</span> <span class="dv">100</span>),</span>
<span id="cb6-82"><a href="#cb6-82" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_24m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_24m_pct <span class="sc">/</span> <span class="dv">100</span>)</span>
<span id="cb6-83"><a href="#cb6-83" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-84"><a href="#cb6-84" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-85"><a href="#cb6-85" aria-hidden="true" tabindex="-1"></a><span class="co"># Compute 12m and 24m T-scores</span></span>
<span id="cb6-86"><a href="#cb6-86" aria-hidden="true" tabindex="-1"></a>ref_spine_mean <span class="ot">&lt;-</span> <span class="fl">1.065</span></span>
<span id="cb6-87"><a href="#cb6-87" aria-hidden="true" tabindex="-1"></a>ref_spine_sd   <span class="ot">&lt;-</span> <span class="fl">0.122</span></span>
<span id="cb6-88"><a href="#cb6-88" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-89"><a href="#cb6-89" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-90"><a href="#cb6-90" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-91"><a href="#cb6-91" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_12m =</span> (bmd_spine_12m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd,</span>
<span id="cb6-92"><a href="#cb6-92" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_24m =</span> (bmd_spine_24m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd</span>
<span id="cb6-93"><a href="#cb6-93" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-94"><a href="#cb6-94" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-95"><a href="#cb6-95" aria-hidden="true" tabindex="-1"></a><span class="co"># Classify at 24 months</span></span>
<span id="cb6-96"><a href="#cb6-96" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-97"><a href="#cb6-97" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-98"><a href="#cb6-98" aria-hidden="true" tabindex="-1"></a>    <span class="at">spine_class_24m =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-99"><a href="#cb6-99" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&gt;=</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">~</span> <span class="st">"Normal"</span>,</span>
<span id="cb6-100"><a href="#cb6-100" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">&amp;</span> tscore_spine_24m <span class="sc">&gt;</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteopenia"</span>,</span>
<span id="cb6-101"><a href="#cb6-101" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;=</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteoporosis"</span>,</span>
<span id="cb6-102"><a href="#cb6-102" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb6-103"><a href="#cb6-103" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb6-104"><a href="#cb6-104" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-105"><a href="#cb6-105" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-106"><a href="#cb6-106" aria-hidden="true" tabindex="-1"></a><span class="co"># 5)  Simulate fractures</span></span>
<span id="cb6-107"><a href="#cb6-107" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">123</span>)</span>
<span id="cb6-108"><a href="#cb6-108" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-109"><a href="#cb6-109" aria-hidden="true" tabindex="-1"></a>p_fract_ctrl <span class="ot">&lt;-</span> <span class="fl">0.126</span></span>
<span id="cb6-110"><a href="#cb6-110" aria-hidden="true" tabindex="-1"></a>p_fract_trt  <span class="ot">&lt;-</span> <span class="fl">0.090</span></span>
<span id="cb6-111"><a href="#cb6-111" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-112"><a href="#cb6-112" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-113"><a href="#cb6-113" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-114"><a href="#cb6-114" aria-hidden="true" tabindex="-1"></a>    <span class="at">fracture_event =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-115"><a href="#cb6-115" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span>   <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, p_fract_ctrl),</span>
<span id="cb6-116"><a href="#cb6-116" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, p_fract_trt),</span>
<span id="cb6-117"><a href="#cb6-117" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb6-118"><a href="#cb6-118" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb6-119"><a href="#cb6-119" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb6-120"><a href="#cb6-120" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-121"><a href="#cb6-121" aria-hidden="true" tabindex="-1"></a><span class="co"># 6) Apply discontinuation effect: those who discontinue lose partial benefit</span></span>
<span id="cb6-122"><a href="#cb6-122" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-123"><a href="#cb6-123" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb6-124"><a href="#cb6-124" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-125"><a href="#cb6-125" aria-hidden="true" tabindex="-1"></a>    <span class="co"># Step 1: Randomly assign discontinuation at 12 months based on adherence</span></span>
<span id="cb6-126"><a href="#cb6-126" aria-hidden="true" tabindex="-1"></a>    <span class="at">discontinued =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-127"><a href="#cb6-127" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span>     <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.10</span>),</span>
<span id="cb6-128"><a href="#cb6-128" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.30</span>),</span>
<span id="cb6-129"><a href="#cb6-129" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span>     <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.60</span>),</span>
<span id="cb6-130"><a href="#cb6-130" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="dv">0</span></span>
<span id="cb6-131"><a href="#cb6-131" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb6-132"><a href="#cb6-132" aria-hidden="true" tabindex="-1"></a>    <span class="co"># Step 2: For 24-month BMD, if discontinued, apply control decline from 12m BMD</span></span>
<span id="cb6-133"><a href="#cb6-133" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_24m_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-134"><a href="#cb6-134" aria-hidden="true" tabindex="-1"></a>      discontinued <span class="sc">==</span> <span class="dv">1</span> <span class="sc">~</span> bmd_change_12m_pct <span class="sc">+</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ctrl, <span class="at">sd =</span> sd_inc),</span>
<span id="cb6-135"><a href="#cb6-135" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span>             <span class="sc">~</span> bmd_change_12m_pct <span class="sc">+</span> bmd_inc_12to24_pct  <span class="co"># adherent patients follow original increment</span></span>
<span id="cb6-136"><a href="#cb6-136" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb6-137"><a href="#cb6-137" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb6-138"><a href="#cb6-138" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Step 3: Recalculate 24-month BMD and T-score</span></span>
<span id="cb6-139"><a href="#cb6-139" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb6-140"><a href="#cb6-140" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_24m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_24m_pct <span class="sc">/</span> <span class="dv">100</span>),</span>
<span id="cb6-141"><a href="#cb6-141" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_24m =</span> (bmd_spine_24m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd,</span>
<span id="cb6-142"><a href="#cb6-142" aria-hidden="true" tabindex="-1"></a>    <span class="at">spine_class_24m =</span> <span class="fu">case_when</span>(</span>
<span id="cb6-143"><a href="#cb6-143" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&gt;=</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">~</span> <span class="st">"Normal"</span>,</span>
<span id="cb6-144"><a href="#cb6-144" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">&amp;</span> tscore_spine_24m <span class="sc">&gt;</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteopenia"</span>,</span>
<span id="cb6-145"><a href="#cb6-145" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;=</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteoporosis"</span>,</span>
<span id="cb6-146"><a href="#cb6-146" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb6-147"><a href="#cb6-147" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb6-148"><a href="#cb6-148" aria-hidden="true" tabindex="-1"></a>  )</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
</section>
<section id="analysis" class="level4">
<h4 class="anchored" data-anchor-id="analysis">Analysis</h4>
<p>The analysis section examines the efficacy of the study drug, OsteoGuard, by comparing lumbar spine BMD outcomes across adherence groups. Summary statistics include mean BMD at 24 months, percentage change from baseline, and adherence-stratified comparisons to illustrate the impact of treatment and adherence on bone health.</p>
<p>The following table summarizes lumbar spine BMD at baseline and 24 months across adherence groups. It includes the mean and standard deviation at each time point, as well as the percentage change from baseline, providing a clear view of treatment-related bone gains. Higher percentage increases in the high adherence group illustrate the efficacy of the study drug relative to lower adherence, discontinued and control groups.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb7"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Summarize baseline, 24-month BMD, and percent change by adherence group</span></span>
<span id="cb7-2"><a href="#cb7-2" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb7-3"><a href="#cb7-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb7-4"><a href="#cb7-4" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group_updated =</span> <span class="fu">case_when</span>(</span>
<span id="cb7-5"><a href="#cb7-5" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="st">"Control"</span>,</span>
<span id="cb7-6"><a href="#cb7-6" aria-hidden="true" tabindex="-1"></a>      discontinued <span class="sc">==</span> <span class="dv">1</span> <span class="sc">~</span> <span class="st">"Discontinued"</span>,</span>
<span id="cb7-7"><a href="#cb7-7" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="fu">as.character</span>(adherence_group)</span>
<span id="cb7-8"><a href="#cb7-8" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb7-9"><a href="#cb7-9" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group_updated =</span> <span class="fu">factor</span>(adherence_group_updated,</span>
<span id="cb7-10"><a href="#cb7-10" aria-hidden="true" tabindex="-1"></a>                              <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"Control"</span>, <span class="st">"Poor"</span>, <span class="st">"Moderate"</span>, <span class="st">"High"</span>, <span class="st">"Discontinued"</span>))</span>
<span id="cb7-11"><a href="#cb7-11" aria-hidden="true" tabindex="-1"></a>  ) </span>
<span id="cb7-12"><a href="#cb7-12" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb7-13"><a href="#cb7-13" aria-hidden="true" tabindex="-1"></a>bmd_summary <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span> </span>
<span id="cb7-14"><a href="#cb7-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(adherence_group_updated) <span class="sc">%&gt;%</span></span>
<span id="cb7-15"><a href="#cb7-15" aria-hidden="true" tabindex="-1"></a>  <span class="fu">summarize</span>(</span>
<span id="cb7-16"><a href="#cb7-16" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Baseline BMD (g/cm²)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>(DXXLSBMD, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb7-17"><a href="#cb7-17" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Baseline SD</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">sd</span>(DXXLSBMD, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb7-18"><a href="#cb7-18" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">24-Month BMD (g/cm²)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>(bmd_spine_24m, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb7-19"><a href="#cb7-19" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">24-Month SD</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">sd</span>(bmd_spine_24m, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb7-20"><a href="#cb7-20" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Percent Change (%)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>((bmd_spine_24m <span class="sc">-</span> DXXLSBMD) <span class="sc">/</span> DXXLSBMD <span class="sc">*</span> <span class="dv">100</span>, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb7-21"><a href="#cb7-21" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">n</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">n</span>(),</span>
<span id="cb7-22"><a href="#cb7-22" aria-hidden="true" tabindex="-1"></a>    <span class="at">.groups =</span> <span class="st">"drop"</span></span>
<span id="cb7-23"><a href="#cb7-23" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span> </span>
<span id="cb7-24"><a href="#cb7-24" aria-hidden="true" tabindex="-1"></a>    <span class="fu">rename</span>(<span class="st">`</span><span class="at">Adherence Group</span><span class="st">`</span> <span class="ot">=</span> adherence_group_updated)</span>
<span id="cb7-25"><a href="#cb7-25" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb7-26"><a href="#cb7-26" aria-hidden="true" tabindex="-1"></a><span class="co"># Render the table</span></span>
<span id="cb7-27"><a href="#cb7-27" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(bmd_summary,</span>
<span id="cb7-28"><a href="#cb7-28" aria-hidden="true" tabindex="-1"></a>    <span class="at">caption =</span> <span class="st">"Lumbar Spine BMD at Baseline and 24 Months by Adherence Group"</span>,</span>
<span id="cb7-29"><a href="#cb7-29" aria-hidden="true" tabindex="-1"></a>    <span class="at">digits =</span> <span class="dv">3</span>) <span class="sc">%&gt;%</span></span>
<span id="cb7-30"><a href="#cb7-30" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(<span class="at">full_width =</span> <span class="cn">FALSE</span>, <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>))</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="table table-condensed table-hover caption-top table-sm table-striped small">
<caption>Lumbar Spine BMD at Baseline and 24 Months by Adherence Group</caption>
<thead>
<tr class="header">
<th style="text-align: left;" data-quarto-table-cell-role="th">Adherence Group</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Baseline BMD (g/cm²)</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Baseline SD</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">24-Month BMD (g/cm²)</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">24-Month SD</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Percent Change (%)</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">n</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;">Control</td>
<td style="text-align: right;">0.858</td>
<td style="text-align: right;">0.067</td>
<td style="text-align: right;">0.845</td>
<td style="text-align: right;">0.066</td>
<td style="text-align: right;">-1.552</td>
<td style="text-align: right;">254</td>
</tr>
<tr class="even">
<td style="text-align: left;">Poor</td>
<td style="text-align: right;">0.867</td>
<td style="text-align: right;">0.073</td>
<td style="text-align: right;">0.881</td>
<td style="text-align: right;">0.076</td>
<td style="text-align: right;">1.604</td>
<td style="text-align: right;">39</td>
</tr>
<tr class="odd">
<td style="text-align: left;">Moderate</td>
<td style="text-align: right;">0.857</td>
<td style="text-align: right;">0.073</td>
<td style="text-align: right;">0.887</td>
<td style="text-align: right;">0.076</td>
<td style="text-align: right;">3.439</td>
<td style="text-align: right;">62</td>
</tr>
<tr class="even">
<td style="text-align: left;">High</td>
<td style="text-align: right;">0.846</td>
<td style="text-align: right;">0.068</td>
<td style="text-align: right;">0.892</td>
<td style="text-align: right;">0.072</td>
<td style="text-align: right;">5.359</td>
<td style="text-align: right;">87</td>
</tr>
<tr class="odd">
<td style="text-align: left;">Discontinued</td>
<td style="text-align: right;">0.855</td>
<td style="text-align: right;">0.065</td>
<td style="text-align: right;">0.864</td>
<td style="text-align: right;">0.067</td>
<td style="text-align: right;">1.073</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb8"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Preparing data in long format for plotting</span></span>
<span id="cb8-2"><a href="#cb8-2" aria-hidden="true" tabindex="-1"></a>plot_df <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span></span>
<span id="cb8-3"><a href="#cb8-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">select</span>(treatment_group, DXXLSBMD, bmd_spine_12m, bmd_spine_24m,</span>
<span id="cb8-4"><a href="#cb8-4" aria-hidden="true" tabindex="-1"></a>         tscore_spine, tscore_spine_12m, tscore_spine_24m) <span class="sc">%&gt;%</span></span>
<span id="cb8-5"><a href="#cb8-5" aria-hidden="true" tabindex="-1"></a>  <span class="fu">rename</span>(</span>
<span id="cb8-6"><a href="#cb8-6" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_baseline =</span> DXXLSBMD,</span>
<span id="cb8-7"><a href="#cb8-7" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_baseline =</span> tscore_spine</span>
<span id="cb8-8"><a href="#cb8-8" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb8-9"><a href="#cb8-9" aria-hidden="true" tabindex="-1"></a>  <span class="fu">pivot_longer</span>(</span>
<span id="cb8-10"><a href="#cb8-10" aria-hidden="true" tabindex="-1"></a>    <span class="at">cols =</span> <span class="sc">-</span>treatment_group,</span>
<span id="cb8-11"><a href="#cb8-11" aria-hidden="true" tabindex="-1"></a>    <span class="at">names_to =</span> <span class="fu">c</span>(<span class="st">"Metric"</span>, <span class="st">"Time"</span>),</span>
<span id="cb8-12"><a href="#cb8-12" aria-hidden="true" tabindex="-1"></a>    <span class="at">names_pattern =</span> <span class="st">"([a-z]+).*_?(baseline|12m|24m)$"</span>,</span>
<span id="cb8-13"><a href="#cb8-13" aria-hidden="true" tabindex="-1"></a>    <span class="at">values_to =</span> <span class="st">"Value"</span></span>
<span id="cb8-14"><a href="#cb8-14" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span> </span>
<span id="cb8-15"><a href="#cb8-15" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">Time =</span> <span class="fu">factor</span>(Time, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"baseline"</span>, <span class="st">"12m"</span>, <span class="st">"24m"</span>)))</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
<p>The below line plots provides a visual demonstration of this relationship, showing the average lumbar spine bone mineral density (BMD) and the average lumbar spine T-scores over baseline, 12 months, and 24 months for the treatment and control groups, with standard error bars. Values are calculated as the mean BMD or T-score at each timepoint for each group. The trends are identical as T-scores are derived from BMD scores and indicate that the treatment group experiences an increase in BMD over time, while the control group shows a slight decline, suggesting a positive effect of the therapy on bone density.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb9"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb9-1"><a href="#cb9-1" aria-hidden="true" tabindex="-1"></a><span class="co"># BMD plot</span></span>
<span id="cb9-2"><a href="#cb9-2" aria-hidden="true" tabindex="-1"></a>bmd_plot <span class="ot">&lt;-</span> plot_df <span class="sc">%&gt;%</span></span>
<span id="cb9-3"><a href="#cb9-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(Metric <span class="sc">==</span> <span class="st">"bmd"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb9-4"><a href="#cb9-4" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> Time, <span class="at">y =</span> Value, <span class="at">group =</span> treatment_group, <span class="at">color =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb9-5"><a href="#cb9-5" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun =</span> mean, <span class="at">geom =</span> <span class="st">"line"</span>, <span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb9-6"><a href="#cb9-6" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun.data =</span> mean_se, <span class="at">geom =</span> <span class="st">"errorbar"</span>, <span class="at">width =</span> <span class="fl">0.2</span>) <span class="sc">+</span></span>
<span id="cb9-7"><a href="#cb9-7" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb9-8"><a href="#cb9-8" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Lumbar Spine BMD over time"</span>, <span class="at">x =</span> <span class="st">"Timepoint"</span>, <span class="at">y =</span> <span class="st">"BMD (g/cm²)"</span>, <span class="at">color =</span> <span class="st">"Group"</span>) <span class="sc">+</span></span>
<span id="cb9-9"><a href="#cb9-9" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb9-10"><a href="#cb9-10" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-11"><a href="#cb9-11" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-12"><a href="#cb9-12" aria-hidden="true" tabindex="-1"></a><span class="co"># T-score plot</span></span>
<span id="cb9-13"><a href="#cb9-13" aria-hidden="true" tabindex="-1"></a>tscore_plot <span class="ot">&lt;-</span> plot_df <span class="sc">%&gt;%</span></span>
<span id="cb9-14"><a href="#cb9-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(Metric <span class="sc">==</span> <span class="st">"tscore"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb9-15"><a href="#cb9-15" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> Time, <span class="at">y =</span> Value, <span class="at">group =</span> treatment_group, <span class="at">color =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb9-16"><a href="#cb9-16" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun =</span> mean, <span class="at">geom =</span> <span class="st">"line"</span>, <span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb9-17"><a href="#cb9-17" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun.data =</span> mean_se, <span class="at">geom =</span> <span class="st">"errorbar"</span>, <span class="at">width =</span> <span class="fl">0.2</span>) <span class="sc">+</span></span>
<span id="cb9-18"><a href="#cb9-18" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb9-19"><a href="#cb9-19" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Lumbar Spine T-score over time"</span>, <span class="at">x =</span> <span class="st">"Timepoint"</span>, <span class="at">y =</span> <span class="st">"T-score"</span>, <span class="at">color =</span> <span class="st">"Group"</span>) <span class="sc">+</span></span>
<span id="cb9-20"><a href="#cb9-20" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb9-21"><a href="#cb9-21" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-22"><a href="#cb9-22" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb9-23"><a href="#cb9-23" aria-hidden="true" tabindex="-1"></a><span class="co"># Combine plots side by side</span></span>
<span id="cb9-24"><a href="#cb9-24" aria-hidden="true" tabindex="-1"></a>bmd_plot <span class="sc">+</span> tscore_plot <span class="sc">+</span> </span>
<span id="cb9-25"><a href="#cb9-25" aria-hidden="true" tabindex="-1"></a>  <span class="fu">plot_layout</span>(<span class="at">ncol =</span> <span class="dv">2</span>) <span class="sc">+</span> </span>
<span id="cb9-26"><a href="#cb9-26" aria-hidden="true" tabindex="-1"></a>  <span class="fu">plot_annotation</span>(</span>
<span id="cb9-27"><a href="#cb9-27" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Lumbar Spine Bone Health Over Time"</span>,</span>
<span id="cb9-28"><a href="#cb9-28" aria-hidden="true" tabindex="-1"></a>    <span class="at">subtitle =</span> <span class="st">"BMD (g/cm²) and T-score trends by treatment group"</span></span>
<span id="cb9-29"><a href="#cb9-29" aria-hidden="true" tabindex="-1"></a>  )</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<div>
<figure class="figure">
<p><img src="poe_bone_health_phase_2_files/figure-html/unnamed-chunk-9-1.png" class="img-fluid figure-img" width="1152"></p>
</figure>
</div>
</div>
</div>
<p>This below bar plot shows the proportion of patients experiencing a fracture in the treatment versus control groups over the study period. Fracture rates are calculated as the mean of the binary fracture_event variable within each group. The plot indicates that the treatment group has a lower fracture incidence compared to control, suggesting that the therapy effectively reduces fracture risk.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb10"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb10-1"><a href="#cb10-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Fracture incidence bar plot</span></span>
<span id="cb10-2"><a href="#cb10-2" aria-hidden="true" tabindex="-1"></a>fracture_df <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span></span>
<span id="cb10-3"><a href="#cb10-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(treatment_group) <span class="sc">%&gt;%</span></span>
<span id="cb10-4"><a href="#cb10-4" aria-hidden="true" tabindex="-1"></a>  <span class="fu">summarise</span>(</span>
<span id="cb10-5"><a href="#cb10-5" aria-hidden="true" tabindex="-1"></a>    <span class="at">Fracture_Rate =</span> <span class="fu">mean</span>(fracture_event)</span>
<span id="cb10-6"><a href="#cb10-6" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb10-7"><a href="#cb10-7" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb10-8"><a href="#cb10-8" aria-hidden="true" tabindex="-1"></a>fracture_plot <span class="ot">&lt;-</span> <span class="fu">ggplot</span>(fracture_df, <span class="fu">aes</span>(<span class="at">x =</span> treatment_group, <span class="at">y =</span> Fracture_Rate, <span class="at">fill =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb10-9"><a href="#cb10-9" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_col</span>(<span class="at">width =</span> <span class="fl">0.6</span>) <span class="sc">+</span></span>
<span id="cb10-10"><a href="#cb10-10" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_fill_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb10-11"><a href="#cb10-11" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Fracture Incidence by Treatment Group"</span>, <span class="at">x =</span> <span class="st">"Group"</span>, <span class="at">y =</span> <span class="st">"Proportion"</span>) <span class="sc">+</span></span>
<span id="cb10-12"><a href="#cb10-12" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>) <span class="sc">+</span></span>
<span id="cb10-13"><a href="#cb10-13" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_text</span>(<span class="fu">aes</span>(<span class="at">label =</span> scales<span class="sc">::</span><span class="fu">percent</span>(Fracture_Rate, <span class="at">accuracy =</span> <span class="fl">0.1</span>)), <span class="at">vjust =</span> <span class="sc">-</span><span class="fl">0.5</span>) <span class="sc">+</span></span>
<span id="cb10-14"><a href="#cb10-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme</span>(<span class="at">legend.position =</span> <span class="st">"none"</span>)</span>
<span id="cb10-15"><a href="#cb10-15" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb10-16"><a href="#cb10-16" aria-hidden="true" tabindex="-1"></a>fracture_plot</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<div>
<figure class="figure">
<p><img src="poe_bone_health_phase_2_files/figure-html/unnamed-chunk-10-1.png" class="img-fluid figure-img" width="672"></p>
</figure>
</div>
</div>
</div>
<p>The simulated trial demonstrates that the treatment group experienced meaningful improvements in lumbar spine BMD over 24 months, with gains strongly related to adherence. High adherence patients increased from 0.846g/cm² at baseline to 0.892g/cm² at 24 months, representing a 5.4% increase, while moderate and poor adherence groups showed smaller gains of 3.4% and 1.6%, respectively. Discontinued patients had a modest 1.1% increase, whereas the control group declined slightly from 0.858g/cm² to 0.845g/cm² (−1.6%), reflecting stable or deteriorating bone health without therapy.</p>
<p>These differences highlight the efficacy of the study drug in improving skeletal outcomes. Coupled with lower simulated fracture incidence in the treated cohort, these results provide a clear foundation for the commercial simulation: treatment benefits translate into measurable risk reduction, inform the addressable population, and support revenue projections. The next phase models how enhanced screening and treatment adoption propagate these health gains into financial and market impact.</p>
</section>
</section>
<section id="commercial-analytics" class="level3">
<h3 class="anchored" data-anchor-id="commercial-analytics">Commercial Analytics</h3>
<p>The commercial analytics section translates the simulated clinical trial into market-focused insights. Using the estimated addressable population, screening eligibility, and treatment uptake assumptions, this analysis models drug costs, revenue potential, and market size. The objective is to quantify how the therapy could perform commercially based on population-level adoption and projected patient numbers, providing a foundation for financial and strategic decision-making.</p>
<section id="simulating-commercial-data" class="level4">
<h4 class="anchored" data-anchor-id="simulating-commercial-data">Simulating commercial data</h4>
<p>Similarly to the clinical treatment assumptions, various assumptions were made in order to model the commercial aspects of this project. The below table outlines the key assumptions used in the OsteoGuard market simulation, including treatment pricing, manufacturing costs, and projected market uptake. Each parameter is supported by a reference or rationale, providing transparency and context for the subsequent financial and market impact analyses.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb11"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb11-1"><a href="#cb11-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Commercial assumptions table</span></span>
<span id="cb11-2"><a href="#cb11-2" aria-hidden="true" tabindex="-1"></a>commercial_assumptions_tbl <span class="ot">&lt;-</span> <span class="fu">tribble</span>(</span>
<span id="cb11-3"><a href="#cb11-3" aria-hidden="true" tabindex="-1"></a>  <span class="sc">~</span>Parameter, <span class="sc">~</span>Assumption, <span class="sc">~</span>Reference, <span class="sc">~</span><span class="st">`</span><span class="at">Why it's reasonable</span><span class="st">`</span>,</span>
<span id="cb11-4"><a href="#cb11-4" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-5"><a href="#cb11-5" aria-hidden="true" tabindex="-1"></a><span class="co"># Drug pricing</span></span>
<span id="cb11-6"><a href="#cb11-6" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly treatment price"</span>,</span>
<span id="cb11-7"><a href="#cb11-7" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$10.49"</span>,</span>
<span id="cb11-8"><a href="#cb11-8" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Generic bisphosphonate pricing per month (drugs.com)"</span>,</span>
<span id="cb11-9"><a href="#cb11-9" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents a conservative generic price suitable for scenario modelling."</span>,</span>
<span id="cb11-10"><a href="#cb11-10" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-11"><a href="#cb11-11" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Annual treatment cost (per patient)"</span>,</span>
<span id="cb11-12"><a href="#cb11-12" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$125.88"</span>,</span>
<span id="cb11-13"><a href="#cb11-13" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived from monthly pricing"</span>,</span>
<span id="cb11-14"><a href="#cb11-14" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Simple arithmetic derivation used for transparent cost modelling."</span>,</span>
<span id="cb11-15"><a href="#cb11-15" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-16"><a href="#cb11-16" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Manufacturing cost per patient/month"</span>,</span>
<span id="cb11-17"><a href="#cb11-17" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$1.04"</span>,</span>
<span id="cb11-18"><a href="#cb11-18" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Pharmaceutical Drug Prices and Trends for ALENDRONATE SODIUM, 2026 (drugpatentwatch.com)"</span>,</span>
<span id="cb11-19"><a href="#cb11-19" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Estimation of manufacturing cost based on limited available information."</span>,</span>
<span id="cb11-20"><a href="#cb11-20" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-21"><a href="#cb11-21" aria-hidden="true" tabindex="-1"></a> <span class="co"># Uptake &amp; market penetration</span></span>
<span id="cb11-22"><a href="#cb11-22" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Initial adoption (Month 1)"</span>,</span>
<span id="cb11-23"><a href="#cb11-23" aria-hidden="true" tabindex="-1"></a>  <span class="st">"10,000 patients"</span>,</span>
<span id="cb11-24"><a href="#cb11-24" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled starting point for simulation"</span>,</span>
<span id="cb11-25"><a href="#cb11-25" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects a realistic early adoption starting population for a new therapy."</span>,</span>
<span id="cb11-26"><a href="#cb11-26" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-27"><a href="#cb11-27" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Eligible population (high-risk, untreated adults)"</span>,</span>
<span id="cb11-28"><a href="#cb11-28" aria-hidden="true" tabindex="-1"></a>  <span class="st">"38,000,000"</span>,</span>
<span id="cb11-29"><a href="#cb11-29" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived from US adult population analysis"</span>,</span>
<span id="cb11-30"><a href="#cb11-30" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents total missed high-risk cohort; treatable pool assumed to be 50% (~19M patients), reflecting that not all high-risk adults will be eligible, willing, or clinically appropriate for therapy due to contraindications, comorbidities, or personal choice."</span>,</span>
<span id="cb11-31"><a href="#cb11-31" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-32"><a href="#cb11-32" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly conversion rate of untreated pool"</span>,</span>
<span id="cb11-33"><a href="#cb11-33" aria-hidden="true" tabindex="-1"></a>  <span class="st">"0.8%"</span>,</span>
<span id="cb11-34"><a href="#cb11-34" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb11-35"><a href="#cb11-35" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Slightly optimistic monthly uptake (~8-10% per year) under an aggressive screening program."</span>,</span>
<span id="cb11-36"><a href="#cb11-36" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-37"><a href="#cb11-37" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Market share ramp"</span>,</span>
<span id="cb11-38"><a href="#cb11-38" aria-hidden="true" tabindex="-1"></a>  <span class="st">"8% → 20% over 5 years"</span>,</span>
<span id="cb11-39"><a href="#cb11-39" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb11-40"><a href="#cb11-40" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Gradual adoption of the drug among new starts; logistic ramp reflects early adoption and plateau."</span>,</span>
<span id="cb11-41"><a href="#cb11-41" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-42"><a href="#cb11-42" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly persistence / attrition"</span>,</span>
<span id="cb11-43"><a href="#cb11-43" aria-hidden="true" tabindex="-1"></a>  <span class="st">"97%"</span>,</span>
<span id="cb11-44"><a href="#cb11-44" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb11-45"><a href="#cb11-45" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects real-world oral bisphosphonate discontinuation (~70% annual retention)."</span>,</span>
<span id="cb11-46"><a href="#cb11-46" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-47"><a href="#cb11-47" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Annual growth in market penetration"</span>,</span>
<span id="cb11-48"><a href="#cb11-48" aria-hidden="true" tabindex="-1"></a>  <span class="st">"logistic ramp"</span>,</span>
<span id="cb11-49"><a href="#cb11-49" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb11-50"><a href="#cb11-50" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Aligns with typical treatment adoption curves; incorporates finite pool constraints."</span>,</span>
<span id="cb11-51"><a href="#cb11-51" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-52"><a href="#cb11-52" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Customer Acquisition Cost (CAC)"</span>, </span>
<span id="cb11-53"><a href="#cb11-53" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$100"</span>,</span>
<span id="cb11-54"><a href="#cb11-54" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Market assumption"</span>,</span>
<span id="cb11-55"><a href="#cb11-55" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled estimate combining screening, physician engagement, onboarding; reflects typical early adoption cost for a preventive osteoporosis therapy targeting a small high-risk cohort"</span>,</span>
<span id="cb11-56"><a href="#cb11-56" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-57"><a href="#cb11-57" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Simulation horizon"</span>,</span>
<span id="cb11-58"><a href="#cb11-58" aria-hidden="true" tabindex="-1"></a>  <span class="st">"5 years / 60 months"</span>,</span>
<span id="cb11-59"><a href="#cb11-59" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Project timeline"</span>,</span>
<span id="cb11-60"><a href="#cb11-60" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Long enough to capture ramp, plateau, and early profitability dynamics."</span></span>
<span id="cb11-61"><a href="#cb11-61" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb11-62"><a href="#cb11-62" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb11-63"><a href="#cb11-63" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-64"><a href="#cb11-64" aria-hidden="true" tabindex="-1"></a><span class="co"># Render table</span></span>
<span id="cb11-65"><a href="#cb11-65" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(</span>
<span id="cb11-66"><a href="#cb11-66" aria-hidden="true" tabindex="-1"></a>  commercial_assumptions_tbl,</span>
<span id="cb11-67"><a href="#cb11-67" aria-hidden="true" tabindex="-1"></a>  <span class="at">format =</span> <span class="st">"html"</span>,</span>
<span id="cb11-68"><a href="#cb11-68" aria-hidden="true" tabindex="-1"></a>  <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Parameter"</span>, <span class="st">"Assumption"</span>,</span>
<span id="cb11-69"><a href="#cb11-69" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Reference"</span>, <span class="st">"Why it's reasonable"</span>),</span>
<span id="cb11-70"><a href="#cb11-70" aria-hidden="true" tabindex="-1"></a>  <span class="at">align =</span> <span class="st">"l"</span>,</span>
<span id="cb11-71"><a href="#cb11-71" aria-hidden="true" tabindex="-1"></a>  <span class="at">caption =</span> <span class="st">"Commercial assumptions for OsteoGuard market modelling"</span></span>
<span id="cb11-72"><a href="#cb11-72" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb11-73"><a href="#cb11-73" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb11-74"><a href="#cb11-74" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb11-75"><a href="#cb11-75" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="st">"condensed"</span>,</span>
<span id="cb11-76"><a href="#cb11-76" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb11-77"><a href="#cb11-77" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb11-78"><a href="#cb11-78" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb11-79"><a href="#cb11-79" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">width =</span> <span class="st">"22em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb11-80"><a href="#cb11-80" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"14em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb11-81"><a href="#cb11-81" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">3</span>, <span class="at">width =</span> <span class="st">"20em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb11-82"><a href="#cb11-82" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">4</span>, <span class="at">width =</span> <span class="st">"28em"</span>)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="table table-condensed caption-top table-sm table-striped small">
<caption>Commercial assumptions for OsteoGuard market modelling</caption>
<thead>
<tr class="header">
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Parameter</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Assumption</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Reference</th>
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Why it's reasonable</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Monthly treatment price</td>
<td style="text-align: left; width: 14em;">$10.49</td>
<td style="text-align: left; width: 20em;">Generic bisphosphonate pricing per month (drugs.com)</td>
<td style="text-align: left; width: 28em;">Represents a conservative generic price suitable for scenario modelling.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 22em; font-weight: bold;">Annual treatment cost (per patient)</td>
<td style="text-align: left; width: 14em;">$125.88</td>
<td style="text-align: left; width: 20em;">Derived from monthly pricing</td>
<td style="text-align: left; width: 28em;">Simple arithmetic derivation used for transparent cost modelling.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Manufacturing cost per patient/month</td>
<td style="text-align: left; width: 14em;">$1.04</td>
<td style="text-align: left; width: 20em;">Pharmaceutical Drug Prices and Trends for ALENDRONATE SODIUM, 2026 (drugpatentwatch.com)</td>
<td style="text-align: left; width: 28em;">Estimation of manufacturing cost based on limited available information.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 22em; font-weight: bold;">Initial adoption (Month 1)</td>
<td style="text-align: left; width: 14em;">10,000 patients</td>
<td style="text-align: left; width: 20em;">Modeled starting point for simulation</td>
<td style="text-align: left; width: 28em;">Reflects a realistic early adoption starting population for a new therapy.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Eligible population (high-risk, untreated adults)</td>
<td style="text-align: left; width: 14em;">38,000,000</td>
<td style="text-align: left; width: 20em;">Derived from US adult population analysis</td>
<td style="text-align: left; width: 28em;">Represents total missed high-risk cohort; treatable pool assumed to be 50% (~19M patients), reflecting that not all high-risk adults will be eligible, willing, or clinically appropriate for therapy due to contraindications, comorbidities, or personal choice.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 22em; font-weight: bold;">Monthly conversion rate of untreated pool</td>
<td style="text-align: left; width: 14em;">0.8%</td>
<td style="text-align: left; width: 20em;">Modeled assumption</td>
<td style="text-align: left; width: 28em;">Slightly optimistic monthly uptake (~8-10% per year) under an aggressive screening program.</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Market share ramp</td>
<td style="text-align: left; width: 14em;">8% → 20% over 5 years</td>
<td style="text-align: left; width: 20em;">Modeled assumption</td>
<td style="text-align: left; width: 28em;">Gradual adoption of the drug among new starts; logistic ramp reflects early adoption and plateau.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 22em; font-weight: bold;">Monthly persistence / attrition</td>
<td style="text-align: left; width: 14em;">97%</td>
<td style="text-align: left; width: 20em;">Modeled assumption</td>
<td style="text-align: left; width: 28em;">Reflects real-world oral bisphosphonate discontinuation (~70% annual retention).</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Annual growth in market penetration</td>
<td style="text-align: left; width: 14em;">logistic ramp</td>
<td style="text-align: left; width: 20em;">Modeled assumption</td>
<td style="text-align: left; width: 28em;">Aligns with typical treatment adoption curves; incorporates finite pool constraints.</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 22em; font-weight: bold;">Customer Acquisition Cost (CAC)</td>
<td style="text-align: left; width: 14em;">$100</td>
<td style="text-align: left; width: 20em;">Market assumption</td>
<td style="text-align: left; width: 28em;">Modeled estimate combining screening, physician engagement, onboarding; reflects typical early adoption cost for a preventive osteoporosis therapy targeting a small high-risk cohort</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 22em; font-weight: bold;">Simulation horizon</td>
<td style="text-align: left; width: 14em;">5 years / 60 months</td>
<td style="text-align: left; width: 20em;">Project timeline</td>
<td style="text-align: left; width: 28em;">Long enough to capture ramp, plateau, and early profitability dynamics.</td>
</tr>
</tbody>
</table>
</div>
</div>
<p>The commercial simulation projects patient uptake, market penetration, and financial outcomes for a hypothetical oral weekly bisphosphonate targeting high-risk, unscreened U.S. adults. The model scales from the estimated 38 million adults aged ≥20 who are currently high-risk but not captured under existing age-based screening criteria, of which approximately 50% are realistically treatable (~19 million).</p>
<p>Monthly patient starts are initialized at 10,000, reflecting a conservative early adoption launch, and new patient uptake is modeled as a fraction of the remaining untreated pool (0.8% per month), adjusted for the drug’s logistic market share ramp from 8% to 20% over 5 years. Active patients are updated monthly using a persistence factor of 97% per month (~70% annual retention), reflecting real-world discontinuation rates for oral bisphosphonates. Revenue is calculated as active patients multiplied by the monthly treatment price ($10.49), while costs combine manufacturing ($1.04 per patient per month) and one-time customer acquisition costs ($100 per new patient). The simulation horizon is 5 years, and adoption is assumed to increase gradually before plateauing at 50% of the eligible treatable population. This approach provides a data-driven estimate of the addressable market, demonstrating how expanded screening and optimized treatment adoption could translate into measurable economic impact over a realistic commercial rollout period.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb12"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb12-1"><a href="#cb12-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulating commercial dataset</span></span>
<span id="cb12-2"><a href="#cb12-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-3"><a href="#cb12-3" aria-hidden="true" tabindex="-1"></a><span class="co"># Inputs</span></span>
<span id="cb12-4"><a href="#cb12-4" aria-hidden="true" tabindex="-1"></a>months <span class="ot">&lt;-</span> <span class="dv">0</span><span class="sc">:</span><span class="dv">60</span>                    <span class="co"># 5 years</span></span>
<span id="cb12-5"><a href="#cb12-5" aria-hidden="true" tabindex="-1"></a>addressable_pool <span class="ot">&lt;-</span> <span class="fl">0.5</span><span class="sc">*</span><span class="dv">38000000</span>  <span class="co"># 50% of 38M</span></span>
<span id="cb12-6"><a href="#cb12-6" aria-hidden="true" tabindex="-1"></a>start_patients <span class="ot">&lt;-</span> <span class="dv">10000</span>           <span class="co"># assumption of realistic starting point</span></span>
<span id="cb12-7"><a href="#cb12-7" aria-hidden="true" tabindex="-1"></a>monthly_conversion <span class="ot">&lt;-</span> <span class="fl">0.008</span>       <span class="co"># 0.8% of untreated pool per month</span></span>
<span id="cb12-8"><a href="#cb12-8" aria-hidden="true" tabindex="-1"></a>initial_share <span class="ot">&lt;-</span> <span class="fl">0.08</span></span>
<span id="cb12-9"><a href="#cb12-9" aria-hidden="true" tabindex="-1"></a>max_share <span class="ot">&lt;-</span> <span class="fl">0.20</span></span>
<span id="cb12-10"><a href="#cb12-10" aria-hidden="true" tabindex="-1"></a>share_ramp_speed <span class="ot">&lt;-</span> <span class="fl">0.06</span>           <span class="co"># logistic ramp</span></span>
<span id="cb12-11"><a href="#cb12-11" aria-hidden="true" tabindex="-1"></a>monthly_persistence <span class="ot">&lt;-</span> <span class="fl">0.97</span>       <span class="co"># ~70% annual</span></span>
<span id="cb12-12"><a href="#cb12-12" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-13"><a href="#cb12-13" aria-hidden="true" tabindex="-1"></a>price_per_month <span class="ot">&lt;-</span> <span class="fl">10.49</span></span>
<span id="cb12-14"><a href="#cb12-14" aria-hidden="true" tabindex="-1"></a>costprice_per_month <span class="ot">&lt;-</span> <span class="fl">1.04</span></span>
<span id="cb12-15"><a href="#cb12-15" aria-hidden="true" tabindex="-1"></a>CAC <span class="ot">&lt;-</span> <span class="dv">100</span></span>
<span id="cb12-16"><a href="#cb12-16" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-17"><a href="#cb12-17" aria-hidden="true" tabindex="-1"></a><span class="co"># Initialize dataframe</span></span>
<span id="cb12-18"><a href="#cb12-18" aria-hidden="true" tabindex="-1"></a>commercial_df <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(<span class="at">month =</span> months) <span class="sc">%&gt;%</span></span>
<span id="cb12-19"><a href="#cb12-19" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb12-20"><a href="#cb12-20" aria-hidden="true" tabindex="-1"></a>    <span class="at">market_share =</span> max_share <span class="sc">/</span> (<span class="dv">1</span> <span class="sc">+</span> <span class="fu">exp</span>(<span class="sc">-</span>share_ramp_speed <span class="sc">*</span> (month <span class="sc">-</span> <span class="dv">18</span>))),</span>
<span id="cb12-21"><a href="#cb12-21" aria-hidden="true" tabindex="-1"></a>    <span class="at">untreated_pool =</span> <span class="cn">NA</span>,</span>
<span id="cb12-22"><a href="#cb12-22" aria-hidden="true" tabindex="-1"></a>    <span class="at">new_patients =</span> <span class="cn">NA</span>,</span>
<span id="cb12-23"><a href="#cb12-23" aria-hidden="true" tabindex="-1"></a>    <span class="at">active_patients =</span> <span class="cn">NA</span></span>
<span id="cb12-24"><a href="#cb12-24" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb12-25"><a href="#cb12-25" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-26"><a href="#cb12-26" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulation loop</span></span>
<span id="cb12-27"><a href="#cb12-27" aria-hidden="true" tabindex="-1"></a>untreated <span class="ot">&lt;-</span> addressable_pool</span>
<span id="cb12-28"><a href="#cb12-28" aria-hidden="true" tabindex="-1"></a>active <span class="ot">&lt;-</span> start_patients</span>
<span id="cb12-29"><a href="#cb12-29" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-30"><a href="#cb12-30" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (m <span class="cf">in</span> <span class="dv">1</span><span class="sc">:</span><span class="fu">nrow</span>(commercial_df)) {</span>
<span id="cb12-31"><a href="#cb12-31" aria-hidden="true" tabindex="-1"></a>  share <span class="ot">&lt;-</span> commercial_df<span class="sc">$</span>market_share[m]</span>
<span id="cb12-32"><a href="#cb12-32" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb12-33"><a href="#cb12-33" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Total new treated patients in the market this month</span></span>
<span id="cb12-34"><a href="#cb12-34" aria-hidden="true" tabindex="-1"></a>  total_new_market <span class="ot">&lt;-</span> untreated <span class="sc">*</span> monthly_conversion</span>
<span id="cb12-35"><a href="#cb12-35" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb12-36"><a href="#cb12-36" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Patients captured by our drug</span></span>
<span id="cb12-37"><a href="#cb12-37" aria-hidden="true" tabindex="-1"></a>  new_pts <span class="ot">&lt;-</span> total_new_market <span class="sc">*</span> share</span>
<span id="cb12-38"><a href="#cb12-38" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb12-39"><a href="#cb12-39" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Update active patients with attrition</span></span>
<span id="cb12-40"><a href="#cb12-40" aria-hidden="true" tabindex="-1"></a>  active <span class="ot">&lt;-</span> active <span class="sc">*</span> monthly_persistence <span class="sc">+</span> new_pts</span>
<span id="cb12-41"><a href="#cb12-41" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb12-42"><a href="#cb12-42" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Update untreated pool</span></span>
<span id="cb12-43"><a href="#cb12-43" aria-hidden="true" tabindex="-1"></a>  untreated <span class="ot">&lt;-</span> untreated <span class="sc">-</span> total_new_market</span>
<span id="cb12-44"><a href="#cb12-44" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb12-45"><a href="#cb12-45" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>new_patients[m] <span class="ot">&lt;-</span> new_pts</span>
<span id="cb12-46"><a href="#cb12-46" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>active_patients[m] <span class="ot">&lt;-</span> active</span>
<span id="cb12-47"><a href="#cb12-47" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>untreated_pool[m] <span class="ot">&lt;-</span> untreated</span>
<span id="cb12-48"><a href="#cb12-48" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb12-49"><a href="#cb12-49" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb12-50"><a href="#cb12-50" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate revenue, cost, profit</span></span>
<span id="cb12-51"><a href="#cb12-51" aria-hidden="true" tabindex="-1"></a>commercial_df <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb12-52"><a href="#cb12-52" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb12-53"><a href="#cb12-53" aria-hidden="true" tabindex="-1"></a>    <span class="at">revenue =</span> active_patients <span class="sc">*</span> price_per_month,</span>
<span id="cb12-54"><a href="#cb12-54" aria-hidden="true" tabindex="-1"></a>    <span class="at">cost =</span> (active_patients <span class="sc">*</span> costprice_per_month) <span class="sc">+</span> (new_patients <span class="sc">*</span> CAC),</span>
<span id="cb12-55"><a href="#cb12-55" aria-hidden="true" tabindex="-1"></a>    <span class="at">profit =</span> revenue <span class="sc">-</span> cost</span>
<span id="cb12-56"><a href="#cb12-56" aria-hidden="true" tabindex="-1"></a>  )</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
</div>
</section>
<section id="analysis-1" class="level4">
<h4 class="anchored" data-anchor-id="analysis-1">Analysis</h4>
<p>The commercial analysis quantifies projected market performance of OsteoGuard over key time points. Using the estimated addressable population of 38 million, treatment uptake, and pricing assumptions, this summary focuses on captured patients, revenue, costs, and profit at months 1, 12, 24, 36, 48, and 60.</p>
<p>The per-patient monthly economics for OsteoGuard are shown below. Each patient generates approximately $10.49 in revenue per month, with an estimated manufacturing and distribution cost of $1.04, resulting in a monthly profit of $9.45 per patient excluding acquisition costs. These figures highlight the strong unit economics of the therapy, providing a foundation for projecting cumulative revenue and profit as treatment uptake grows.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb13"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb13-1"><a href="#cb13-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Monthly economics per patient</span></span>
<span id="cb13-2"><a href="#cb13-2" aria-hidden="true" tabindex="-1"></a><span class="co"># Define per-patient monthly economics</span></span>
<span id="cb13-3"><a href="#cb13-3" aria-hidden="true" tabindex="-1"></a>per_patient_tbl <span class="ot">&lt;-</span> <span class="fu">tibble</span>(</span>
<span id="cb13-4"><a href="#cb13-4" aria-hidden="true" tabindex="-1"></a>  <span class="st">`</span><span class="at">Parameter</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">c</span>(<span class="st">"Monthly revenue per patient"</span>, </span>
<span id="cb13-5"><a href="#cb13-5" aria-hidden="true" tabindex="-1"></a>                  <span class="st">"Monthly manufacturing/distribution cost per patient"</span>, </span>
<span id="cb13-6"><a href="#cb13-6" aria-hidden="true" tabindex="-1"></a>                  <span class="st">"Monthly profit per patient"</span>),</span>
<span id="cb13-7"><a href="#cb13-7" aria-hidden="true" tabindex="-1"></a>  <span class="st">`</span><span class="at">Value ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">c</span>(price_per_month, costprice_per_month, price_per_month <span class="sc">-</span> costprice_per_month)</span>
<span id="cb13-8"><a href="#cb13-8" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb13-9"><a href="#cb13-9" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb13-10"><a href="#cb13-10" aria-hidden="true" tabindex="-1"></a><span class="co"># Render the table with kable</span></span>
<span id="cb13-11"><a href="#cb13-11" aria-hidden="true" tabindex="-1"></a>per_patient_tbl <span class="sc">%&gt;%</span></span>
<span id="cb13-12"><a href="#cb13-12" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kbl</span>(</span>
<span id="cb13-13"><a href="#cb13-13" aria-hidden="true" tabindex="-1"></a>    <span class="at">caption =</span> <span class="st">"Per-Patient Monthly Economics for OsteoGuard"</span>,</span>
<span id="cb13-14"><a href="#cb13-14" aria-hidden="true" tabindex="-1"></a>    <span class="at">digits =</span> <span class="dv">2</span>,</span>
<span id="cb13-15"><a href="#cb13-15" aria-hidden="true" tabindex="-1"></a>    <span class="at">align =</span> <span class="fu">c</span>(<span class="st">"l"</span>, <span class="st">"r"</span>)</span>
<span id="cb13-16"><a href="#cb13-16" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb13-17"><a href="#cb13-17" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb13-18"><a href="#cb13-18" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb13-19"><a href="#cb13-19" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>),</span>
<span id="cb13-20"><a href="#cb13-20" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb13-21"><a href="#cb13-21" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb13-22"><a href="#cb13-22" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb13-23"><a href="#cb13-23" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> F, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb13-24"><a href="#cb13-24" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"8em"</span>)</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="table table-condensed table-hover caption-top table-sm table-striped small">
<caption>Per-Patient Monthly Economics for OsteoGuard</caption>
<thead>
<tr class="header">
<th data-quarto-table-cell-role="th" style="text-align: left; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Parameter</th>
<th data-quarto-table-cell-role="th" style="text-align: right; font-weight: bold; background-color: rgba(245, 245, 245, 255) !important;">Value ($)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left; width: 18em;">Monthly revenue per patient</td>
<td style="text-align: right; width: 8em;">10.49</td>
</tr>
<tr class="even">
<td style="text-align: left; width: 18em;">Monthly manufacturing/distribution cost per patient</td>
<td style="text-align: right; width: 8em;">1.04</td>
</tr>
<tr class="odd">
<td style="text-align: left; width: 18em;">Monthly profit per patient</td>
<td style="text-align: right; width: 8em;">9.45</td>
</tr>
</tbody>
</table>
</div>
</div>
<p>Using this per patient profit per month and an estimation of Customer Acquisition Cost (CAC) we can calculate the ratio of cost to lifetime value (LTV). The financial summary indicates that with a CAC of $100 and an average treatment duration of 60 months, OsteoGuard generates an LTV of approximately $567 per patient. This produces a strong CAC:LTV ratio (5.67), suggesting that for every dollar spent acquiring a patient, the therapy is projected to return about $5.67 in profit — highlighting solid commercial potential under the current assumptions.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb14"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb14-1"><a href="#cb14-1" aria-hidden="true" tabindex="-1"></a><span class="co"># CAC:LTV</span></span>
<span id="cb14-2"><a href="#cb14-2" aria-hidden="true" tabindex="-1"></a><span class="co"># Known values</span></span>
<span id="cb14-3"><a href="#cb14-3" aria-hidden="true" tabindex="-1"></a>monthly_profit <span class="ot">&lt;-</span> <span class="fl">9.45</span>         <span class="co"># $ per patient</span></span>
<span id="cb14-4"><a href="#cb14-4" aria-hidden="true" tabindex="-1"></a>avg_treatment_months <span class="ot">&lt;-</span> <span class="dv">60</span>     <span class="co"># 5 years</span></span>
<span id="cb14-5"><a href="#cb14-5" aria-hidden="true" tabindex="-1"></a>CAC <span class="ot">&lt;-</span> <span class="dv">100</span>                      <span class="co"># assumed per patient acquisition cost</span></span>
<span id="cb14-6"><a href="#cb14-6" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-7"><a href="#cb14-7" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-8"><a href="#cb14-8" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate Lifetime Value</span></span>
<span id="cb14-9"><a href="#cb14-9" aria-hidden="true" tabindex="-1"></a>LTV <span class="ot">&lt;-</span> monthly_profit <span class="sc">*</span> avg_treatment_months</span>
<span id="cb14-10"><a href="#cb14-10" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-11"><a href="#cb14-11" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate CAC:LTV ratio</span></span>
<span id="cb14-12"><a href="#cb14-12" aria-hidden="true" tabindex="-1"></a>CAC_LTV_ratio <span class="ot">&lt;-</span> LTV <span class="sc">/</span> CAC</span>
<span id="cb14-13"><a href="#cb14-13" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-14"><a href="#cb14-14" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-15"><a href="#cb14-15" aria-hidden="true" tabindex="-1"></a><span class="co"># Build a data frame</span></span>
<span id="cb14-16"><a href="#cb14-16" aria-hidden="true" tabindex="-1"></a>financial_summary <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(</span>
<span id="cb14-17"><a href="#cb14-17" aria-hidden="true" tabindex="-1"></a>  <span class="at">Parameter =</span> <span class="fu">c</span>(<span class="st">"Customer Acquisition Cost (CAC)"</span>,</span>
<span id="cb14-18"><a href="#cb14-18" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Profit per Patient per Month"</span>,</span>
<span id="cb14-19"><a href="#cb14-19" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Average Treatment Duration (months)"</span>,</span>
<span id="cb14-20"><a href="#cb14-20" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Lifetime Value (LTV)"</span>,</span>
<span id="cb14-21"><a href="#cb14-21" aria-hidden="true" tabindex="-1"></a>                <span class="st">"CAC:LTV Ratio"</span>),</span>
<span id="cb14-22"><a href="#cb14-22" aria-hidden="true" tabindex="-1"></a>  <span class="at">Value =</span> <span class="fu">c</span>(CAC,</span>
<span id="cb14-23"><a href="#cb14-23" aria-hidden="true" tabindex="-1"></a>            monthly_profit,</span>
<span id="cb14-24"><a href="#cb14-24" aria-hidden="true" tabindex="-1"></a>            avg_treatment_months,</span>
<span id="cb14-25"><a href="#cb14-25" aria-hidden="true" tabindex="-1"></a>            <span class="fu">round</span>(LTV, <span class="dv">2</span>),</span>
<span id="cb14-26"><a href="#cb14-26" aria-hidden="true" tabindex="-1"></a>            <span class="fu">round</span>(CAC_LTV_ratio, <span class="dv">2</span>))</span>
<span id="cb14-27"><a href="#cb14-27" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb14-28"><a href="#cb14-28" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb14-29"><a href="#cb14-29" aria-hidden="true" tabindex="-1"></a><span class="co"># Display as a kable table</span></span>
<span id="cb14-30"><a href="#cb14-30" aria-hidden="true" tabindex="-1"></a><span class="fu">kable</span>(financial_summary, </span>
<span id="cb14-31"><a href="#cb14-31" aria-hidden="true" tabindex="-1"></a>      <span class="at">caption =</span> <span class="st">"Financial Summary for OsteoGuard Phase 2 Simulation"</span>,</span>
<span id="cb14-32"><a href="#cb14-32" aria-hidden="true" tabindex="-1"></a>      <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Metric"</span>, <span class="st">"Value ($)"</span>),</span>
<span id="cb14-33"><a href="#cb14-33" aria-hidden="true" tabindex="-1"></a>      <span class="at">align =</span> <span class="fu">c</span>(<span class="st">"l"</span>,<span class="st">"r"</span>))</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="caption-top table table-sm table-striped small">
<caption>Financial Summary for OsteoGuard Phase 2 Simulation</caption>
<thead>
<tr class="header">
<th style="text-align: left;">Metric</th>
<th style="text-align: right;">Value ($)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;">Customer Acquisition Cost (CAC)</td>
<td style="text-align: right;">100.00</td>
</tr>
<tr class="even">
<td style="text-align: left;">Profit per Patient per Month</td>
<td style="text-align: right;">9.45</td>
</tr>
<tr class="odd">
<td style="text-align: left;">Average Treatment Duration (months)</td>
<td style="text-align: right;">60.00</td>
</tr>
<tr class="even">
<td style="text-align: left;">Lifetime Value (LTV)</td>
<td style="text-align: right;">567.00</td>
</tr>
<tr class="odd">
<td style="text-align: left;">CAC:LTV Ratio</td>
<td style="text-align: right;">5.67</td>
</tr>
</tbody>
</table>
</div>
</div>
<p>This table presents the projected commercial performance of the new bisphosphonate therapy over a 5-year horizon at selected key months (1, 12, 24, 36, 48, 60).</p>
<p>At the start of the simulation, the active patient population is approximately 24,877, generating $260,957 in monthly revenue, though total costs of $825,110 result in an initial loss of $564,152.</p>
<p>By the end of the first year (month 12), active patients grow to 111,691, with revenue reaching $1.17 million and losses reduced to just $79,039.</p>
<p>Over the subsequent years, continued patient uptake and retention drive revenue and profit growth, with 213,899 active patients by month 24, producing $2.24 million in revenue and $544,627 in profit.</p>
<p>By month 36, the patient base reaches 313,361, revenue rises to $3.29 million, and profit exceeds $1.26 million. At month 48, 396,353 patients are actively treated, generating $4.16 million in revenue and $1.97 million in profit, and by the end of year five (month 60), the therapy supports 454,632 active patients, $4.77 million in revenue, and $2.56 million in profit.</p>
<p>The simulation illustrates a realistic adoption curve, where initial losses from customer acquisition costs are offset by steady growth in active patients and revenue, with profitability achieved during the second year and sustained thereafter, highlighting the economic potential of expanding treatment to previously under-identified high-risk adults.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb15"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb15-1"><a href="#cb15-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Summary table</span></span>
<span id="cb15-2"><a href="#cb15-2" aria-hidden="true" tabindex="-1"></a>summary_table <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb15-3"><a href="#cb15-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(month <span class="sc">%in%</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">12</span>, <span class="dv">24</span>, <span class="dv">36</span>, <span class="dv">48</span>, <span class="dv">60</span>)) <span class="sc">%&gt;%</span>  <span class="co"># select key months</span></span>
<span id="cb15-4"><a href="#cb15-4" aria-hidden="true" tabindex="-1"></a>  <span class="fu">transmute</span>(</span>
<span id="cb15-5"><a href="#cb15-5" aria-hidden="true" tabindex="-1"></a>    <span class="at">Month =</span> month,</span>
<span id="cb15-6"><a href="#cb15-6" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Active Patients</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(active_patients),</span>
<span id="cb15-7"><a href="#cb15-7" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Revenue ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(revenue, <span class="dv">1</span>),</span>
<span id="cb15-8"><a href="#cb15-8" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Cost ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(cost, <span class="dv">1</span>),</span>
<span id="cb15-9"><a href="#cb15-9" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Profit ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(profit, <span class="dv">1</span>)</span>
<span id="cb15-10"><a href="#cb15-10" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb15-11"><a href="#cb15-11" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kbl</span>(<span class="at">caption =</span> <span class="st">"Commercial Summary at Key Months"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb15-12"><a href="#cb15-12" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(<span class="at">full_width =</span> <span class="cn">FALSE</span>, <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>))</span>
<span id="cb15-13"><a href="#cb15-13" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb15-14"><a href="#cb15-14" aria-hidden="true" tabindex="-1"></a>summary_table</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<table class="table table-condensed table-hover caption-top table-sm table-striped small">
<caption>Commercial Summary at Key Months</caption>
<thead>
<tr class="header">
<th style="text-align: right;" data-quarto-table-cell-role="th">Month</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Active Patients</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Revenue ($)</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Cost ($)</th>
<th style="text-align: right;" data-quarto-table-cell-role="th">Profit ($)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: right;">1</td>
<td style="text-align: right;">24877</td>
<td style="text-align: right;">260957.3</td>
<td style="text-align: right;">825109.7</td>
<td style="text-align: right;">-564152.4</td>
</tr>
<tr class="even">
<td style="text-align: right;">12</td>
<td style="text-align: right;">111691</td>
<td style="text-align: right;">1171641.7</td>
<td style="text-align: right;">1250680.5</td>
<td style="text-align: right;">-79038.8</td>
</tr>
<tr class="odd">
<td style="text-align: right;">24</td>
<td style="text-align: right;">213899</td>
<td style="text-align: right;">2243804.8</td>
<td style="text-align: right;">1699177.7</td>
<td style="text-align: right;">544627.2</td>
</tr>
<tr class="even">
<td style="text-align: right;">36</td>
<td style="text-align: right;">313361</td>
<td style="text-align: right;">3287158.5</td>
<td style="text-align: right;">2025391.4</td>
<td style="text-align: right;">1261767.1</td>
</tr>
<tr class="odd">
<td style="text-align: right;">48</td>
<td style="text-align: right;">396353</td>
<td style="text-align: right;">4157739.8</td>
<td style="text-align: right;">2186382.0</td>
<td style="text-align: right;">1971357.7</td>
</tr>
<tr class="even">
<td style="text-align: right;">60</td>
<td style="text-align: right;">454632</td>
<td style="text-align: right;">4769087.1</td>
<td style="text-align: right;">2210479.3</td>
<td style="text-align: right;">2558607.8</td>
</tr>
</tbody>
</table>
</div>
</div>
<p>Building on the per-patient and aggregated financial summaries, the below figure illustrates the projected financial performance of the new bisphosphonate therapy over a 5-year (60-month) horizon.</p>
<p>Revenue (dark purple line) steadily increases as the patient base grows, reaching nearly $5 million by month 60.</p>
<p>Costs (lighter purple line) rise initially due to both manufacturing expenses and one-time customer acquisition costs (CAC), then plateau around $2.2 million as new patient starts slow and the active patient pool stabilizes.</p>
<p>Profit (medium purple line) starts negative due to upfront CAC investments but steadily improves, crossing into profitability between months 20 and 25. By year 5, projected profit approaches $2.5 million.</p>
<p>The model reflects realistic commercial dynamics: early losses driven by onboarding costs, gradual patient uptake, and treatment persistence leading to sustained revenue growth. The cost plateau demonstrates diminishing acquisition expenses as market saturation approaches. Overall, the therapy achieves profitability within approximately two years, with strong profit growth through year five, supporting a compelling economic case for expanding osteoporosis treatment to previously under-identified missed high-risk populations.</p>
<div class="cell">
<details class="code-fold">
<summary>Show code</summary>
<div class="code-copy-outer-scaffold"><div class="sourceCode cell-code" id="cb16"><pre class="sourceCode r code-with-copy"><code class="sourceCode r"><span id="cb16-1"><a href="#cb16-1" aria-hidden="true" tabindex="-1"></a><span class="co"># Time-series figure:revenue, cost, and profit</span></span>
<span id="cb16-2"><a href="#cb16-2" aria-hidden="true" tabindex="-1"></a>financial_plot <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb16-3"><a href="#cb16-3" aria-hidden="true" tabindex="-1"></a>  <span class="fu">pivot_longer</span>(<span class="at">cols =</span> <span class="fu">c</span>(revenue, cost, profit), <span class="at">names_to =</span> <span class="st">"Metric"</span>, <span class="at">values_to =</span> <span class="st">"Value"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb16-4"><a href="#cb16-4" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> month, <span class="at">y =</span> Value, <span class="at">color =</span> Metric)) <span class="sc">+</span>  </span>
<span id="cb16-5"><a href="#cb16-5" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_line</span>(<span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb16-6"><a href="#cb16-6" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"revenue"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>, <span class="st">"cost"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"profit"</span> <span class="ot">=</span> <span class="st">"purple"</span>)) <span class="sc">+</span></span>
<span id="cb16-7"><a href="#cb16-7" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_y_continuous</span>(<span class="at">labels =</span> comma) <span class="sc">+</span>  <span class="co"># format with commas</span></span>
<span id="cb16-8"><a href="#cb16-8" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(</span>
<span id="cb16-9"><a href="#cb16-9" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Revenue, Cost, and Profit Over Time"</span>,</span>
<span id="cb16-10"><a href="#cb16-10" aria-hidden="true" tabindex="-1"></a>    <span class="at">x =</span> <span class="st">"Month"</span>,</span>
<span id="cb16-11"><a href="#cb16-11" aria-hidden="true" tabindex="-1"></a>    <span class="at">y =</span> <span class="st">"USD ($)"</span>,</span>
<span id="cb16-12"><a href="#cb16-12" aria-hidden="true" tabindex="-1"></a>    <span class="at">color =</span> <span class="st">"Metric"</span></span>
<span id="cb16-13"><a href="#cb16-13" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">+</span></span>
<span id="cb16-14"><a href="#cb16-14" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb16-15"><a href="#cb16-15" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb16-16"><a href="#cb16-16" aria-hidden="true" tabindex="-1"></a>financial_plot</span></code></pre></div><button title="Copy to Clipboard" class="code-copy-button"><i class="bi"></i></button></div>
</details>
<div class="cell-output-display">
<div>
<figure class="figure">
<p><img src="poe_bone_health_phase_2_files/figure-html/unnamed-chunk-16-1.png" class="img-fluid figure-img" width="672"></p>
</figure>
</div>
</div>
</div>
</section>
</section>
<section id="conclusion" class="level3">
<h3 class="anchored" data-anchor-id="conclusion">Conclusion</h3>
<p>The Phase 2 simulations clearly demonstrate that earlier identification of high-risk patients through improved screening, combined with timely initiation of OsteoGuard therapy, can meaningfully prevent fractures and slow the progression of osteoporosis. In our simulated cohort, patients receiving treatment showed up to a <strong>5.4% increase in lumbar spine BMD over 24 months</strong>, compared with a <strong>1.6% gain or slight decline in low-adherence and control groups</strong>, respectively. Even partial adherence or early discontinuation conferred measurable benefit, highlighting the clinical value of targeting treatment to the right population.</p>
<p>From a commercial perspective, this represents a <strong>substantial market opportunity</strong>. By expanding screening and driving uptake among eligible patients, OsteoGuard could capture a growing share of the addressable population, generating significant revenue and profit per patient while delivering tangible health benefits. Running an aggressive early-screening campaign, including physician outreach, patient education, and targeted risk-assessment programs, could accelerate identification of missed high-risk adults and maximize therapy adoption. Such initiatives would help reach the untapped portion of the market, ensuring that high-risk individuals who would otherwise remain undetected have the opportunity to benefit from treatment. The simulations underscore that therapies with preventative potential—when combined with strategic patient identification and proactive outreach—can both improve outcomes and unlock meaningful commercial value, establishing a compelling case for investment in screening programs, adherence support, and market rollout strategies.</p>
</section>
<section id="references" class="level3">
<h3 class="anchored" data-anchor-id="references">References</h3>
<p>Alendronate Prices, Coupons, Copay &amp; Patient Assistance. Drugs.com, www.drugs.com/price-guide/alendronate.</p>
<p>“Bisphosphonates | International Osteoporosis Foundation.” www.osteoporosis.foundation, www.osteoporosis.foundation/health-professionals/treatment/bisphosphonates.</p>
<p>Fatoye, F., Smith, P., Gebrye, T., &amp; Yeowell, G. (2019). Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open, 9(4), e027049. https://doi.org/10.1136/bmjopen-2018-027049</p>
<p>Haderslev, K. V., Tjellesen, L., Sorensen, H. A., &amp; Staun, M. (2000). Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology, 119(3), 639–646. https://doi.org/10.1053/gast.2000.16518</p>
<p>Hui, R. L., Adams, A. L., Niu, F., Ettinger, B., Yi, D. K., Chandra, M., &amp; Lo, J. C. (2017). Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. Journal of Managed Care &amp; Specialty Pharmacy, 23(4), 503–512. https://doi.org/10.18553/jmcp.2017.23.4.503</p>
<p>Karpf, D. B., Shapiro, D. R., Seeman, E., Ensrud, K. E., Johnston, C. C., Jr, Adami, S., Harris, S. T., Santora, A. C., 2nd, Hirsch, L. J., Oppenheimer, L., &amp; Thompson, D. (1997). Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA, 277(14), 1159–1164.</p>
<p>Pharmaceutical drug prices and trends for ALENDRONATE SODIUM. (2026). Deep Knowledge on Small-Molecule Drugs and the Global Patents Covering Them. https://www.drugpatentwatch.com/p/drug-price/drugname/ALENDRONATE%2BSODIUM)</p>
<p>“Popular Bisphosphonates List, Drug Prices and Medication Information.” GoodRx, 2024, www.goodrx.com/classes/bisphosphonates.</p>


<!-- -->

</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
  window.document.addEventListener("DOMContentLoaded", function (event) {
    const icon = "";
    const anchorJS = new window.AnchorJS();
    anchorJS.options = {
      placement: 'right',
      icon: icon
    };
    anchorJS.add('.anchored');
    const isCodeAnnotation = (el) => {
      for (const clz of el.classList) {
        if (clz.startsWith('code-annotation-')) {                     
          return true;
        }
      }
      return false;
    }
    const onCopySuccess = function(e) {
      // button target
      const button = e.trigger;
      // don't keep focus
      button.blur();
      // flash "checked"
      button.classList.add('code-copy-button-checked');
      var currentTitle = button.getAttribute("title");
      button.setAttribute("title", "Copied!");
      let tooltip;
      if (window.bootstrap) {
        button.setAttribute("data-bs-toggle", "tooltip");
        button.setAttribute("data-bs-placement", "left");
        button.setAttribute("data-bs-title", "Copied!");
        tooltip = new bootstrap.Tooltip(button, 
          { trigger: "manual", 
            customClass: "code-copy-button-tooltip",
            offset: [0, -8]});
        tooltip.show();    
      }
      setTimeout(function() {
        if (tooltip) {
          tooltip.hide();
          button.removeAttribute("data-bs-title");
          button.removeAttribute("data-bs-toggle");
          button.removeAttribute("data-bs-placement");
        }
        button.setAttribute("title", currentTitle);
        button.classList.remove('code-copy-button-checked');
      }, 1000);
      // clear code selection
      e.clearSelection();
    }
    const getTextToCopy = function(trigger) {
      const outerScaffold = trigger.parentElement.cloneNode(true);
      const codeEl = outerScaffold.querySelector('code');
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
    const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
      text: getTextToCopy
    });
    clipboard.on('success', onCopySuccess);
    if (window.document.getElementById('quarto-embedded-source-code-modal')) {
      const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
        text: getTextToCopy,
        container: window.document.getElementById('quarto-embedded-source-code-modal')
      });
      clipboardModal.on('success', onCopySuccess);
    }
    const viewSource = window.document.getElementById('quarto-view-source') ||
                       window.document.getElementById('quarto-code-tools-source');
    if (viewSource) {
      const sourceUrl = viewSource.getAttribute("data-quarto-source-url");
      viewSource.addEventListener("click", function(e) {
        if (sourceUrl) {
          // rstudio viewer pane
          if (/\bcapabilities=\b/.test(window.location)) {
            window.open(sourceUrl);
          } else {
            window.location.href = sourceUrl;
          }
        } else {
          const modal = new bootstrap.Modal(document.getElementById('quarto-embedded-source-code-modal'));
          modal.show();
        }
        return false;
      });
    }
    function toggleCodeHandler(show) {
      return function(e) {
        const detailsSrc = window.document.querySelectorAll(".cell > details > .sourceCode");
        for (let i=0; i<detailsSrc.length; i++) {
          const details = detailsSrc[i].parentElement;
          if (show) {
            details.open = true;
          } else {
            details.removeAttribute("open");
          }
        }
        const cellCodeDivs = window.document.querySelectorAll(".cell > .sourceCode");
        const fromCls = show ? "hidden" : "unhidden";
        const toCls = show ? "unhidden" : "hidden";
        for (let i=0; i<cellCodeDivs.length; i++) {
          const codeDiv = cellCodeDivs[i];
          if (codeDiv.classList.contains(fromCls)) {
            codeDiv.classList.remove(fromCls);
            codeDiv.classList.add(toCls);
          } 
        }
        return false;
      }
    }
    const hideAllCode = window.document.getElementById("quarto-hide-all-code");
    if (hideAllCode) {
      hideAllCode.addEventListener("click", toggleCodeHandler(false));
    }
    const showAllCode = window.document.getElementById("quarto-show-all-code");
    if (showAllCode) {
      showAllCode.addEventListener("click", toggleCodeHandler(true));
    }
      var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
      var mailtoRegex = new RegExp(/^mailto:/);
        var filterRegex = new RegExp('/' + window.location.host + '/');
      var isInternal = (href) => {
          return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
      }
      // Inspect non-navigation links and adorn them if external
     var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
      for (var i=0; i<links.length; i++) {
        const link = links[i];
        if (!isInternal(link.href)) {
          // undo the damage that might have been done by quarto-nav.js in the case of
          // links that we want to consider external
          if (link.dataset.originalHref !== undefined) {
            link.href = link.dataset.originalHref;
          }
        }
      }
    function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
      const config = {
        allowHTML: true,
        maxWidth: 500,
        delay: 100,
        arrow: false,
        appendTo: function(el) {
            return el.parentElement;
        },
        interactive: true,
        interactiveBorder: 10,
        theme: 'quarto',
        placement: 'bottom-start',
      };
      if (contentFn) {
        config.content = contentFn;
      }
      if (onTriggerFn) {
        config.onTrigger = onTriggerFn;
      }
      if (onUntriggerFn) {
        config.onUntrigger = onUntriggerFn;
      }
      window.tippy(el, config); 
    }
    const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
    for (var i=0; i<noterefs.length; i++) {
      const ref = noterefs[i];
      tippyHover(ref, function() {
        // use id or data attribute instead here
        let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
        try { href = new URL(href).hash; } catch {}
        const id = href.replace(/^#\/?/, "");
        const note = window.document.getElementById(id);
        if (note) {
          return note.innerHTML;
        } else {
          return "";
        }
      });
    }
    const xrefs = window.document.querySelectorAll('a.quarto-xref');
    const processXRef = (id, note) => {
      // Strip column container classes
      const stripColumnClz = (el) => {
        el.classList.remove("page-full", "page-columns");
        if (el.children) {
          for (const child of el.children) {
            stripColumnClz(child);
          }
        }
      }
      stripColumnClz(note)
      if (id === null || id.startsWith('sec-')) {
        // Special case sections, only their first couple elements
        const container = document.createElement("div");
        if (note.children && note.children.length > 2) {
          container.appendChild(note.children[0].cloneNode(true));
          for (let i = 1; i < note.children.length; i++) {
            const child = note.children[i];
            if (child.tagName === "P" && child.innerText === "") {
              continue;
            } else {
              container.appendChild(child.cloneNode(true));
              break;
            }
          }
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(container);
          }
          return container.innerHTML
        } else {
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(note);
          }
          return note.innerHTML;
        }
      } else {
        // Remove any anchor links if they are present
        const anchorLink = note.querySelector('a.anchorjs-link');
        if (anchorLink) {
          anchorLink.remove();
        }
        if (window.Quarto?.typesetMath) {
          window.Quarto.typesetMath(note);
        }
        if (note.classList.contains("callout")) {
          return note.outerHTML;
        } else {
          return note.innerHTML;
        }
      }
    }
    for (var i=0; i<xrefs.length; i++) {
      const xref = xrefs[i];
      tippyHover(xref, undefined, function(instance) {
        instance.disable();
        let url = xref.getAttribute('href');
        let hash = undefined; 
        if (url.startsWith('#')) {
          hash = url;
        } else {
          try { hash = new URL(url).hash; } catch {}
        }
        if (hash) {
          const id = hash.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          if (note !== null) {
            try {
              const html = processXRef(id, note.cloneNode(true));
              instance.setContent(html);
            } finally {
              instance.enable();
              instance.show();
            }
          } else {
            // See if we can fetch this
            fetch(url.split('#')[0])
            .then(res => res.text())
            .then(html => {
              const parser = new DOMParser();
              const htmlDoc = parser.parseFromString(html, "text/html");
              const note = htmlDoc.getElementById(id);
              if (note !== null) {
                const html = processXRef(id, note);
                instance.setContent(html);
              } 
            }).finally(() => {
              instance.enable();
              instance.show();
            });
          }
        } else {
          // See if we can fetch a full url (with no hash to target)
          // This is a special case and we should probably do some content thinning / targeting
          fetch(url)
          .then(res => res.text())
          .then(html => {
            const parser = new DOMParser();
            const htmlDoc = parser.parseFromString(html, "text/html");
            const note = htmlDoc.querySelector('main.content');
            if (note !== null) {
              // This should only happen for chapter cross references
              // (since there is no id in the URL)
              // remove the first header
              if (note.children.length > 0 && note.children[0].tagName === "HEADER") {
                note.children[0].remove();
              }
              const html = processXRef(null, note);
              instance.setContent(html);
            } 
          }).finally(() => {
            instance.enable();
            instance.show();
          });
        }
      }, function(instance) {
      });
    }
        let selectedAnnoteEl;
        const selectorForAnnotation = ( cell, annotation) => {
          let cellAttr = 'data-code-cell="' + cell + '"';
          let lineAttr = 'data-code-annotation="' +  annotation + '"';
          const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
          return selector;
        }
        const selectCodeLines = (annoteEl) => {
          const doc = window.document;
          const targetCell = annoteEl.getAttribute("data-target-cell");
          const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
          const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
          const lines = annoteSpan.getAttribute("data-code-lines").split(",");
          const lineIds = lines.map((line) => {
            return targetCell + "-" + line;
          })
          let top = null;
          let height = null;
          let parent = null;
          if (lineIds.length > 0) {
              //compute the position of the single el (top and bottom and make a div)
              const el = window.document.getElementById(lineIds[0]);
              top = el.offsetTop;
              height = el.offsetHeight;
              parent = el.parentElement.parentElement;
            if (lineIds.length > 1) {
              const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
              const bottom = lastEl.offsetTop + lastEl.offsetHeight;
              height = bottom - top;
            }
            if (top !== null && height !== null && parent !== null) {
              // cook up a div (if necessary) and position it 
              let div = window.document.getElementById("code-annotation-line-highlight");
              if (div === null) {
                div = window.document.createElement("div");
                div.setAttribute("id", "code-annotation-line-highlight");
                div.style.position = 'absolute';
                parent.appendChild(div);
              }
              div.style.top = top - 2 + "px";
              div.style.height = height + 4 + "px";
              div.style.left = 0;
              let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
              if (gutterDiv === null) {
                gutterDiv = window.document.createElement("div");
                gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
                gutterDiv.style.position = 'absolute';
                const codeCell = window.document.getElementById(targetCell);
                const gutter = codeCell.querySelector('.code-annotation-gutter');
                gutter.appendChild(gutterDiv);
              }
              gutterDiv.style.top = top - 2 + "px";
              gutterDiv.style.height = height + 4 + "px";
            }
            selectedAnnoteEl = annoteEl;
          }
        };
        const unselectCodeLines = () => {
          const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
          elementsIds.forEach((elId) => {
            const div = window.document.getElementById(elId);
            if (div) {
              div.remove();
            }
          });
          selectedAnnoteEl = undefined;
        };
          // Handle positioning of the toggle
      window.addEventListener(
        "resize",
        throttle(() => {
          elRect = undefined;
          if (selectedAnnoteEl) {
            selectCodeLines(selectedAnnoteEl);
          }
        }, 10)
      );
      function throttle(fn, ms) {
      let throttle = false;
      let timer;
        return (...args) => {
          if(!throttle) { // first call gets through
              fn.apply(this, args);
              throttle = true;
          } else { // all the others get throttled
              if(timer) clearTimeout(timer); // cancel #2
              timer = setTimeout(() => {
                fn.apply(this, args);
                timer = throttle = false;
              }, ms);
          }
        };
      }
        // Attach click handler to the DT
        const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
        for (const annoteDlNode of annoteDls) {
          annoteDlNode.addEventListener('click', (event) => {
            const clickedEl = event.target;
            if (clickedEl !== selectedAnnoteEl) {
              unselectCodeLines();
              const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
              if (activeEl) {
                activeEl.classList.remove('code-annotation-active');
              }
              selectCodeLines(clickedEl);
              clickedEl.classList.add('code-annotation-active');
            } else {
              // Unselect the line
              unselectCodeLines();
              clickedEl.classList.remove('code-annotation-active');
            }
          });
        }
    const findCites = (el) => {
      const parentEl = el.parentElement;
      if (parentEl) {
        const cites = parentEl.dataset.cites;
        if (cites) {
          return {
            el,
            cites: cites.split(' ')
          };
        } else {
          return findCites(el.parentElement)
        }
      } else {
        return undefined;
      }
    };
    var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
    for (var i=0; i<bibliorefs.length; i++) {
      const ref = bibliorefs[i];
      const citeInfo = findCites(ref);
      if (citeInfo) {
        tippyHover(citeInfo.el, function() {
          var popup = window.document.createElement('div');
          citeInfo.cites.forEach(function(cite) {
            var citeDiv = window.document.createElement('div');
            citeDiv.classList.add('hanging-indent');
            citeDiv.classList.add('csl-entry');
            var biblioDiv = window.document.getElementById('ref-' + cite);
            if (biblioDiv) {
              citeDiv.innerHTML = biblioDiv.innerHTML;
            }
            popup.appendChild(citeDiv);
          });
          return popup.innerHTML;
        });
      }
    }
  });
  </script><div class="modal fade" id="quarto-embedded-source-code-modal" tabindex="-1" aria-labelledby="quarto-embedded-source-code-modal-label" aria-hidden="true"><div class="modal-dialog modal-dialog-scrollable"><div class="modal-content"><div class="modal-header"><h5 class="modal-title" id="quarto-embedded-source-code-modal-label">Source Code</h5><button class="btn-close" data-bs-dismiss="modal"></button></div><div class="modal-body"><div class="">
<div class="code-copy-outer-scaffold"><div class="sourceCode" id="cb17" data-shortcodes="false"><pre class="sourceCode markdown code-with-copy"><code class="sourceCode markdown"><span id="cb17-1"><a href="#cb17-1" aria-hidden="true" tabindex="-1"></a>::: text-center</span>
<span id="cb17-2"><a href="#cb17-2" aria-hidden="true" tabindex="-1"></a><span class="al">![](image/company_logo.png)</span>{width="180px"}</span>
<span id="cb17-3"><a href="#cb17-3" aria-hidden="true" tabindex="-1"></a>:::</span>
<span id="cb17-4"><a href="#cb17-4" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-5"><a href="#cb17-5" aria-hidden="true" tabindex="-1"></a>---</span>
<span id="cb17-6"><a href="#cb17-6" aria-hidden="true" tabindex="-1"></a>title: "Bone Health - Treatment Outcomes - Phase 2"</span>
<span id="cb17-7"><a href="#cb17-7" aria-hidden="true" tabindex="-1"></a>author: "Tilabo Williamson, Caitlin Buenk &amp; Jürgen Becker (Project Lead) - AX Consult Group"</span>
<span id="cb17-8"><a href="#cb17-8" aria-hidden="true" tabindex="-1"></a>date: "2026-02-17"</span>
<span id="cb17-9"><a href="#cb17-9" aria-hidden="true" tabindex="-1"></a>format:</span>
<span id="cb17-10"><a href="#cb17-10" aria-hidden="true" tabindex="-1"></a>  html:</span>
<span id="cb17-11"><a href="#cb17-11" aria-hidden="true" tabindex="-1"></a>    theme: cosmo</span>
<span id="cb17-12"><a href="#cb17-12" aria-hidden="true" tabindex="-1"></a>    code-fold: true</span>
<span id="cb17-13"><a href="#cb17-13" aria-hidden="true" tabindex="-1"></a>    code-summary: "Show code"</span>
<span id="cb17-14"><a href="#cb17-14" aria-hidden="true" tabindex="-1"></a>    code-tools: true</span>
<span id="cb17-15"><a href="#cb17-15" aria-hidden="true" tabindex="-1"></a>    toc: true</span>
<span id="cb17-16"><a href="#cb17-16" aria-hidden="true" tabindex="-1"></a>    toc-depth: 3</span>
<span id="cb17-17"><a href="#cb17-17" aria-hidden="true" tabindex="-1"></a>    output-dir: docs</span>
<span id="cb17-18"><a href="#cb17-18" aria-hidden="true" tabindex="-1"></a>---</span>
<span id="cb17-19"><a href="#cb17-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-22"><a href="#cb17-22" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-23"><a href="#cb17-23" aria-hidden="true" tabindex="-1"></a><span class="fu">library</span>(pacman)</span>
<span id="cb17-24"><a href="#cb17-24" aria-hidden="true" tabindex="-1"></a><span class="fu">p_load</span>(magrittr, tidyverse, psych, dplyr, ggplot2, haven, janitor, readxl, writexl, knitr, kableExtra, scales, tibble, tidyr, patchwork, ggrepel)</span>
<span id="cb17-25"><a href="#cb17-25" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-26"><a href="#cb17-26" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-27"><a href="#cb17-27" aria-hidden="true" tabindex="-1"></a><span class="fu">### Background</span></span>
<span id="cb17-28"><a href="#cb17-28" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-29"><a href="#cb17-29" aria-hidden="true" tabindex="-1"></a>Osteoporosis is a progressive condition characterised by reduced bone mineral density (BMD) and deterioration of bone structure, leading to increased fracture risk. Many individuals at high risk of fracture remain unidentified under current age-based screening guidelines, particularly those who present with clinical or lifestyle risk factors but do not meet standard screening age thresholds.</span>
<span id="cb17-30"><a href="#cb17-30" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-31"><a href="#cb17-31" aria-hidden="true" tabindex="-1"></a>Phase 1 of this project used secondary population data (smoking, physical activity, body measurements, prior fracture history) to identify individuals at elevated bone-health risk and to quantify the proportion of high-risk individuals who are not captured by current screening criteria. This revealed a substantial “missed high-risk” population who may benefit from earlier identification and intervention.</span>
<span id="cb17-32"><a href="#cb17-32" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-33"><a href="#cb17-33" aria-hidden="true" tabindex="-1"></a>Phase 2 builds on these findings by simulating the clinical and commercial impact of a hypothetical osteoporosis treatment if this missed high-risk population were successfully identified and treated. The purpose of this phase is to demonstrate how screening improvements could translate into improved clinical outcomes and potential commercial value in a realistic biopharmaceutical analytics context.</span>
<span id="cb17-34"><a href="#cb17-34" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-35"><a href="#cb17-35" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Phase 1 summary</span></span>
<span id="cb17-36"><a href="#cb17-36" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-37"><a href="#cb17-37" aria-hidden="true" tabindex="-1"></a>Individuals were classified as high bone risk in Phase 1 using a lumbar spine T-score–led definition. Participants with a lumbar spine T-score in the osteoporosis range (≤ −2.5) were classified as high risk regardless of other factors. Participants with a lumbar spine T-score in the osteopenia range (between −1.0 and −2.5) were classified as high risk only if at least one additional risk indicator was present. Risk indicators included low body mass index, current or former smoking, a history of fracture at the hip, wrist, or spine, or low levels of physical activity. This approach recognizes that moderately reduced bone density becomes more important when combined with other risk factors.</span>
<span id="cb17-38"><a href="#cb17-38" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-39"><a href="#cb17-39" aria-hidden="true" tabindex="-1"></a>The Phase 1 analysis was conducted using data from **3,107 individuals** in the NHANES 2005–2006 cohort, all aged 20 years or older. Among this study population, **540 individuals were classified as high-risk** for osteoporosis based on bone mineral density (BMD) and additional clinical or lifestyle risk factors. Importantly, **508 of these high-risk individuals were not identified** under current age- and guideline-based screening criteria. This represents approximately **16.35% of the total study population**, highlighting a substantial “missed high-risk” group.</span>
<span id="cb17-40"><a href="#cb17-40" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-41"><a href="#cb17-41" aria-hidden="true" tabindex="-1"></a>NHANES employs a complex, multistage probability sampling design, meaning raw sample proportions cannot be interpreted as nationally representative without adjustment. Therefore, survey weights (WTMEC2YR), strata (SDMVSTRA), and primary sampling units (SDMVPSU) were applied to account for oversampling and clustering within the National Health and Nutrition Examination Survey framework. After incorporating these design elements, the weighted prevalence of missed high-risk adults was 15.22%. This survey-adjusted estimate provides a nationally representative prevalence that can be used to project the number of U.S. adults aged ≥20 who may fall into this under-identified high-risk category today.</span>
<span id="cb17-42"><a href="#cb17-42" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-43"><a href="#cb17-43" aria-hidden="true" tabindex="-1"></a>Applying the weighted prevalence estimate of 15.22% to the current U.S. adult population aged ≥20 (approximately 250 million individuals based on recent Census age distributions) suggests that roughly:</span>
<span id="cb17-44"><a href="#cb17-44" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-45"><a href="#cb17-45" aria-hidden="true" tabindex="-1"></a>250,000,000 × 0.1522 = 38,050,000</span>
<span id="cb17-46"><a href="#cb17-46" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-47"><a href="#cb17-47" aria-hidden="true" tabindex="-1"></a>≈ 38 million U.S. adults may fall into this expanded high-risk category yet remain unidentified under current age-based screening criteria.</span>
<span id="cb17-48"><a href="#cb17-48" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-49"><a href="#cb17-49" aria-hidden="true" tabindex="-1"></a>From a public health and commercial perspective, these individuals represent a potentially addressable market for osteoporosis screening and treatment interventions. By targeting this missed population, there is an opportunity to improve early detection, initiate timely therapy, and potentially reduce fracture risk, while also quantifying the market potential for a treatment like OsteoGuard.</span>
<span id="cb17-50"><a href="#cb17-50" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-51"><a href="#cb17-51" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-54"><a href="#cb17-54" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-55"><a href="#cb17-55" aria-hidden="true" tabindex="-1"></a><span class="co"># Reading in data from phase 1</span></span>
<span id="cb17-56"><a href="#cb17-56" aria-hidden="true" tabindex="-1"></a>phase_1 <span class="ot">&lt;-</span> <span class="fu">read_xpt</span>(<span class="st">"data/poe_bone_health_phase1 - 2026.02.12.xpt"</span>)</span>
<span id="cb17-57"><a href="#cb17-57" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-58"><a href="#cb17-58" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-59"><a href="#cb17-59" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-60"><a href="#cb17-60" aria-hidden="true" tabindex="-1"></a><span class="in">```{r, out.width="100%"}</span></span>
<span id="cb17-61"><a href="#cb17-61" aria-hidden="true" tabindex="-1"></a><span class="co"># Pie chart</span></span>
<span id="cb17-62"><a href="#cb17-62" aria-hidden="true" tabindex="-1"></a><span class="co"># Counts</span></span>
<span id="cb17-63"><a href="#cb17-63" aria-hidden="true" tabindex="-1"></a>total_count <span class="ot">&lt;-</span> <span class="fu">nrow</span>(phase_1) </span>
<span id="cb17-64"><a href="#cb17-64" aria-hidden="true" tabindex="-1"></a>high_risk_count <span class="ot">&lt;-</span> <span class="fu">sum</span>(phase_1<span class="sc">$</span>high_bone_risk <span class="sc">==</span> <span class="dv">1</span>)</span>
<span id="cb17-65"><a href="#cb17-65" aria-hidden="true" tabindex="-1"></a>missed_high_risk_count <span class="ot">&lt;-</span> <span class="fu">sum</span>(phase_1<span class="sc">$</span>missed_high_risk <span class="sc">==</span> <span class="dv">1</span>)</span>
<span id="cb17-66"><a href="#cb17-66" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-67"><a href="#cb17-67" aria-hidden="true" tabindex="-1"></a><span class="co"># Preparing df</span></span>
<span id="cb17-68"><a href="#cb17-68" aria-hidden="true" tabindex="-1"></a>pie_data <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(</span>
<span id="cb17-69"><a href="#cb17-69" aria-hidden="true" tabindex="-1"></a>  <span class="at">group =</span> <span class="fu">c</span>( <span class="st">"High Risk and Screened"</span>, <span class="st">"Missed High Risk"</span>, <span class="st">"Not at Risk"</span>),</span>
<span id="cb17-70"><a href="#cb17-70" aria-hidden="true" tabindex="-1"></a>  <span class="at">count =</span> <span class="fu">c</span>(high_risk_count <span class="sc">-</span> missed_high_risk_count,</span>
<span id="cb17-71"><a href="#cb17-71" aria-hidden="true" tabindex="-1"></a>            missed_high_risk_count,</span>
<span id="cb17-72"><a href="#cb17-72" aria-hidden="true" tabindex="-1"></a>            total_count <span class="sc">-</span> high_risk_count)</span>
<span id="cb17-73"><a href="#cb17-73" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb17-74"><a href="#cb17-74" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-75"><a href="#cb17-75" aria-hidden="true" tabindex="-1"></a>    <span class="at">percent =</span> <span class="fu">round</span>(count <span class="sc">/</span> <span class="fu">sum</span>(count) <span class="sc">*</span> <span class="dv">100</span>, <span class="dv">1</span>),</span>
<span id="cb17-76"><a href="#cb17-76" aria-hidden="true" tabindex="-1"></a>    <span class="at">label =</span> <span class="fu">paste0</span>(group, <span class="st">": "</span>, count, <span class="st">" ("</span>, percent, <span class="st">"%)"</span>),</span>
<span id="cb17-77"><a href="#cb17-77" aria-hidden="true" tabindex="-1"></a>    <span class="at">ymax =</span> <span class="fu">cumsum</span>(count),</span>
<span id="cb17-78"><a href="#cb17-78" aria-hidden="true" tabindex="-1"></a>    <span class="at">ymin =</span> <span class="fu">c</span>(<span class="dv">0</span>, <span class="fu">head</span>(ymax, <span class="at">n =</span> <span class="sc">-</span><span class="dv">1</span>)),</span>
<span id="cb17-79"><a href="#cb17-79" aria-hidden="true" tabindex="-1"></a>    <span class="at">mid =</span> (ymax <span class="sc">+</span> ymin) <span class="sc">/</span> <span class="dv">2</span></span>
<span id="cb17-80"><a href="#cb17-80" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-81"><a href="#cb17-81" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-82"><a href="#cb17-82" aria-hidden="true" tabindex="-1"></a><span class="co"># Rendering plot</span></span>
<span id="cb17-83"><a href="#cb17-83" aria-hidden="true" tabindex="-1"></a>pie_data  <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-84"><a href="#cb17-84" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-85"><a href="#cb17-85" aria-hidden="true" tabindex="-1"></a>    <span class="at">label_y =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-86"><a href="#cb17-86" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"High Risk and Screened"</span>        <span class="sc">~</span> mid,   <span class="co"># middle of wedge</span></span>
<span id="cb17-87"><a href="#cb17-87" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Missed High Risk"</span> <span class="sc">~</span> ymax,  <span class="co"># top of wedge</span></span>
<span id="cb17-88"><a href="#cb17-88" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Not at Risk"</span>      <span class="sc">~</span> mid    <span class="co"># middle of wedge</span></span>
<span id="cb17-89"><a href="#cb17-89" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb17-90"><a href="#cb17-90" aria-hidden="true" tabindex="-1"></a>    <span class="at">label_x =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-91"><a href="#cb17-91" aria-hidden="true" tabindex="-1"></a>      group <span class="sc">==</span> <span class="st">"Missed High Risk"</span> <span class="sc">~</span> <span class="fl">5.4</span>,   <span class="co"># push to the right</span></span>
<span id="cb17-92"><a href="#cb17-92" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span>                        <span class="sc">~</span> <span class="fl">4.5</span>    <span class="co"># default for others</span></span>
<span id="cb17-93"><a href="#cb17-93" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb17-94"><a href="#cb17-94" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-95"><a href="#cb17-95" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-96"><a href="#cb17-96" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-97"><a href="#cb17-97" aria-hidden="true" tabindex="-1"></a><span class="fu">ggplot</span>(pie_data, <span class="fu">aes</span>(<span class="at">ymax =</span> ymax, <span class="at">ymin =</span> ymin, <span class="at">xmax =</span> <span class="dv">4</span>, <span class="at">xmin =</span> <span class="dv">3</span>, <span class="at">fill =</span> group)) <span class="sc">+</span></span>
<span id="cb17-98"><a href="#cb17-98" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_rect</span>(<span class="at">color =</span> <span class="st">"white"</span>) <span class="sc">+</span></span>
<span id="cb17-99"><a href="#cb17-99" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_label</span>(</span>
<span id="cb17-100"><a href="#cb17-100" aria-hidden="true" tabindex="-1"></a>    <span class="fu">aes</span>(<span class="at">x =</span> label_x, <span class="at">y =</span> label_y, <span class="at">label =</span> label, <span class="at">fill =</span> group),</span>
<span id="cb17-101"><a href="#cb17-101" aria-hidden="true" tabindex="-1"></a>    <span class="at">color =</span> <span class="st">"white"</span>,</span>
<span id="cb17-102"><a href="#cb17-102" aria-hidden="true" tabindex="-1"></a>    <span class="at">show.legend =</span> <span class="cn">FALSE</span>,</span>
<span id="cb17-103"><a href="#cb17-103" aria-hidden="true" tabindex="-1"></a>    <span class="at">label.size =</span> <span class="fl">0.2</span></span>
<span id="cb17-104"><a href="#cb17-104" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">+</span></span>
<span id="cb17-105"><a href="#cb17-105" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_fill_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"#E0B6E4"</span>, <span class="st">"#9A4EAE"</span>, <span class="st">"#7E3285"</span>)) <span class="sc">+</span></span>
<span id="cb17-106"><a href="#cb17-106" aria-hidden="true" tabindex="-1"></a>  <span class="fu">coord_polar</span>(<span class="at">theta =</span> <span class="st">"y"</span>, <span class="at">clip =</span> <span class="st">"off"</span>)<span class="sc">+</span></span>
<span id="cb17-107"><a href="#cb17-107" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_void</span>() <span class="sc">+</span></span>
<span id="cb17-108"><a href="#cb17-108" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(</span>
<span id="cb17-109"><a href="#cb17-109" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Phase 1 Study Population Breakdown: Osteoporosis Risk (N = 3107)"</span>,</span>
<span id="cb17-110"><a href="#cb17-110" aria-hidden="true" tabindex="-1"></a>    <span class="at">fill =</span> <span class="st">"Group"</span></span>
<span id="cb17-111"><a href="#cb17-111" aria-hidden="true" tabindex="-1"></a>  )<span class="sc">+</span> </span>
<span id="cb17-112"><a href="#cb17-112" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme</span>(</span>
<span id="cb17-113"><a href="#cb17-113" aria-hidden="true" tabindex="-1"></a>    <span class="at">legend.position =</span> <span class="st">"bottom"</span>,</span>
<span id="cb17-114"><a href="#cb17-114" aria-hidden="true" tabindex="-1"></a>    <span class="at">plot.margin =</span> <span class="fu">margin</span>(<span class="at">t =</span> <span class="dv">10</span>, <span class="at">r =</span> <span class="dv">80</span>, <span class="at">b =</span> <span class="dv">10</span>, <span class="at">l =</span> <span class="dv">10</span>)</span>
<span id="cb17-115"><a href="#cb17-115" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-116"><a href="#cb17-116" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-117"><a href="#cb17-117" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-118"><a href="#cb17-118" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-119"><a href="#cb17-119" aria-hidden="true" tabindex="-1"></a><span class="fu">#### OsteoGuard</span></span>
<span id="cb17-120"><a href="#cb17-120" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-121"><a href="#cb17-121" aria-hidden="true" tabindex="-1"></a>For the purposes of this analysis, a hypothetical osteoporosis therapy, OsteoGuard, is introduced. OsteoGuard is modelled as a bisphosphonate-like treatment designed to improve bone mineral density and reduce fracture risk in high-risk individuals.</span>
<span id="cb17-122"><a href="#cb17-122" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-123"><a href="#cb17-123" aria-hidden="true" tabindex="-1"></a>The simulated treatment is assumed to behave similarly to established bisphosphonates used in clinical practice. These therapies are known to increase lumbar spine bone mineral density, reduce fracture risk, and slow the progression from osteopenia to osteoporosis when adherence is maintained. OsteoGuard is assumed to be prescribed to individuals classified as high bone-health risk in Phase 1, with particular focus on those who would otherwise be missed under current screening guidelines.</span>
<span id="cb17-124"><a href="#cb17-124" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-125"><a href="#cb17-125" aria-hidden="true" tabindex="-1"></a>All clinical and commercial data used in this phase are simulated but grounded in published literature and typical real-world treatment patterns to ensure plausibility.</span>
<span id="cb17-126"><a href="#cb17-126" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-127"><a href="#cb17-127" aria-hidden="true" tabindex="-1"></a><span class="fu">### OsteoGuard Efficacy</span></span>
<span id="cb17-128"><a href="#cb17-128" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-129"><a href="#cb17-129" aria-hidden="true" tabindex="-1"></a>The simulation of OsteoGuard treatment outcomes was informed by established clinical norms, Phase 1 study population parameters, published bisphosphonate efficacy studies, and pragmatic assumptions regarding adherence, safety, and commercial context.</span>
<span id="cb17-130"><a href="#cb17-130" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-131"><a href="#cb17-131" aria-hidden="true" tabindex="-1"></a>The table below summarises all key modelling assumptions and their sources to ensure transparency, reproducibility, and interpretability of the simulated clinical and economic outcomes.</span>
<span id="cb17-132"><a href="#cb17-132" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-135"><a href="#cb17-135" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-136"><a href="#cb17-136" aria-hidden="true" tabindex="-1"></a><span class="co"># Assumptions table</span></span>
<span id="cb17-137"><a href="#cb17-137" aria-hidden="true" tabindex="-1"></a>assumptions_tbl <span class="ot">&lt;-</span> <span class="fu">tribble</span>(</span>
<span id="cb17-138"><a href="#cb17-138" aria-hidden="true" tabindex="-1"></a>  <span class="sc">~</span>Section, <span class="sc">~</span>Parameter, <span class="sc">~</span>Assumption, <span class="sc">~</span>Reference, <span class="sc">~</span><span class="st">`</span><span class="at">Why it's reasonable</span><span class="st">`</span>,</span>
<span id="cb17-139"><a href="#cb17-139" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-140"><a href="#cb17-140" aria-hidden="true" tabindex="-1"></a>  <span class="co">#Baseline clinical norms</span></span>
<span id="cb17-141"><a href="#cb17-141" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Normal"</span>, <span class="st">"&gt;= -1.0"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb17-142"><a href="#cb17-142" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Standard clinical threshold used in DXA reporting."</span>,</span>
<span id="cb17-143"><a href="#cb17-143" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Osteopenia"</span>, <span class="st">"-1.0 to -2.5"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb17-144"><a href="#cb17-144" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Widely accepted range indicating low bone mass and higher future fracture risk."</span>,</span>
<span id="cb17-145"><a href="#cb17-145" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Baseline clinical norms"</span>, <span class="st">"T-score interpretation: Osteoporosis"</span>, <span class="st">"&lt;= -2.5"</span>, <span class="st">"Clinical DXA conventions"</span>,</span>
<span id="cb17-146"><a href="#cb17-146" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Standard diagnostic threshold used across guidelines and trials."</span>,</span>
<span id="cb17-147"><a href="#cb17-147" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-148"><a href="#cb17-148" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Phase 1 study population baselines</span></span>
<span id="cb17-149"><a href="#cb17-149" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"Mean lumbar T-score (high risk)"</span>, <span class="st">"-1.73"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb17-150"><a href="#cb17-150" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical mean from the Phase 1 high-risk cohort; anchors simulation to observed baseline distribution."</span>,</span>
<span id="cb17-151"><a href="#cb17-151" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"SD lumbar T-score (high risk)"</span>, <span class="st">"0.57"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb17-152"><a href="#cb17-152" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical variability from Phase 1; aligns with typical dispersion in osteopenic/osteoporotic samples."</span>,</span>
<span id="cb17-153"><a href="#cb17-153" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"Mean lumbar T-score (total sample)"</span>, <span class="st">"-0.09"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb17-154"><a href="#cb17-154" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical mean from the Phase 1 full analytic sample; represents general population baseline."</span>,</span>
<span id="cb17-155"><a href="#cb17-155" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Phase 1 study population parameters"</span>, <span class="st">"SD lumbar T-score (total sample)"</span>, <span class="st">"1.31"</span>, <span class="st">"Phase 1 analytic dataset"</span>,</span>
<span id="cb17-156"><a href="#cb17-156" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Empirical variability from Phase 1; reflects broad mix of low-to-normal bone density in the sample."</span>,</span>
<span id="cb17-157"><a href="#cb17-157" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-158"><a href="#cb17-158" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Treatment efficacy </span></span>
<span id="cb17-159"><a href="#cb17-159" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (ideal adherence)"</span>, <span class="st">"+4.6%"</span>, <span class="st">"Haderslev et al., 2000"</span>,</span>
<span id="cb17-160"><a href="#cb17-160" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Anchored to published trial evidence for spine BMD response over 12 months."</span>,</span>
<span id="cb17-161"><a href="#cb17-161" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (average adherence)"</span>, <span class="st">"+2.8%"</span>, <span class="st">"Scaled from Haderslev et al., 2000"</span>,</span>
<span id="cb17-162"><a href="#cb17-162" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents partial effectiveness under less-than-ideal adherence, consistent with real-world attenuation."</span>,</span>
<span id="cb17-163"><a href="#cb17-163" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (poor adherence)"</span>, <span class="st">"+1.2%"</span>, <span class="st">"Scaled from Haderslev et al., 2000"</span>,</span>
<span id="cb17-164"><a href="#cb17-164" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Conservative partial benefit reflecting low exposure/persistence with therapy."</span>,</span>
<span id="cb17-165"><a href="#cb17-165" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"12m BMD change (control)"</span>, <span class="st">"-0.9%"</span>, <span class="st">"Haderslev et al., 2000"</span>,</span>
<span id="cb17-166"><a href="#cb17-166" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Published untreated trajectory provides a realistic counterfactual baseline."</span>,</span>
<span id="cb17-167"><a href="#cb17-167" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (high adherence)"</span>, <span class="st">"~5.4%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb17-168"><a href="#cb17-168" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Year-2 gains are typically smaller than year-1; projection maintains plausible 2-year cumulative improvement."</span>,</span>
<span id="cb17-169"><a href="#cb17-169" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (moderate adherence)"</span>, <span class="st">"~3.3%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb17-170"><a href="#cb17-170" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived by scaling the high-adherence projection to reflect reduced exposure/persistence."</span>,</span>
<span id="cb17-171"><a href="#cb17-171" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Treatment efficacy"</span>, <span class="st">"24m projected change (poor adherence)"</span>, <span class="st">"~1.4%"</span>, <span class="st">"Interpolated from 12m &amp; IOF evidence"</span>,</span>
<span id="cb17-172"><a href="#cb17-172" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Conservative assumption: small incremental gain beyond 12 months under poor adherence."</span>,</span>
<span id="cb17-173"><a href="#cb17-173" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-174"><a href="#cb17-174" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Fracture assumptions</span></span>
<span id="cb17-175"><a href="#cb17-175" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Control cumulative fracture incidence"</span>, <span class="st">"12.6%"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb17-176"><a href="#cb17-176" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Anchors fracture risk to multi-year bisphosphonate trial evidence for high-risk populations."</span>,</span>
<span id="cb17-177"><a href="#cb17-177" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Treatment cumulative fracture incidence"</span>, <span class="st">"9.0%"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb17-178"><a href="#cb17-178" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents clinically meaningful fracture reduction consistent with trial findings."</span>,</span>
<span id="cb17-179"><a href="#cb17-179" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Relative risk"</span>, <span class="st">"0.71"</span>, <span class="st">"Karpf et al., 1997"</span>,</span>
<span id="cb17-180"><a href="#cb17-180" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Directly implied by published incidence values; simple and interpretable for simulation."</span>,</span>
<span id="cb17-181"><a href="#cb17-181" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Fracture risk"</span>, <span class="st">"Simulation horizon"</span>, <span class="st">"2-year proxy using multi-year trial evidence"</span>, <span class="st">"Portfolio modelling assumption"</span>,</span>
<span id="cb17-182"><a href="#cb17-182" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Pragmatic approximation for a prototype: uses published cumulative incidence as a 2-year proxy with sensitivity checks planned."</span>,</span>
<span id="cb17-183"><a href="#cb17-183" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-184"><a href="#cb17-184" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Adherence</span></span>
<span id="cb17-185"><a href="#cb17-185" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"High adherence proportion"</span>, <span class="st">"40%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-186"><a href="#cb17-186" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Consistent with real-world persistence patterns where a minority maintain high adherence long-term."</span>,</span>
<span id="cb17-187"><a href="#cb17-187" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Moderate adherence proportion"</span>, <span class="st">"35%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-188"><a href="#cb17-188" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents partial adherence/persistence typical in observational settings."</span>,</span>
<span id="cb17-189"><a href="#cb17-189" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Poor adherence proportion"</span>, <span class="st">"25%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-190"><a href="#cb17-190" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects drop-off and low persistence commonly reported for oral therapies."</span>,</span>
<span id="cb17-191"><a href="#cb17-191" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (high)"</span>, <span class="st">"10%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-192"><a href="#cb17-192" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Low discontinuation expected among high-adherence patients."</span>,</span>
<span id="cb17-193"><a href="#cb17-193" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (moderate)"</span>, <span class="st">"30%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-194"><a href="#cb17-194" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Moderate discontinuation aligns with partial persistence across the first year."</span>,</span>
<span id="cb17-195"><a href="#cb17-195" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Adherence"</span>, <span class="st">"Discontinue by year 1 (poor)"</span>, <span class="st">"60%"</span>, <span class="st">"Hui et al., 2017; Fatoye et al., 2019"</span>,</span>
<span id="cb17-196"><a href="#cb17-196" aria-hidden="true" tabindex="-1"></a>  <span class="st">"High discontinuation is typical for poor adherence groups and supports conservative effectiveness."</span>,</span>
<span id="cb17-197"><a href="#cb17-197" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-198"><a href="#cb17-198" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb17-199"><a href="#cb17-199" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-200"><a href="#cb17-200" aria-hidden="true" tabindex="-1"></a><span class="co"># Rendering table</span></span>
<span id="cb17-201"><a href="#cb17-201" aria-hidden="true" tabindex="-1"></a><span class="co"># Create display version that blanks repeated sections</span></span>
<span id="cb17-202"><a href="#cb17-202" aria-hidden="true" tabindex="-1"></a>assumptions_display <span class="ot">&lt;-</span> assumptions_tbl <span class="sc">%&gt;%</span></span>
<span id="cb17-203"><a href="#cb17-203" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(Section) <span class="sc">%&gt;%</span></span>
<span id="cb17-204"><a href="#cb17-204" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-205"><a href="#cb17-205" aria-hidden="true" tabindex="-1"></a>    <span class="at">Section =</span> <span class="fu">ifelse</span>(<span class="fu">row_number</span>() <span class="sc">==</span> <span class="dv">1</span>, Section, <span class="st">""</span>)</span>
<span id="cb17-206"><a href="#cb17-206" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-207"><a href="#cb17-207" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ungroup</span>()</span>
<span id="cb17-208"><a href="#cb17-208" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-209"><a href="#cb17-209" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(</span>
<span id="cb17-210"><a href="#cb17-210" aria-hidden="true" tabindex="-1"></a>  assumptions_display,</span>
<span id="cb17-211"><a href="#cb17-211" aria-hidden="true" tabindex="-1"></a>  <span class="at">format =</span> <span class="st">"html"</span>,</span>
<span id="cb17-212"><a href="#cb17-212" aria-hidden="true" tabindex="-1"></a>  <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Section"</span>, <span class="st">"Parameter"</span>, <span class="st">"Assumption"</span>,</span>
<span id="cb17-213"><a href="#cb17-213" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Reference"</span>, <span class="st">"Why it's reasonable"</span>),</span>
<span id="cb17-214"><a href="#cb17-214" aria-hidden="true" tabindex="-1"></a>  <span class="at">align =</span> <span class="st">"l"</span>,</span>
<span id="cb17-215"><a href="#cb17-215" aria-hidden="true" tabindex="-1"></a>  <span class="at">caption =</span> <span class="st">"Simulation assumptions for OsteoGuard treatment modelling"</span></span>
<span id="cb17-216"><a href="#cb17-216" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb17-217"><a href="#cb17-217" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb17-218"><a href="#cb17-218" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb17-219"><a href="#cb17-219" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="st">"condensed"</span>,   <span class="co"># no striped</span></span>
<span id="cb17-220"><a href="#cb17-220" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb17-221"><a href="#cb17-221" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-222"><a href="#cb17-222" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-223"><a href="#cb17-223" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-224"><a href="#cb17-224" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"22em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-225"><a href="#cb17-225" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">3</span>, <span class="at">width =</span> <span class="st">"14em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-226"><a href="#cb17-226" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">4</span>, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-227"><a href="#cb17-227" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">5</span>, <span class="at">width =</span> <span class="st">"26em"</span>)</span>
<span id="cb17-228"><a href="#cb17-228" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-229"><a href="#cb17-229" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-230"><a href="#cb17-230" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-231"><a href="#cb17-231" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-232"><a href="#cb17-232" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Cleaning Phase 1 data</span></span>
<span id="cb17-233"><a href="#cb17-233" aria-hidden="true" tabindex="-1"></a>Phase 1 included all 3,107 individuals in the analytic sample, encompassing both those classified as at risk</span>
<span id="cb17-234"><a href="#cb17-234" aria-hidden="true" tabindex="-1"></a>and not at risk under the revised screening logic.</span>
<span id="cb17-235"><a href="#cb17-235" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-236"><a href="#cb17-236" aria-hidden="true" tabindex="-1"></a>For Phase 2, the dataset was restricted to the missed high-risk subgroup (n = 508) - individuals who met</span>
<span id="cb17-237"><a href="#cb17-237" aria-hidden="true" tabindex="-1"></a>high-risk clinical criteria but were not captured under current screening guidelines.</span>
<span id="cb17-238"><a href="#cb17-238" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-239"><a href="#cb17-239" aria-hidden="true" tabindex="-1"></a>Missed high-risk individuals were defined as those with either:</span>
<span id="cb17-240"><a href="#cb17-240" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-241"><a href="#cb17-241" aria-hidden="true" tabindex="-1"></a><span class="ss">- </span>Osteoporosis-range DXA T-scores (≤ -2.5), or</span>
<span id="cb17-242"><a href="#cb17-242" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-243"><a href="#cb17-243" aria-hidden="true" tabindex="-1"></a><span class="ss">- </span>Osteopenia-range T-scores (-1.0 to -2.5) plus at least one additional risk factor (prior fracture, smoking</span>
<span id="cb17-244"><a href="#cb17-244" aria-hidden="true" tabindex="-1"></a>history, low BMI, or low physical activity),</span>
<span id="cb17-245"><a href="#cb17-245" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-246"><a href="#cb17-246" aria-hidden="true" tabindex="-1"></a>and who would not have been eligible for screening under age-based criteria.</span>
<span id="cb17-247"><a href="#cb17-247" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-248"><a href="#cb17-248" aria-hidden="true" tabindex="-1"></a>This subgroup represents a clinically meaningful and commercially untapped population.</span>
<span id="cb17-249"><a href="#cb17-249" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-252"><a href="#cb17-252" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-253"><a href="#cb17-253" aria-hidden="true" tabindex="-1"></a><span class="co"># Filtering for missed high risk individuals only</span></span>
<span id="cb17-254"><a href="#cb17-254" aria-hidden="true" tabindex="-1"></a>data <span class="ot">&lt;-</span> phase_1 <span class="sc">%&gt;%</span></span>
<span id="cb17-255"><a href="#cb17-255" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(missed_high_risk <span class="sc">==</span> <span class="dv">1</span>)</span>
<span id="cb17-256"><a href="#cb17-256" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-257"><a href="#cb17-257" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-258"><a href="#cb17-258" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-259"><a href="#cb17-259" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Simulating OsteoGuard data</span></span>
<span id="cb17-260"><a href="#cb17-260" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-261"><a href="#cb17-261" aria-hidden="true" tabindex="-1"></a>Using the Phase 1 dataset, which included baseline DXA measurements and risk factor data, we simulated follow-up data at 12- and 24-months. This included:</span>
<span id="cb17-262"><a href="#cb17-262" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-263"><a href="#cb17-263" aria-hidden="true" tabindex="-1"></a>-&gt; Longitudinal BMD values for the lumbar spine</span>
<span id="cb17-264"><a href="#cb17-264" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-265"><a href="#cb17-265" aria-hidden="true" tabindex="-1"></a>-&gt; Corresponding T-scores calculated from the simulated BMDs</span>
<span id="cb17-266"><a href="#cb17-266" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-267"><a href="#cb17-267" aria-hidden="true" tabindex="-1"></a>-&gt; Fracture risk profiles</span>
<span id="cb17-268"><a href="#cb17-268" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-269"><a href="#cb17-269" aria-hidden="true" tabindex="-1"></a>-&gt; Discontinuation</span>
<span id="cb17-270"><a href="#cb17-270" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-271"><a href="#cb17-271" aria-hidden="true" tabindex="-1"></a>The simulated dataset reflects expected clinical trajectories and allows evaluation of OsteoGuard screening logic and bisphosphonate eligibility over a 2-year follow-up period.</span>
<span id="cb17-272"><a href="#cb17-272" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-275"><a href="#cb17-275" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-276"><a href="#cb17-276" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulating treatment data</span></span>
<span id="cb17-277"><a href="#cb17-277" aria-hidden="true" tabindex="-1"></a><span class="co"># 1) 50/50 randomization</span></span>
<span id="cb17-278"><a href="#cb17-278" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">123</span>)</span>
<span id="cb17-279"><a href="#cb17-279" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-280"><a href="#cb17-280" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-281"><a href="#cb17-281" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(missed_high_risk) <span class="sc">%&gt;%</span></span>
<span id="cb17-282"><a href="#cb17-282" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">treatment_group =</span> <span class="fu">sample</span>(<span class="fu">rep</span>(<span class="fu">c</span>(<span class="st">"Treatment"</span>, <span class="st">"Control"</span>), <span class="at">length.out =</span> <span class="fu">n</span>()))) <span class="sc">%&gt;%</span></span>
<span id="cb17-283"><a href="#cb17-283" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ungroup</span>() <span class="sc">%&gt;%</span></span>
<span id="cb17-284"><a href="#cb17-284" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">treatment_group =</span> <span class="fu">factor</span>(treatment_group, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"Control"</span>, <span class="st">"Treatment"</span>)))</span>
<span id="cb17-285"><a href="#cb17-285" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-286"><a href="#cb17-286" aria-hidden="true" tabindex="-1"></a><span class="co"># 2) Assigning adherence</span></span>
<span id="cb17-287"><a href="#cb17-287" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">125</span>)</span>
<span id="cb17-288"><a href="#cb17-288" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-289"><a href="#cb17-289" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-290"><a href="#cb17-290" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-291"><a href="#cb17-291" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-292"><a href="#cb17-292" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">~</span> <span class="fu">sample</span>(</span>
<span id="cb17-293"><a href="#cb17-293" aria-hidden="true" tabindex="-1"></a>        <span class="at">x =</span> <span class="fu">c</span>(<span class="st">"High"</span>, <span class="st">"Moderate"</span>, <span class="st">"Poor"</span>),</span>
<span id="cb17-294"><a href="#cb17-294" aria-hidden="true" tabindex="-1"></a>        <span class="at">size =</span> <span class="fu">n</span>(),</span>
<span id="cb17-295"><a href="#cb17-295" aria-hidden="true" tabindex="-1"></a>        <span class="at">replace =</span> <span class="cn">TRUE</span>,</span>
<span id="cb17-296"><a href="#cb17-296" aria-hidden="true" tabindex="-1"></a>        <span class="at">prob =</span> <span class="fu">c</span>(<span class="fl">0.40</span>, <span class="fl">0.35</span>, <span class="fl">0.25</span>)</span>
<span id="cb17-297"><a href="#cb17-297" aria-hidden="true" tabindex="-1"></a>      ),</span>
<span id="cb17-298"><a href="#cb17-298" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb17-299"><a href="#cb17-299" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb17-300"><a href="#cb17-300" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group =</span> <span class="fu">factor</span>(adherence_group, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"High"</span>, <span class="st">"Moderate"</span>, <span class="st">"Poor"</span>))</span>
<span id="cb17-301"><a href="#cb17-301" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-302"><a href="#cb17-302" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-303"><a href="#cb17-303" aria-hidden="true" tabindex="-1"></a><span class="co"># 3) Simulate BMD % change (12m) + incremental gain (12→24m)</span></span>
<span id="cb17-304"><a href="#cb17-304" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-305"><a href="#cb17-305" aria-hidden="true" tabindex="-1"></a><span class="co"># SD for 12-month % change</span></span>
<span id="cb17-306"><a href="#cb17-306" aria-hidden="true" tabindex="-1"></a>sd_bmd_12 <span class="ot">&lt;-</span> <span class="fl">0.8</span></span>
<span id="cb17-307"><a href="#cb17-307" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-308"><a href="#cb17-308" aria-hidden="true" tabindex="-1"></a><span class="co"># 12-month means </span></span>
<span id="cb17-309"><a href="#cb17-309" aria-hidden="true" tabindex="-1"></a>mu_12_ideal <span class="ot">&lt;-</span> <span class="fl">4.6</span></span>
<span id="cb17-310"><a href="#cb17-310" aria-hidden="true" tabindex="-1"></a>mu_12_avg   <span class="ot">&lt;-</span> <span class="fl">2.8</span></span>
<span id="cb17-311"><a href="#cb17-311" aria-hidden="true" tabindex="-1"></a>mu_12_poor  <span class="ot">&lt;-</span> <span class="fl">1.2</span></span>
<span id="cb17-312"><a href="#cb17-312" aria-hidden="true" tabindex="-1"></a>mu_12_ctrl  <span class="ot">&lt;-</span> <span class="sc">-</span><span class="fl">0.9</span></span>
<span id="cb17-313"><a href="#cb17-313" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-314"><a href="#cb17-314" aria-hidden="true" tabindex="-1"></a><span class="co"># Incremental change from 12m to 24m (percentage points)</span></span>
<span id="cb17-315"><a href="#cb17-315" aria-hidden="true" tabindex="-1"></a><span class="co"># (Year-2 gains are smaller than Year-1; control continues to decline)</span></span>
<span id="cb17-316"><a href="#cb17-316" aria-hidden="true" tabindex="-1"></a>sd_inc <span class="ot">&lt;-</span> <span class="fl">0.4</span></span>
<span id="cb17-317"><a href="#cb17-317" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-318"><a href="#cb17-318" aria-hidden="true" tabindex="-1"></a>inc_ideal <span class="ot">&lt;-</span> <span class="fl">0.8</span>   <span class="co"># additional gain (High adherence)</span></span>
<span id="cb17-319"><a href="#cb17-319" aria-hidden="true" tabindex="-1"></a>inc_avg   <span class="ot">&lt;-</span> <span class="fl">0.5</span>   <span class="co"># additional gain (Moderate adherence)</span></span>
<span id="cb17-320"><a href="#cb17-320" aria-hidden="true" tabindex="-1"></a>inc_poor  <span class="ot">&lt;-</span> <span class="fl">0.2</span>   <span class="co"># additional gain (Poor adherence)</span></span>
<span id="cb17-321"><a href="#cb17-321" aria-hidden="true" tabindex="-1"></a>inc_ctrl  <span class="ot">&lt;-</span> <span class="sc">-</span><span class="fl">0.6</span>  <span class="co"># additional decline in control arm</span></span>
<span id="cb17-322"><a href="#cb17-322" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-323"><a href="#cb17-323" aria-hidden="true" tabindex="-1"></a><span class="co"># Assigning BMD</span></span>
<span id="cb17-324"><a href="#cb17-324" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">125</span>)</span>
<span id="cb17-325"><a href="#cb17-325" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-326"><a href="#cb17-326" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-327"><a href="#cb17-327" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-328"><a href="#cb17-328" aria-hidden="true" tabindex="-1"></a>    <span class="co"># 12-month % change</span></span>
<span id="cb17-329"><a href="#cb17-329" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_12m_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-330"><a href="#cb17-330" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ctrl, <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb17-331"><a href="#cb17-331" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span>     <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ideal, <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb17-332"><a href="#cb17-332" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_avg,   <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb17-333"><a href="#cb17-333" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span>     <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_poor,  <span class="at">sd =</span> sd_bmd_12),</span>
<span id="cb17-334"><a href="#cb17-334" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb17-335"><a href="#cb17-335" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb17-336"><a href="#cb17-336" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-337"><a href="#cb17-337" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-338"><a href="#cb17-338" aria-hidden="true" tabindex="-1"></a>  <span class="co"># incremental 12→24m % change </span></span>
<span id="cb17-339"><a href="#cb17-339" aria-hidden="true" tabindex="-1"></a>  <span class="at">bmd_inc_12to24_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-340"><a href="#cb17-340" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_ctrl, <span class="at">sd =</span> sd_inc),</span>
<span id="cb17-341"><a href="#cb17-341" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_ideal, <span class="at">sd =</span> sd_inc), <span class="fl">0.2</span>),   <span class="co"># min 0.2%</span></span>
<span id="cb17-342"><a href="#cb17-342" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_avg, <span class="at">sd =</span> sd_inc), <span class="fl">0.1</span>), <span class="co"># min 0.1%</span></span>
<span id="cb17-343"><a href="#cb17-343" aria-hidden="true" tabindex="-1"></a>   treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span> <span class="sc">~</span> <span class="fu">pmax</span>(<span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> inc_poor, <span class="at">sd =</span> sd_inc), <span class="dv">0</span>),  <span class="co"># allow 0 or small gains</span></span>
<span id="cb17-344"><a href="#cb17-344" aria-hidden="true" tabindex="-1"></a>   <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb17-345"><a href="#cb17-345" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb17-346"><a href="#cb17-346" aria-hidden="true" tabindex="-1"></a>,</span>
<span id="cb17-347"><a href="#cb17-347" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-348"><a href="#cb17-348" aria-hidden="true" tabindex="-1"></a>    <span class="co"># 24-month % change = 12-month + increment</span></span>
<span id="cb17-349"><a href="#cb17-349" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_24m_pct =</span> bmd_change_12m_pct <span class="sc">+</span> bmd_inc_12to24_pct</span>
<span id="cb17-350"><a href="#cb17-350" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-351"><a href="#cb17-351" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-352"><a href="#cb17-352" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-353"><a href="#cb17-353" aria-hidden="true" tabindex="-1"></a><span class="co"># 4) Convert % change → post-treatment BMD and T-score</span></span>
<span id="cb17-354"><a href="#cb17-354" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-355"><a href="#cb17-355" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-356"><a href="#cb17-356" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_12m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_12m_pct <span class="sc">/</span> <span class="dv">100</span>),</span>
<span id="cb17-357"><a href="#cb17-357" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_24m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_24m_pct <span class="sc">/</span> <span class="dv">100</span>)</span>
<span id="cb17-358"><a href="#cb17-358" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-359"><a href="#cb17-359" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-360"><a href="#cb17-360" aria-hidden="true" tabindex="-1"></a><span class="co"># Compute 12m and 24m T-scores</span></span>
<span id="cb17-361"><a href="#cb17-361" aria-hidden="true" tabindex="-1"></a>ref_spine_mean <span class="ot">&lt;-</span> <span class="fl">1.065</span></span>
<span id="cb17-362"><a href="#cb17-362" aria-hidden="true" tabindex="-1"></a>ref_spine_sd   <span class="ot">&lt;-</span> <span class="fl">0.122</span></span>
<span id="cb17-363"><a href="#cb17-363" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-364"><a href="#cb17-364" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-365"><a href="#cb17-365" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-366"><a href="#cb17-366" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_12m =</span> (bmd_spine_12m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd,</span>
<span id="cb17-367"><a href="#cb17-367" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_24m =</span> (bmd_spine_24m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd</span>
<span id="cb17-368"><a href="#cb17-368" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-369"><a href="#cb17-369" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-370"><a href="#cb17-370" aria-hidden="true" tabindex="-1"></a><span class="co"># Classify at 24 months</span></span>
<span id="cb17-371"><a href="#cb17-371" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-372"><a href="#cb17-372" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-373"><a href="#cb17-373" aria-hidden="true" tabindex="-1"></a>    <span class="at">spine_class_24m =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-374"><a href="#cb17-374" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&gt;=</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">~</span> <span class="st">"Normal"</span>,</span>
<span id="cb17-375"><a href="#cb17-375" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">&amp;</span> tscore_spine_24m <span class="sc">&gt;</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteopenia"</span>,</span>
<span id="cb17-376"><a href="#cb17-376" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;=</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteoporosis"</span>,</span>
<span id="cb17-377"><a href="#cb17-377" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb17-378"><a href="#cb17-378" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb17-379"><a href="#cb17-379" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-380"><a href="#cb17-380" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-381"><a href="#cb17-381" aria-hidden="true" tabindex="-1"></a><span class="co"># 5)  Simulate fractures</span></span>
<span id="cb17-382"><a href="#cb17-382" aria-hidden="true" tabindex="-1"></a><span class="fu">set.seed</span>(<span class="dv">123</span>)</span>
<span id="cb17-383"><a href="#cb17-383" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-384"><a href="#cb17-384" aria-hidden="true" tabindex="-1"></a>p_fract_ctrl <span class="ot">&lt;-</span> <span class="fl">0.126</span></span>
<span id="cb17-385"><a href="#cb17-385" aria-hidden="true" tabindex="-1"></a>p_fract_trt  <span class="ot">&lt;-</span> <span class="fl">0.090</span></span>
<span id="cb17-386"><a href="#cb17-386" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-387"><a href="#cb17-387" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-388"><a href="#cb17-388" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-389"><a href="#cb17-389" aria-hidden="true" tabindex="-1"></a>    <span class="at">fracture_event =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-390"><a href="#cb17-390" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span>   <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, p_fract_ctrl),</span>
<span id="cb17-391"><a href="#cb17-391" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, p_fract_trt),</span>
<span id="cb17-392"><a href="#cb17-392" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_real_</span></span>
<span id="cb17-393"><a href="#cb17-393" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb17-394"><a href="#cb17-394" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-395"><a href="#cb17-395" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-396"><a href="#cb17-396" aria-hidden="true" tabindex="-1"></a><span class="co"># 6) Apply discontinuation effect: those who discontinue lose partial benefit</span></span>
<span id="cb17-397"><a href="#cb17-397" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-398"><a href="#cb17-398" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-399"><a href="#cb17-399" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-400"><a href="#cb17-400" aria-hidden="true" tabindex="-1"></a>    <span class="co"># Step 1: Randomly assign discontinuation at 12 months based on adherence</span></span>
<span id="cb17-401"><a href="#cb17-401" aria-hidden="true" tabindex="-1"></a>    <span class="at">discontinued =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-402"><a href="#cb17-402" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"High"</span>     <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.10</span>),</span>
<span id="cb17-403"><a href="#cb17-403" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Moderate"</span> <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.30</span>),</span>
<span id="cb17-404"><a href="#cb17-404" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Treatment"</span> <span class="sc">&amp;</span> adherence_group <span class="sc">==</span> <span class="st">"Poor"</span>     <span class="sc">~</span> <span class="fu">rbinom</span>(<span class="fu">n</span>(), <span class="dv">1</span>, <span class="fl">0.60</span>),</span>
<span id="cb17-405"><a href="#cb17-405" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="dv">0</span></span>
<span id="cb17-406"><a href="#cb17-406" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb17-407"><a href="#cb17-407" aria-hidden="true" tabindex="-1"></a>    <span class="co"># Step 2: For 24-month BMD, if discontinued, apply control decline from 12m BMD</span></span>
<span id="cb17-408"><a href="#cb17-408" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_change_24m_pct =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-409"><a href="#cb17-409" aria-hidden="true" tabindex="-1"></a>      discontinued <span class="sc">==</span> <span class="dv">1</span> <span class="sc">~</span> bmd_change_12m_pct <span class="sc">+</span> <span class="fu">rnorm</span>(<span class="fu">n</span>(), <span class="at">mean =</span> mu_12_ctrl, <span class="at">sd =</span> sd_inc),</span>
<span id="cb17-410"><a href="#cb17-410" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span>             <span class="sc">~</span> bmd_change_12m_pct <span class="sc">+</span> bmd_inc_12to24_pct  <span class="co"># adherent patients follow original increment</span></span>
<span id="cb17-411"><a href="#cb17-411" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb17-412"><a href="#cb17-412" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-413"><a href="#cb17-413" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Step 3: Recalculate 24-month BMD and T-score</span></span>
<span id="cb17-414"><a href="#cb17-414" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-415"><a href="#cb17-415" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_spine_24m =</span> DXXLSBMD <span class="sc">*</span> (<span class="dv">1</span> <span class="sc">+</span> bmd_change_24m_pct <span class="sc">/</span> <span class="dv">100</span>),</span>
<span id="cb17-416"><a href="#cb17-416" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_spine_24m =</span> (bmd_spine_24m <span class="sc">-</span> ref_spine_mean) <span class="sc">/</span> ref_spine_sd,</span>
<span id="cb17-417"><a href="#cb17-417" aria-hidden="true" tabindex="-1"></a>    <span class="at">spine_class_24m =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-418"><a href="#cb17-418" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&gt;=</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">~</span> <span class="st">"Normal"</span>,</span>
<span id="cb17-419"><a href="#cb17-419" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;</span> <span class="sc">-</span><span class="dv">1</span> <span class="sc">&amp;</span> tscore_spine_24m <span class="sc">&gt;</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteopenia"</span>,</span>
<span id="cb17-420"><a href="#cb17-420" aria-hidden="true" tabindex="-1"></a>      tscore_spine_24m <span class="sc">&lt;=</span> <span class="sc">-</span><span class="fl">2.5</span> <span class="sc">~</span> <span class="st">"Osteoporosis"</span>,</span>
<span id="cb17-421"><a href="#cb17-421" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="cn">NA_character_</span></span>
<span id="cb17-422"><a href="#cb17-422" aria-hidden="true" tabindex="-1"></a>    )</span>
<span id="cb17-423"><a href="#cb17-423" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-424"><a href="#cb17-424" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-425"><a href="#cb17-425" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-426"><a href="#cb17-426" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-427"><a href="#cb17-427" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-428"><a href="#cb17-428" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-429"><a href="#cb17-429" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Analysis</span></span>
<span id="cb17-430"><a href="#cb17-430" aria-hidden="true" tabindex="-1"></a>The analysis section examines the efficacy of the study drug, OsteoGuard, by comparing lumbar spine BMD outcomes across adherence groups. Summary statistics include mean BMD at 24 months, percentage change from baseline, and adherence-stratified comparisons to illustrate the impact of treatment and adherence on bone health.</span>
<span id="cb17-431"><a href="#cb17-431" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-432"><a href="#cb17-432" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-433"><a href="#cb17-433" aria-hidden="true" tabindex="-1"></a>The following table summarizes lumbar spine BMD at baseline and 24 months across adherence groups. It includes the mean and standard deviation at each time point, as well as the percentage change from baseline, providing a clear view of treatment-related bone gains. Higher percentage increases in the high adherence group illustrate the efficacy of the study drug relative to lower adherence, discontinued and control groups.</span>
<span id="cb17-436"><a href="#cb17-436" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-437"><a href="#cb17-437" aria-hidden="true" tabindex="-1"></a><span class="co"># Summarize baseline, 24-month BMD, and percent change by adherence group</span></span>
<span id="cb17-438"><a href="#cb17-438" aria-hidden="true" tabindex="-1"></a>data <span class="sc">%&lt;&gt;%</span></span>
<span id="cb17-439"><a href="#cb17-439" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-440"><a href="#cb17-440" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group_updated =</span> <span class="fu">case_when</span>(</span>
<span id="cb17-441"><a href="#cb17-441" aria-hidden="true" tabindex="-1"></a>      treatment_group <span class="sc">==</span> <span class="st">"Control"</span> <span class="sc">~</span> <span class="st">"Control"</span>,</span>
<span id="cb17-442"><a href="#cb17-442" aria-hidden="true" tabindex="-1"></a>      discontinued <span class="sc">==</span> <span class="dv">1</span> <span class="sc">~</span> <span class="st">"Discontinued"</span>,</span>
<span id="cb17-443"><a href="#cb17-443" aria-hidden="true" tabindex="-1"></a>      <span class="cn">TRUE</span> <span class="sc">~</span> <span class="fu">as.character</span>(adherence_group)</span>
<span id="cb17-444"><a href="#cb17-444" aria-hidden="true" tabindex="-1"></a>    ),</span>
<span id="cb17-445"><a href="#cb17-445" aria-hidden="true" tabindex="-1"></a>    <span class="at">adherence_group_updated =</span> <span class="fu">factor</span>(adherence_group_updated,</span>
<span id="cb17-446"><a href="#cb17-446" aria-hidden="true" tabindex="-1"></a>                              <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"Control"</span>, <span class="st">"Poor"</span>, <span class="st">"Moderate"</span>, <span class="st">"High"</span>, <span class="st">"Discontinued"</span>))</span>
<span id="cb17-447"><a href="#cb17-447" aria-hidden="true" tabindex="-1"></a>  ) </span>
<span id="cb17-448"><a href="#cb17-448" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-449"><a href="#cb17-449" aria-hidden="true" tabindex="-1"></a>bmd_summary <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span> </span>
<span id="cb17-450"><a href="#cb17-450" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(adherence_group_updated) <span class="sc">%&gt;%</span></span>
<span id="cb17-451"><a href="#cb17-451" aria-hidden="true" tabindex="-1"></a>  <span class="fu">summarize</span>(</span>
<span id="cb17-452"><a href="#cb17-452" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Baseline BMD (g/cm²)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>(DXXLSBMD, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb17-453"><a href="#cb17-453" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Baseline SD</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">sd</span>(DXXLSBMD, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb17-454"><a href="#cb17-454" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">24-Month BMD (g/cm²)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>(bmd_spine_24m, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb17-455"><a href="#cb17-455" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">24-Month SD</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">sd</span>(bmd_spine_24m, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb17-456"><a href="#cb17-456" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Percent Change (%)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">mean</span>((bmd_spine_24m <span class="sc">-</span> DXXLSBMD) <span class="sc">/</span> DXXLSBMD <span class="sc">*</span> <span class="dv">100</span>, <span class="at">na.rm =</span> <span class="cn">TRUE</span>),</span>
<span id="cb17-457"><a href="#cb17-457" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">n</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">n</span>(),</span>
<span id="cb17-458"><a href="#cb17-458" aria-hidden="true" tabindex="-1"></a>    <span class="at">.groups =</span> <span class="st">"drop"</span></span>
<span id="cb17-459"><a href="#cb17-459" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span> </span>
<span id="cb17-460"><a href="#cb17-460" aria-hidden="true" tabindex="-1"></a>    <span class="fu">rename</span>(<span class="st">`</span><span class="at">Adherence Group</span><span class="st">`</span> <span class="ot">=</span> adherence_group_updated)</span>
<span id="cb17-461"><a href="#cb17-461" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-462"><a href="#cb17-462" aria-hidden="true" tabindex="-1"></a><span class="co"># Render the table</span></span>
<span id="cb17-463"><a href="#cb17-463" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(bmd_summary,</span>
<span id="cb17-464"><a href="#cb17-464" aria-hidden="true" tabindex="-1"></a>    <span class="at">caption =</span> <span class="st">"Lumbar Spine BMD at Baseline and 24 Months by Adherence Group"</span>,</span>
<span id="cb17-465"><a href="#cb17-465" aria-hidden="true" tabindex="-1"></a>    <span class="at">digits =</span> <span class="dv">3</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-466"><a href="#cb17-466" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(<span class="at">full_width =</span> <span class="cn">FALSE</span>, <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>))</span>
<span id="cb17-467"><a href="#cb17-467" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-468"><a href="#cb17-468" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-469"><a href="#cb17-469" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-470"><a href="#cb17-470" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-473"><a href="#cb17-473" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-474"><a href="#cb17-474" aria-hidden="true" tabindex="-1"></a><span class="co"># Preparing data in long format for plotting</span></span>
<span id="cb17-475"><a href="#cb17-475" aria-hidden="true" tabindex="-1"></a>plot_df <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span></span>
<span id="cb17-476"><a href="#cb17-476" aria-hidden="true" tabindex="-1"></a>  <span class="fu">select</span>(treatment_group, DXXLSBMD, bmd_spine_12m, bmd_spine_24m,</span>
<span id="cb17-477"><a href="#cb17-477" aria-hidden="true" tabindex="-1"></a>         tscore_spine, tscore_spine_12m, tscore_spine_24m) <span class="sc">%&gt;%</span></span>
<span id="cb17-478"><a href="#cb17-478" aria-hidden="true" tabindex="-1"></a>  <span class="fu">rename</span>(</span>
<span id="cb17-479"><a href="#cb17-479" aria-hidden="true" tabindex="-1"></a>    <span class="at">bmd_baseline =</span> DXXLSBMD,</span>
<span id="cb17-480"><a href="#cb17-480" aria-hidden="true" tabindex="-1"></a>    <span class="at">tscore_baseline =</span> tscore_spine</span>
<span id="cb17-481"><a href="#cb17-481" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-482"><a href="#cb17-482" aria-hidden="true" tabindex="-1"></a>  <span class="fu">pivot_longer</span>(</span>
<span id="cb17-483"><a href="#cb17-483" aria-hidden="true" tabindex="-1"></a>    <span class="at">cols =</span> <span class="sc">-</span>treatment_group,</span>
<span id="cb17-484"><a href="#cb17-484" aria-hidden="true" tabindex="-1"></a>    <span class="at">names_to =</span> <span class="fu">c</span>(<span class="st">"Metric"</span>, <span class="st">"Time"</span>),</span>
<span id="cb17-485"><a href="#cb17-485" aria-hidden="true" tabindex="-1"></a>    <span class="at">names_pattern =</span> <span class="st">"([a-z]+).*_?(baseline|12m|24m)$"</span>,</span>
<span id="cb17-486"><a href="#cb17-486" aria-hidden="true" tabindex="-1"></a>    <span class="at">values_to =</span> <span class="st">"Value"</span></span>
<span id="cb17-487"><a href="#cb17-487" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span> </span>
<span id="cb17-488"><a href="#cb17-488" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(<span class="at">Time =</span> <span class="fu">factor</span>(Time, <span class="at">levels =</span> <span class="fu">c</span>(<span class="st">"baseline"</span>, <span class="st">"12m"</span>, <span class="st">"24m"</span>)))</span>
<span id="cb17-489"><a href="#cb17-489" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-490"><a href="#cb17-490" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-491"><a href="#cb17-491" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-492"><a href="#cb17-492" aria-hidden="true" tabindex="-1"></a>The below line plots provides a visual demonstration of this relationship, showing the average lumbar spine bone mineral density (BMD) and the average lumbar spine T-scores over baseline, 12 months, and 24 months for the treatment and control groups, with standard error bars. Values are calculated as the mean BMD or T-score at each timepoint for each group. The trends are identical as T-scores are derived from BMD scores and indicate that the treatment group experiences an increase in BMD over time, while the control group shows a slight decline, suggesting a positive effect of the therapy on bone density.</span>
<span id="cb17-493"><a href="#cb17-493" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-496"><a href="#cb17-496" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-497"><a href="#cb17-497" aria-hidden="true" tabindex="-1"></a><span class="co">#| fig-height: 4</span></span>
<span id="cb17-498"><a href="#cb17-498" aria-hidden="true" tabindex="-1"></a><span class="co">#| fig-width: 12</span></span>
<span id="cb17-499"><a href="#cb17-499" aria-hidden="true" tabindex="-1"></a><span class="co"># BMD plot</span></span>
<span id="cb17-500"><a href="#cb17-500" aria-hidden="true" tabindex="-1"></a>bmd_plot <span class="ot">&lt;-</span> plot_df <span class="sc">%&gt;%</span></span>
<span id="cb17-501"><a href="#cb17-501" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(Metric <span class="sc">==</span> <span class="st">"bmd"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-502"><a href="#cb17-502" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> Time, <span class="at">y =</span> Value, <span class="at">group =</span> treatment_group, <span class="at">color =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb17-503"><a href="#cb17-503" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun =</span> mean, <span class="at">geom =</span> <span class="st">"line"</span>, <span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb17-504"><a href="#cb17-504" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun.data =</span> mean_se, <span class="at">geom =</span> <span class="st">"errorbar"</span>, <span class="at">width =</span> <span class="fl">0.2</span>) <span class="sc">+</span></span>
<span id="cb17-505"><a href="#cb17-505" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb17-506"><a href="#cb17-506" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Lumbar Spine BMD over time"</span>, <span class="at">x =</span> <span class="st">"Timepoint"</span>, <span class="at">y =</span> <span class="st">"BMD (g/cm²)"</span>, <span class="at">color =</span> <span class="st">"Group"</span>) <span class="sc">+</span></span>
<span id="cb17-507"><a href="#cb17-507" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb17-508"><a href="#cb17-508" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-509"><a href="#cb17-509" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-510"><a href="#cb17-510" aria-hidden="true" tabindex="-1"></a><span class="co"># T-score plot</span></span>
<span id="cb17-511"><a href="#cb17-511" aria-hidden="true" tabindex="-1"></a>tscore_plot <span class="ot">&lt;-</span> plot_df <span class="sc">%&gt;%</span></span>
<span id="cb17-512"><a href="#cb17-512" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(Metric <span class="sc">==</span> <span class="st">"tscore"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-513"><a href="#cb17-513" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> Time, <span class="at">y =</span> Value, <span class="at">group =</span> treatment_group, <span class="at">color =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb17-514"><a href="#cb17-514" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun =</span> mean, <span class="at">geom =</span> <span class="st">"line"</span>, <span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb17-515"><a href="#cb17-515" aria-hidden="true" tabindex="-1"></a>  <span class="fu">stat_summary</span>(<span class="at">fun.data =</span> mean_se, <span class="at">geom =</span> <span class="st">"errorbar"</span>, <span class="at">width =</span> <span class="fl">0.2</span>) <span class="sc">+</span></span>
<span id="cb17-516"><a href="#cb17-516" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb17-517"><a href="#cb17-517" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Lumbar Spine T-score over time"</span>, <span class="at">x =</span> <span class="st">"Timepoint"</span>, <span class="at">y =</span> <span class="st">"T-score"</span>, <span class="at">color =</span> <span class="st">"Group"</span>) <span class="sc">+</span></span>
<span id="cb17-518"><a href="#cb17-518" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb17-519"><a href="#cb17-519" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-520"><a href="#cb17-520" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-521"><a href="#cb17-521" aria-hidden="true" tabindex="-1"></a><span class="co"># Combine plots side by side</span></span>
<span id="cb17-522"><a href="#cb17-522" aria-hidden="true" tabindex="-1"></a>bmd_plot <span class="sc">+</span> tscore_plot <span class="sc">+</span> </span>
<span id="cb17-523"><a href="#cb17-523" aria-hidden="true" tabindex="-1"></a>  <span class="fu">plot_layout</span>(<span class="at">ncol =</span> <span class="dv">2</span>) <span class="sc">+</span> </span>
<span id="cb17-524"><a href="#cb17-524" aria-hidden="true" tabindex="-1"></a>  <span class="fu">plot_annotation</span>(</span>
<span id="cb17-525"><a href="#cb17-525" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Lumbar Spine Bone Health Over Time"</span>,</span>
<span id="cb17-526"><a href="#cb17-526" aria-hidden="true" tabindex="-1"></a>    <span class="at">subtitle =</span> <span class="st">"BMD (g/cm²) and T-score trends by treatment group"</span></span>
<span id="cb17-527"><a href="#cb17-527" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-528"><a href="#cb17-528" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-529"><a href="#cb17-529" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-530"><a href="#cb17-530" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-531"><a href="#cb17-531" aria-hidden="true" tabindex="-1"></a>This below bar plot shows the proportion of patients experiencing a fracture in the treatment versus control groups over the study period. Fracture rates are calculated as the mean of the binary fracture_event variable within each group. The plot indicates that the treatment group has a lower fracture incidence compared to control, suggesting that the therapy effectively reduces fracture risk.</span>
<span id="cb17-532"><a href="#cb17-532" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-535"><a href="#cb17-535" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-536"><a href="#cb17-536" aria-hidden="true" tabindex="-1"></a><span class="co"># Fracture incidence bar plot</span></span>
<span id="cb17-537"><a href="#cb17-537" aria-hidden="true" tabindex="-1"></a>fracture_df <span class="ot">&lt;-</span> data <span class="sc">%&gt;%</span></span>
<span id="cb17-538"><a href="#cb17-538" aria-hidden="true" tabindex="-1"></a>  <span class="fu">group_by</span>(treatment_group) <span class="sc">%&gt;%</span></span>
<span id="cb17-539"><a href="#cb17-539" aria-hidden="true" tabindex="-1"></a>  <span class="fu">summarise</span>(</span>
<span id="cb17-540"><a href="#cb17-540" aria-hidden="true" tabindex="-1"></a>    <span class="at">Fracture_Rate =</span> <span class="fu">mean</span>(fracture_event)</span>
<span id="cb17-541"><a href="#cb17-541" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-542"><a href="#cb17-542" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-543"><a href="#cb17-543" aria-hidden="true" tabindex="-1"></a>fracture_plot <span class="ot">&lt;-</span> <span class="fu">ggplot</span>(fracture_df, <span class="fu">aes</span>(<span class="at">x =</span> treatment_group, <span class="at">y =</span> Fracture_Rate, <span class="at">fill =</span> treatment_group)) <span class="sc">+</span></span>
<span id="cb17-544"><a href="#cb17-544" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_col</span>(<span class="at">width =</span> <span class="fl">0.6</span>) <span class="sc">+</span></span>
<span id="cb17-545"><a href="#cb17-545" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_fill_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"Control"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"Treatment"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>)) <span class="sc">+</span></span>
<span id="cb17-546"><a href="#cb17-546" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(<span class="at">title =</span> <span class="st">"Fracture Incidence by Treatment Group"</span>, <span class="at">x =</span> <span class="st">"Group"</span>, <span class="at">y =</span> <span class="st">"Proportion"</span>) <span class="sc">+</span></span>
<span id="cb17-547"><a href="#cb17-547" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>) <span class="sc">+</span></span>
<span id="cb17-548"><a href="#cb17-548" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_text</span>(<span class="fu">aes</span>(<span class="at">label =</span> scales<span class="sc">::</span><span class="fu">percent</span>(Fracture_Rate, <span class="at">accuracy =</span> <span class="fl">0.1</span>)), <span class="at">vjust =</span> <span class="sc">-</span><span class="fl">0.5</span>) <span class="sc">+</span></span>
<span id="cb17-549"><a href="#cb17-549" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme</span>(<span class="at">legend.position =</span> <span class="st">"none"</span>)</span>
<span id="cb17-550"><a href="#cb17-550" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-551"><a href="#cb17-551" aria-hidden="true" tabindex="-1"></a>fracture_plot</span>
<span id="cb17-552"><a href="#cb17-552" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-553"><a href="#cb17-553" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-554"><a href="#cb17-554" aria-hidden="true" tabindex="-1"></a>The simulated trial demonstrates that the treatment group experienced meaningful improvements in lumbar spine BMD over 24 months, with gains strongly related to adherence. High adherence patients increased from 0.846g/cm² at baseline to 0.892g/cm² at 24 months, representing a 5.4% increase, while moderate and poor adherence groups showed smaller gains of 3.4% and 1.6%, respectively. Discontinued patients had a modest 1.1% increase, whereas the control group declined slightly from 0.858g/cm² to 0.845g/cm² (−1.6%), reflecting stable or deteriorating bone health without therapy.</span>
<span id="cb17-555"><a href="#cb17-555" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-556"><a href="#cb17-556" aria-hidden="true" tabindex="-1"></a>These differences highlight the efficacy of the study drug in improving skeletal outcomes. Coupled with lower simulated fracture incidence in the treated cohort, these results provide a clear foundation for the commercial simulation: treatment benefits translate into measurable risk reduction, inform the addressable population, and support revenue projections. The next phase models how enhanced screening and treatment adoption propagate these health gains into financial and market impact.</span>
<span id="cb17-557"><a href="#cb17-557" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-558"><a href="#cb17-558" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-559"><a href="#cb17-559" aria-hidden="true" tabindex="-1"></a><span class="fu">### Commercial Analytics</span></span>
<span id="cb17-560"><a href="#cb17-560" aria-hidden="true" tabindex="-1"></a>The commercial analytics section translates the simulated clinical trial into market-focused insights. Using the estimated addressable population, screening eligibility, and treatment uptake assumptions, this analysis models drug costs, revenue potential, and market size. The objective is to quantify how the therapy could perform commercially based on population-level adoption and projected patient numbers, providing a foundation for financial and strategic decision-making.</span>
<span id="cb17-561"><a href="#cb17-561" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-562"><a href="#cb17-562" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Simulating commercial data</span></span>
<span id="cb17-563"><a href="#cb17-563" aria-hidden="true" tabindex="-1"></a>Similarly to the clinical treatment assumptions, various assumptions were made in order to model the commercial aspects of this project. The below table outlines the key assumptions used in the OsteoGuard market simulation, including treatment pricing, manufacturing costs, and projected market uptake. Each parameter is supported by a reference or rationale, providing transparency and context for the subsequent financial and market impact analyses.</span>
<span id="cb17-566"><a href="#cb17-566" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-567"><a href="#cb17-567" aria-hidden="true" tabindex="-1"></a><span class="co"># Commercial assumptions table</span></span>
<span id="cb17-568"><a href="#cb17-568" aria-hidden="true" tabindex="-1"></a>commercial_assumptions_tbl <span class="ot">&lt;-</span> <span class="fu">tribble</span>(</span>
<span id="cb17-569"><a href="#cb17-569" aria-hidden="true" tabindex="-1"></a>  <span class="sc">~</span>Parameter, <span class="sc">~</span>Assumption, <span class="sc">~</span>Reference, <span class="sc">~</span><span class="st">`</span><span class="at">Why it's reasonable</span><span class="st">`</span>,</span>
<span id="cb17-570"><a href="#cb17-570" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-571"><a href="#cb17-571" aria-hidden="true" tabindex="-1"></a><span class="co"># Drug pricing</span></span>
<span id="cb17-572"><a href="#cb17-572" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly treatment price"</span>,</span>
<span id="cb17-573"><a href="#cb17-573" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$10.49"</span>,</span>
<span id="cb17-574"><a href="#cb17-574" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Generic bisphosphonate pricing per month (drugs.com)"</span>,</span>
<span id="cb17-575"><a href="#cb17-575" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents a conservative generic price suitable for scenario modelling."</span>,</span>
<span id="cb17-576"><a href="#cb17-576" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-577"><a href="#cb17-577" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Annual treatment cost (per patient)"</span>,</span>
<span id="cb17-578"><a href="#cb17-578" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$125.88"</span>,</span>
<span id="cb17-579"><a href="#cb17-579" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived from monthly pricing"</span>,</span>
<span id="cb17-580"><a href="#cb17-580" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Simple arithmetic derivation used for transparent cost modelling."</span>,</span>
<span id="cb17-581"><a href="#cb17-581" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-582"><a href="#cb17-582" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Manufacturing cost per patient/month"</span>,</span>
<span id="cb17-583"><a href="#cb17-583" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$1.04"</span>,</span>
<span id="cb17-584"><a href="#cb17-584" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Pharmaceutical Drug Prices and Trends for ALENDRONATE SODIUM, 2026 (drugpatentwatch.com)"</span>,</span>
<span id="cb17-585"><a href="#cb17-585" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Estimation of manufacturing cost based on limited available information."</span>,</span>
<span id="cb17-586"><a href="#cb17-586" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-587"><a href="#cb17-587" aria-hidden="true" tabindex="-1"></a> <span class="co"># Uptake &amp; market penetration</span></span>
<span id="cb17-588"><a href="#cb17-588" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Initial adoption (Month 1)"</span>,</span>
<span id="cb17-589"><a href="#cb17-589" aria-hidden="true" tabindex="-1"></a>  <span class="st">"10,000 patients"</span>,</span>
<span id="cb17-590"><a href="#cb17-590" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled starting point for simulation"</span>,</span>
<span id="cb17-591"><a href="#cb17-591" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects a realistic early adoption starting population for a new therapy."</span>,</span>
<span id="cb17-592"><a href="#cb17-592" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-593"><a href="#cb17-593" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Eligible population (high-risk, untreated adults)"</span>,</span>
<span id="cb17-594"><a href="#cb17-594" aria-hidden="true" tabindex="-1"></a>  <span class="st">"38,000,000"</span>,</span>
<span id="cb17-595"><a href="#cb17-595" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Derived from US adult population analysis"</span>,</span>
<span id="cb17-596"><a href="#cb17-596" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Represents total missed high-risk cohort; treatable pool assumed to be 50% (~19M patients), reflecting that not all high-risk adults will be eligible, willing, or clinically appropriate for therapy due to contraindications, comorbidities, or personal choice."</span>,</span>
<span id="cb17-597"><a href="#cb17-597" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-598"><a href="#cb17-598" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly conversion rate of untreated pool"</span>,</span>
<span id="cb17-599"><a href="#cb17-599" aria-hidden="true" tabindex="-1"></a>  <span class="st">"0.8%"</span>,</span>
<span id="cb17-600"><a href="#cb17-600" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb17-601"><a href="#cb17-601" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Slightly optimistic monthly uptake (~8-10% per year) under an aggressive screening program."</span>,</span>
<span id="cb17-602"><a href="#cb17-602" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-603"><a href="#cb17-603" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Market share ramp"</span>,</span>
<span id="cb17-604"><a href="#cb17-604" aria-hidden="true" tabindex="-1"></a>  <span class="st">"8% → 20% over 5 years"</span>,</span>
<span id="cb17-605"><a href="#cb17-605" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb17-606"><a href="#cb17-606" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Gradual adoption of the drug among new starts; logistic ramp reflects early adoption and plateau."</span>,</span>
<span id="cb17-607"><a href="#cb17-607" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-608"><a href="#cb17-608" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Monthly persistence / attrition"</span>,</span>
<span id="cb17-609"><a href="#cb17-609" aria-hidden="true" tabindex="-1"></a>  <span class="st">"97%"</span>,</span>
<span id="cb17-610"><a href="#cb17-610" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb17-611"><a href="#cb17-611" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Reflects real-world oral bisphosphonate discontinuation (~70% annual retention)."</span>,</span>
<span id="cb17-612"><a href="#cb17-612" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-613"><a href="#cb17-613" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Annual growth in market penetration"</span>,</span>
<span id="cb17-614"><a href="#cb17-614" aria-hidden="true" tabindex="-1"></a>  <span class="st">"logistic ramp"</span>,</span>
<span id="cb17-615"><a href="#cb17-615" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled assumption"</span>,</span>
<span id="cb17-616"><a href="#cb17-616" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Aligns with typical treatment adoption curves; incorporates finite pool constraints."</span>,</span>
<span id="cb17-617"><a href="#cb17-617" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-618"><a href="#cb17-618" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Customer Acquisition Cost (CAC)"</span>, </span>
<span id="cb17-619"><a href="#cb17-619" aria-hidden="true" tabindex="-1"></a>  <span class="st">"$100"</span>,</span>
<span id="cb17-620"><a href="#cb17-620" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Market assumption"</span>,</span>
<span id="cb17-621"><a href="#cb17-621" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Modeled estimate combining screening, physician engagement, onboarding; reflects typical early adoption cost for a preventive osteoporosis therapy targeting a small high-risk cohort"</span>,</span>
<span id="cb17-622"><a href="#cb17-622" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-623"><a href="#cb17-623" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Simulation horizon"</span>,</span>
<span id="cb17-624"><a href="#cb17-624" aria-hidden="true" tabindex="-1"></a>  <span class="st">"5 years / 60 months"</span>,</span>
<span id="cb17-625"><a href="#cb17-625" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Project timeline"</span>,</span>
<span id="cb17-626"><a href="#cb17-626" aria-hidden="true" tabindex="-1"></a>  <span class="st">"Long enough to capture ramp, plateau, and early profitability dynamics."</span></span>
<span id="cb17-627"><a href="#cb17-627" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-628"><a href="#cb17-628" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb17-629"><a href="#cb17-629" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-630"><a href="#cb17-630" aria-hidden="true" tabindex="-1"></a><span class="co"># Render table</span></span>
<span id="cb17-631"><a href="#cb17-631" aria-hidden="true" tabindex="-1"></a><span class="fu">kbl</span>(</span>
<span id="cb17-632"><a href="#cb17-632" aria-hidden="true" tabindex="-1"></a>  commercial_assumptions_tbl,</span>
<span id="cb17-633"><a href="#cb17-633" aria-hidden="true" tabindex="-1"></a>  <span class="at">format =</span> <span class="st">"html"</span>,</span>
<span id="cb17-634"><a href="#cb17-634" aria-hidden="true" tabindex="-1"></a>  <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Parameter"</span>, <span class="st">"Assumption"</span>,</span>
<span id="cb17-635"><a href="#cb17-635" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Reference"</span>, <span class="st">"Why it's reasonable"</span>),</span>
<span id="cb17-636"><a href="#cb17-636" aria-hidden="true" tabindex="-1"></a>  <span class="at">align =</span> <span class="st">"l"</span>,</span>
<span id="cb17-637"><a href="#cb17-637" aria-hidden="true" tabindex="-1"></a>  <span class="at">caption =</span> <span class="st">"Commercial assumptions for OsteoGuard market modelling"</span></span>
<span id="cb17-638"><a href="#cb17-638" aria-hidden="true" tabindex="-1"></a>) <span class="sc">%&gt;%</span></span>
<span id="cb17-639"><a href="#cb17-639" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb17-640"><a href="#cb17-640" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb17-641"><a href="#cb17-641" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="st">"condensed"</span>,</span>
<span id="cb17-642"><a href="#cb17-642" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb17-643"><a href="#cb17-643" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-644"><a href="#cb17-644" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-645"><a href="#cb17-645" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">width =</span> <span class="st">"22em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-646"><a href="#cb17-646" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"14em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-647"><a href="#cb17-647" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">3</span>, <span class="at">width =</span> <span class="st">"20em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-648"><a href="#cb17-648" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">4</span>, <span class="at">width =</span> <span class="st">"28em"</span>)</span>
<span id="cb17-649"><a href="#cb17-649" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-650"><a href="#cb17-650" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-651"><a href="#cb17-651" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-652"><a href="#cb17-652" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-653"><a href="#cb17-653" aria-hidden="true" tabindex="-1"></a>The commercial simulation projects patient uptake, market penetration, and financial outcomes for a hypothetical oral weekly bisphosphonate targeting high-risk, unscreened U.S. adults. The model scales from the estimated 38 million adults aged ≥20 who are currently high-risk but not captured under existing age-based screening criteria, of which approximately 50% are realistically treatable (~19 million). </span>
<span id="cb17-654"><a href="#cb17-654" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-655"><a href="#cb17-655" aria-hidden="true" tabindex="-1"></a>Monthly patient starts are initialized at 10,000, reflecting a conservative early adoption launch, and new patient uptake is modeled as a fraction of the remaining untreated pool (0.8% per month), adjusted for the drug’s logistic market share ramp from 8% to 20% over 5 years. Active patients are updated monthly using a persistence factor of 97% per month (~70% annual retention), reflecting real-world discontinuation rates for oral bisphosphonates. Revenue is calculated as active patients multiplied by the monthly treatment price ($10.49), while costs combine manufacturing ($1.04 per patient per month) and one-time customer acquisition costs ($100 per new patient). The simulation horizon is 5 years, and adoption is assumed to increase gradually before plateauing at 50% of the eligible treatable population. This approach provides a data-driven estimate of the addressable market, demonstrating how expanded screening and optimized treatment adoption could translate into measurable economic impact over a realistic commercial rollout period.</span>
<span id="cb17-656"><a href="#cb17-656" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-659"><a href="#cb17-659" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-660"><a href="#cb17-660" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulating commercial dataset</span></span>
<span id="cb17-661"><a href="#cb17-661" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-662"><a href="#cb17-662" aria-hidden="true" tabindex="-1"></a><span class="co"># Inputs</span></span>
<span id="cb17-663"><a href="#cb17-663" aria-hidden="true" tabindex="-1"></a>months <span class="ot">&lt;-</span> <span class="dv">0</span><span class="sc">:</span><span class="dv">60</span>                    <span class="co"># 5 years</span></span>
<span id="cb17-664"><a href="#cb17-664" aria-hidden="true" tabindex="-1"></a>addressable_pool <span class="ot">&lt;-</span> <span class="fl">0.5</span><span class="sc">*</span><span class="dv">38000000</span>  <span class="co"># 50% of 38M</span></span>
<span id="cb17-665"><a href="#cb17-665" aria-hidden="true" tabindex="-1"></a>start_patients <span class="ot">&lt;-</span> <span class="dv">10000</span>           <span class="co"># assumption of realistic starting point</span></span>
<span id="cb17-666"><a href="#cb17-666" aria-hidden="true" tabindex="-1"></a>monthly_conversion <span class="ot">&lt;-</span> <span class="fl">0.008</span>       <span class="co"># 0.8% of untreated pool per month</span></span>
<span id="cb17-667"><a href="#cb17-667" aria-hidden="true" tabindex="-1"></a>initial_share <span class="ot">&lt;-</span> <span class="fl">0.08</span></span>
<span id="cb17-668"><a href="#cb17-668" aria-hidden="true" tabindex="-1"></a>max_share <span class="ot">&lt;-</span> <span class="fl">0.20</span></span>
<span id="cb17-669"><a href="#cb17-669" aria-hidden="true" tabindex="-1"></a>share_ramp_speed <span class="ot">&lt;-</span> <span class="fl">0.06</span>           <span class="co"># logistic ramp</span></span>
<span id="cb17-670"><a href="#cb17-670" aria-hidden="true" tabindex="-1"></a>monthly_persistence <span class="ot">&lt;-</span> <span class="fl">0.97</span>       <span class="co"># ~70% annual</span></span>
<span id="cb17-671"><a href="#cb17-671" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-672"><a href="#cb17-672" aria-hidden="true" tabindex="-1"></a>price_per_month <span class="ot">&lt;-</span> <span class="fl">10.49</span></span>
<span id="cb17-673"><a href="#cb17-673" aria-hidden="true" tabindex="-1"></a>costprice_per_month <span class="ot">&lt;-</span> <span class="fl">1.04</span></span>
<span id="cb17-674"><a href="#cb17-674" aria-hidden="true" tabindex="-1"></a>CAC <span class="ot">&lt;-</span> <span class="dv">100</span></span>
<span id="cb17-675"><a href="#cb17-675" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-676"><a href="#cb17-676" aria-hidden="true" tabindex="-1"></a><span class="co"># Initialize dataframe</span></span>
<span id="cb17-677"><a href="#cb17-677" aria-hidden="true" tabindex="-1"></a>commercial_df <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(<span class="at">month =</span> months) <span class="sc">%&gt;%</span></span>
<span id="cb17-678"><a href="#cb17-678" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-679"><a href="#cb17-679" aria-hidden="true" tabindex="-1"></a>    <span class="at">market_share =</span> max_share <span class="sc">/</span> (<span class="dv">1</span> <span class="sc">+</span> <span class="fu">exp</span>(<span class="sc">-</span>share_ramp_speed <span class="sc">*</span> (month <span class="sc">-</span> <span class="dv">18</span>))),</span>
<span id="cb17-680"><a href="#cb17-680" aria-hidden="true" tabindex="-1"></a>    <span class="at">untreated_pool =</span> <span class="cn">NA</span>,</span>
<span id="cb17-681"><a href="#cb17-681" aria-hidden="true" tabindex="-1"></a>    <span class="at">new_patients =</span> <span class="cn">NA</span>,</span>
<span id="cb17-682"><a href="#cb17-682" aria-hidden="true" tabindex="-1"></a>    <span class="at">active_patients =</span> <span class="cn">NA</span></span>
<span id="cb17-683"><a href="#cb17-683" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-684"><a href="#cb17-684" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-685"><a href="#cb17-685" aria-hidden="true" tabindex="-1"></a><span class="co"># Simulation loop</span></span>
<span id="cb17-686"><a href="#cb17-686" aria-hidden="true" tabindex="-1"></a>untreated <span class="ot">&lt;-</span> addressable_pool</span>
<span id="cb17-687"><a href="#cb17-687" aria-hidden="true" tabindex="-1"></a>active <span class="ot">&lt;-</span> start_patients</span>
<span id="cb17-688"><a href="#cb17-688" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-689"><a href="#cb17-689" aria-hidden="true" tabindex="-1"></a><span class="cf">for</span> (m <span class="cf">in</span> <span class="dv">1</span><span class="sc">:</span><span class="fu">nrow</span>(commercial_df)) {</span>
<span id="cb17-690"><a href="#cb17-690" aria-hidden="true" tabindex="-1"></a>  share <span class="ot">&lt;-</span> commercial_df<span class="sc">$</span>market_share[m]</span>
<span id="cb17-691"><a href="#cb17-691" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-692"><a href="#cb17-692" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Total new treated patients in the market this month</span></span>
<span id="cb17-693"><a href="#cb17-693" aria-hidden="true" tabindex="-1"></a>  total_new_market <span class="ot">&lt;-</span> untreated <span class="sc">*</span> monthly_conversion</span>
<span id="cb17-694"><a href="#cb17-694" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-695"><a href="#cb17-695" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Patients captured by our drug</span></span>
<span id="cb17-696"><a href="#cb17-696" aria-hidden="true" tabindex="-1"></a>  new_pts <span class="ot">&lt;-</span> total_new_market <span class="sc">*</span> share</span>
<span id="cb17-697"><a href="#cb17-697" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-698"><a href="#cb17-698" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Update active patients with attrition</span></span>
<span id="cb17-699"><a href="#cb17-699" aria-hidden="true" tabindex="-1"></a>  active <span class="ot">&lt;-</span> active <span class="sc">*</span> monthly_persistence <span class="sc">+</span> new_pts</span>
<span id="cb17-700"><a href="#cb17-700" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-701"><a href="#cb17-701" aria-hidden="true" tabindex="-1"></a>  <span class="co"># Update untreated pool</span></span>
<span id="cb17-702"><a href="#cb17-702" aria-hidden="true" tabindex="-1"></a>  untreated <span class="ot">&lt;-</span> untreated <span class="sc">-</span> total_new_market</span>
<span id="cb17-703"><a href="#cb17-703" aria-hidden="true" tabindex="-1"></a>  </span>
<span id="cb17-704"><a href="#cb17-704" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>new_patients[m] <span class="ot">&lt;-</span> new_pts</span>
<span id="cb17-705"><a href="#cb17-705" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>active_patients[m] <span class="ot">&lt;-</span> active</span>
<span id="cb17-706"><a href="#cb17-706" aria-hidden="true" tabindex="-1"></a>  commercial_df<span class="sc">$</span>untreated_pool[m] <span class="ot">&lt;-</span> untreated</span>
<span id="cb17-707"><a href="#cb17-707" aria-hidden="true" tabindex="-1"></a>}</span>
<span id="cb17-708"><a href="#cb17-708" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-709"><a href="#cb17-709" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate revenue, cost, profit</span></span>
<span id="cb17-710"><a href="#cb17-710" aria-hidden="true" tabindex="-1"></a>commercial_df <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb17-711"><a href="#cb17-711" aria-hidden="true" tabindex="-1"></a>  <span class="fu">mutate</span>(</span>
<span id="cb17-712"><a href="#cb17-712" aria-hidden="true" tabindex="-1"></a>    <span class="at">revenue =</span> active_patients <span class="sc">*</span> price_per_month,</span>
<span id="cb17-713"><a href="#cb17-713" aria-hidden="true" tabindex="-1"></a>    <span class="at">cost =</span> (active_patients <span class="sc">*</span> costprice_per_month) <span class="sc">+</span> (new_patients <span class="sc">*</span> CAC),</span>
<span id="cb17-714"><a href="#cb17-714" aria-hidden="true" tabindex="-1"></a>    <span class="at">profit =</span> revenue <span class="sc">-</span> cost</span>
<span id="cb17-715"><a href="#cb17-715" aria-hidden="true" tabindex="-1"></a>  )</span>
<span id="cb17-716"><a href="#cb17-716" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-717"><a href="#cb17-717" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-718"><a href="#cb17-718" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-719"><a href="#cb17-719" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-720"><a href="#cb17-720" aria-hidden="true" tabindex="-1"></a><span class="fu">#### Analysis</span></span>
<span id="cb17-721"><a href="#cb17-721" aria-hidden="true" tabindex="-1"></a>The commercial analysis quantifies projected market performance of OsteoGuard over key time points. Using the estimated addressable population of 38 million, treatment uptake, and pricing assumptions, this summary focuses on captured patients, revenue, costs, and profit at months 1, 12, 24, 36, 48, and 60.</span>
<span id="cb17-722"><a href="#cb17-722" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-723"><a href="#cb17-723" aria-hidden="true" tabindex="-1"></a>The per-patient monthly economics for OsteoGuard are shown below. Each patient generates approximately $10.49 in revenue per month, with an estimated manufacturing and distribution cost of $1.04, resulting in a monthly profit of $9.45 per patient excluding acquisition costs. These figures highlight the strong unit economics of the therapy, providing a foundation for projecting cumulative revenue and profit as treatment uptake grows.</span>
<span id="cb17-726"><a href="#cb17-726" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-727"><a href="#cb17-727" aria-hidden="true" tabindex="-1"></a><span class="co"># Monthly economics per patient</span></span>
<span id="cb17-728"><a href="#cb17-728" aria-hidden="true" tabindex="-1"></a><span class="co"># Define per-patient monthly economics</span></span>
<span id="cb17-729"><a href="#cb17-729" aria-hidden="true" tabindex="-1"></a>per_patient_tbl <span class="ot">&lt;-</span> <span class="fu">tibble</span>(</span>
<span id="cb17-730"><a href="#cb17-730" aria-hidden="true" tabindex="-1"></a>  <span class="st">`</span><span class="at">Parameter</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">c</span>(<span class="st">"Monthly revenue per patient"</span>, </span>
<span id="cb17-731"><a href="#cb17-731" aria-hidden="true" tabindex="-1"></a>                  <span class="st">"Monthly manufacturing/distribution cost per patient"</span>, </span>
<span id="cb17-732"><a href="#cb17-732" aria-hidden="true" tabindex="-1"></a>                  <span class="st">"Monthly profit per patient"</span>),</span>
<span id="cb17-733"><a href="#cb17-733" aria-hidden="true" tabindex="-1"></a>  <span class="st">`</span><span class="at">Value ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">c</span>(price_per_month, costprice_per_month, price_per_month <span class="sc">-</span> costprice_per_month)</span>
<span id="cb17-734"><a href="#cb17-734" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb17-735"><a href="#cb17-735" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-736"><a href="#cb17-736" aria-hidden="true" tabindex="-1"></a><span class="co"># Render the table with kable</span></span>
<span id="cb17-737"><a href="#cb17-737" aria-hidden="true" tabindex="-1"></a>per_patient_tbl <span class="sc">%&gt;%</span></span>
<span id="cb17-738"><a href="#cb17-738" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kbl</span>(</span>
<span id="cb17-739"><a href="#cb17-739" aria-hidden="true" tabindex="-1"></a>    <span class="at">caption =</span> <span class="st">"Per-Patient Monthly Economics for OsteoGuard"</span>,</span>
<span id="cb17-740"><a href="#cb17-740" aria-hidden="true" tabindex="-1"></a>    <span class="at">digits =</span> <span class="dv">2</span>,</span>
<span id="cb17-741"><a href="#cb17-741" aria-hidden="true" tabindex="-1"></a>    <span class="at">align =</span> <span class="fu">c</span>(<span class="st">"l"</span>, <span class="st">"r"</span>)</span>
<span id="cb17-742"><a href="#cb17-742" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-743"><a href="#cb17-743" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(</span>
<span id="cb17-744"><a href="#cb17-744" aria-hidden="true" tabindex="-1"></a>    <span class="at">full_width =</span> <span class="cn">FALSE</span>,</span>
<span id="cb17-745"><a href="#cb17-745" aria-hidden="true" tabindex="-1"></a>    <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>),</span>
<span id="cb17-746"><a href="#cb17-746" aria-hidden="true" tabindex="-1"></a>    <span class="at">position =</span> <span class="st">"left"</span></span>
<span id="cb17-747"><a href="#cb17-747" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-748"><a href="#cb17-748" aria-hidden="true" tabindex="-1"></a>  <span class="fu">row_spec</span>(<span class="dv">0</span>, <span class="at">bold =</span> <span class="cn">TRUE</span>, <span class="at">background =</span> <span class="st">"#f5f5f5"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-749"><a href="#cb17-749" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">1</span>, <span class="at">bold =</span> F, <span class="at">width =</span> <span class="st">"18em"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-750"><a href="#cb17-750" aria-hidden="true" tabindex="-1"></a>  <span class="fu">column_spec</span>(<span class="dv">2</span>, <span class="at">width =</span> <span class="st">"8em"</span>)</span>
<span id="cb17-751"><a href="#cb17-751" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-752"><a href="#cb17-752" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-753"><a href="#cb17-753" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-754"><a href="#cb17-754" aria-hidden="true" tabindex="-1"></a>Using this per patient profit per month and an estimation of Customer Acquisition Cost (CAC) we can calculate the ratio of cost to lifetime value (LTV). The financial summary indicates that with a CAC of $100 and an average treatment duration of 60 months, OsteoGuard generates an LTV of approximately $567 per patient. This produces a strong CAC:LTV ratio (5.67), suggesting that for every dollar spent acquiring a patient, the therapy is projected to return about $5.67 in profit — highlighting solid commercial potential under the current assumptions.</span>
<span id="cb17-755"><a href="#cb17-755" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-758"><a href="#cb17-758" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-759"><a href="#cb17-759" aria-hidden="true" tabindex="-1"></a><span class="co"># CAC:LTV</span></span>
<span id="cb17-760"><a href="#cb17-760" aria-hidden="true" tabindex="-1"></a><span class="co"># Known values</span></span>
<span id="cb17-761"><a href="#cb17-761" aria-hidden="true" tabindex="-1"></a>monthly_profit <span class="ot">&lt;-</span> <span class="fl">9.45</span>         <span class="co"># $ per patient</span></span>
<span id="cb17-762"><a href="#cb17-762" aria-hidden="true" tabindex="-1"></a>avg_treatment_months <span class="ot">&lt;-</span> <span class="dv">60</span>     <span class="co"># 5 years</span></span>
<span id="cb17-763"><a href="#cb17-763" aria-hidden="true" tabindex="-1"></a>CAC <span class="ot">&lt;-</span> <span class="dv">100</span>                      <span class="co"># assumed per patient acquisition cost</span></span>
<span id="cb17-764"><a href="#cb17-764" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-765"><a href="#cb17-765" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-766"><a href="#cb17-766" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate Lifetime Value</span></span>
<span id="cb17-767"><a href="#cb17-767" aria-hidden="true" tabindex="-1"></a>LTV <span class="ot">&lt;-</span> monthly_profit <span class="sc">*</span> avg_treatment_months</span>
<span id="cb17-768"><a href="#cb17-768" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-769"><a href="#cb17-769" aria-hidden="true" tabindex="-1"></a><span class="co"># Calculate CAC:LTV ratio</span></span>
<span id="cb17-770"><a href="#cb17-770" aria-hidden="true" tabindex="-1"></a>CAC_LTV_ratio <span class="ot">&lt;-</span> LTV <span class="sc">/</span> CAC</span>
<span id="cb17-771"><a href="#cb17-771" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-772"><a href="#cb17-772" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-773"><a href="#cb17-773" aria-hidden="true" tabindex="-1"></a><span class="co"># Build a data frame</span></span>
<span id="cb17-774"><a href="#cb17-774" aria-hidden="true" tabindex="-1"></a>financial_summary <span class="ot">&lt;-</span> <span class="fu">data.frame</span>(</span>
<span id="cb17-775"><a href="#cb17-775" aria-hidden="true" tabindex="-1"></a>  <span class="at">Parameter =</span> <span class="fu">c</span>(<span class="st">"Customer Acquisition Cost (CAC)"</span>,</span>
<span id="cb17-776"><a href="#cb17-776" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Profit per Patient per Month"</span>,</span>
<span id="cb17-777"><a href="#cb17-777" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Average Treatment Duration (months)"</span>,</span>
<span id="cb17-778"><a href="#cb17-778" aria-hidden="true" tabindex="-1"></a>                <span class="st">"Lifetime Value (LTV)"</span>,</span>
<span id="cb17-779"><a href="#cb17-779" aria-hidden="true" tabindex="-1"></a>                <span class="st">"CAC:LTV Ratio"</span>),</span>
<span id="cb17-780"><a href="#cb17-780" aria-hidden="true" tabindex="-1"></a>  <span class="at">Value =</span> <span class="fu">c</span>(CAC,</span>
<span id="cb17-781"><a href="#cb17-781" aria-hidden="true" tabindex="-1"></a>            monthly_profit,</span>
<span id="cb17-782"><a href="#cb17-782" aria-hidden="true" tabindex="-1"></a>            avg_treatment_months,</span>
<span id="cb17-783"><a href="#cb17-783" aria-hidden="true" tabindex="-1"></a>            <span class="fu">round</span>(LTV, <span class="dv">2</span>),</span>
<span id="cb17-784"><a href="#cb17-784" aria-hidden="true" tabindex="-1"></a>            <span class="fu">round</span>(CAC_LTV_ratio, <span class="dv">2</span>))</span>
<span id="cb17-785"><a href="#cb17-785" aria-hidden="true" tabindex="-1"></a>)</span>
<span id="cb17-786"><a href="#cb17-786" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-787"><a href="#cb17-787" aria-hidden="true" tabindex="-1"></a><span class="co"># Display as a kable table</span></span>
<span id="cb17-788"><a href="#cb17-788" aria-hidden="true" tabindex="-1"></a><span class="fu">kable</span>(financial_summary, </span>
<span id="cb17-789"><a href="#cb17-789" aria-hidden="true" tabindex="-1"></a>      <span class="at">caption =</span> <span class="st">"Financial Summary for OsteoGuard Phase 2 Simulation"</span>,</span>
<span id="cb17-790"><a href="#cb17-790" aria-hidden="true" tabindex="-1"></a>      <span class="at">col.names =</span> <span class="fu">c</span>(<span class="st">"Metric"</span>, <span class="st">"Value ($)"</span>),</span>
<span id="cb17-791"><a href="#cb17-791" aria-hidden="true" tabindex="-1"></a>      <span class="at">align =</span> <span class="fu">c</span>(<span class="st">"l"</span>,<span class="st">"r"</span>))</span>
<span id="cb17-792"><a href="#cb17-792" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-793"><a href="#cb17-793" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-794"><a href="#cb17-794" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-795"><a href="#cb17-795" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-796"><a href="#cb17-796" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-797"><a href="#cb17-797" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-798"><a href="#cb17-798" aria-hidden="true" tabindex="-1"></a>This table presents the projected commercial performance of the new bisphosphonate therapy over a 5-year horizon at selected key months (1, 12, 24, 36, 48, 60). </span>
<span id="cb17-799"><a href="#cb17-799" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-800"><a href="#cb17-800" aria-hidden="true" tabindex="-1"></a> At the start of the simulation, the active patient population is approximately 24,877, generating $260,957 in monthly revenue, though total costs of $825,110 result in an initial loss of $564,152. </span>
<span id="cb17-801"><a href="#cb17-801" aria-hidden="true" tabindex="-1"></a> </span>
<span id="cb17-802"><a href="#cb17-802" aria-hidden="true" tabindex="-1"></a> By the end of the first year (month 12), active patients grow to 111,691, with revenue reaching $1.17 million and losses reduced to just $79,039. </span>
<span id="cb17-803"><a href="#cb17-803" aria-hidden="true" tabindex="-1"></a> </span>
<span id="cb17-804"><a href="#cb17-804" aria-hidden="true" tabindex="-1"></a> Over the subsequent years, continued patient uptake and retention drive revenue and profit growth, with 213,899 active patients by month 24, producing $2.24 million in revenue and $544,627 in profit. </span>
<span id="cb17-805"><a href="#cb17-805" aria-hidden="true" tabindex="-1"></a> </span>
<span id="cb17-806"><a href="#cb17-806" aria-hidden="true" tabindex="-1"></a> By month 36, the patient base reaches 313,361, revenue rises to $3.29 million, and profit exceeds $1.26 million. At month 48, 396,353 patients are actively treated, generating $4.16 million in revenue and $1.97 million in profit, and by the end of year five (month 60), the therapy supports 454,632 active patients, $4.77 million in revenue, and $2.56 million in profit. </span>
<span id="cb17-807"><a href="#cb17-807" aria-hidden="true" tabindex="-1"></a> </span>
<span id="cb17-808"><a href="#cb17-808" aria-hidden="true" tabindex="-1"></a>The simulation illustrates a realistic adoption curve, where initial losses from customer acquisition costs are offset by steady growth in active patients and revenue, with profitability achieved during the second year and sustained thereafter, highlighting the economic potential of expanding treatment to previously under-identified high-risk adults.</span>
<span id="cb17-809"><a href="#cb17-809" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-812"><a href="#cb17-812" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-813"><a href="#cb17-813" aria-hidden="true" tabindex="-1"></a><span class="co"># Summary table</span></span>
<span id="cb17-814"><a href="#cb17-814" aria-hidden="true" tabindex="-1"></a>summary_table <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb17-815"><a href="#cb17-815" aria-hidden="true" tabindex="-1"></a>  <span class="fu">filter</span>(month <span class="sc">%in%</span> <span class="fu">c</span>(<span class="dv">1</span>, <span class="dv">12</span>, <span class="dv">24</span>, <span class="dv">36</span>, <span class="dv">48</span>, <span class="dv">60</span>)) <span class="sc">%&gt;%</span>  <span class="co"># select key months</span></span>
<span id="cb17-816"><a href="#cb17-816" aria-hidden="true" tabindex="-1"></a>  <span class="fu">transmute</span>(</span>
<span id="cb17-817"><a href="#cb17-817" aria-hidden="true" tabindex="-1"></a>    <span class="at">Month =</span> month,</span>
<span id="cb17-818"><a href="#cb17-818" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Active Patients</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(active_patients),</span>
<span id="cb17-819"><a href="#cb17-819" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Revenue ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(revenue, <span class="dv">1</span>),</span>
<span id="cb17-820"><a href="#cb17-820" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Cost ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(cost, <span class="dv">1</span>),</span>
<span id="cb17-821"><a href="#cb17-821" aria-hidden="true" tabindex="-1"></a>    <span class="st">`</span><span class="at">Profit ($)</span><span class="st">`</span> <span class="ot">=</span> <span class="fu">round</span>(profit, <span class="dv">1</span>)</span>
<span id="cb17-822"><a href="#cb17-822" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">%&gt;%</span></span>
<span id="cb17-823"><a href="#cb17-823" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kbl</span>(<span class="at">caption =</span> <span class="st">"Commercial Summary at Key Months"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-824"><a href="#cb17-824" aria-hidden="true" tabindex="-1"></a>  <span class="fu">kable_styling</span>(<span class="at">full_width =</span> <span class="cn">FALSE</span>, <span class="at">bootstrap_options =</span> <span class="fu">c</span>(<span class="st">"condensed"</span>, <span class="st">"hover"</span>))</span>
<span id="cb17-825"><a href="#cb17-825" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-826"><a href="#cb17-826" aria-hidden="true" tabindex="-1"></a>summary_table</span>
<span id="cb17-827"><a href="#cb17-827" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-828"><a href="#cb17-828" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-829"><a href="#cb17-829" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-830"><a href="#cb17-830" aria-hidden="true" tabindex="-1"></a>Building on the per-patient and aggregated financial summaries, the below figure illustrates the projected financial performance of the new bisphosphonate therapy over a 5-year (60-month) horizon.</span>
<span id="cb17-831"><a href="#cb17-831" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-832"><a href="#cb17-832" aria-hidden="true" tabindex="-1"></a>Revenue (dark purple line) steadily increases as the patient base grows, reaching nearly $5 million by month 60.</span>
<span id="cb17-833"><a href="#cb17-833" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-834"><a href="#cb17-834" aria-hidden="true" tabindex="-1"></a>Costs (lighter purple line) rise initially due to both manufacturing expenses and one-time customer acquisition costs (CAC), then plateau around $2.2 million as new patient starts slow and the active patient pool stabilizes.</span>
<span id="cb17-835"><a href="#cb17-835" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-836"><a href="#cb17-836" aria-hidden="true" tabindex="-1"></a>Profit (medium purple line) starts negative due to upfront CAC investments but steadily improves, crossing into profitability between months 20 and 25. By year 5, projected profit approaches $2.5 million.</span>
<span id="cb17-837"><a href="#cb17-837" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-838"><a href="#cb17-838" aria-hidden="true" tabindex="-1"></a>The model reflects realistic commercial dynamics: early losses driven by onboarding costs, gradual patient uptake, and treatment persistence leading to sustained revenue growth. The cost plateau demonstrates diminishing acquisition expenses as market saturation approaches. Overall, the therapy achieves profitability within approximately two years, with strong profit growth through year five, supporting a compelling economic case for expanding osteoporosis treatment to previously under-identified missed high-risk populations.</span>
<span id="cb17-839"><a href="#cb17-839" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-842"><a href="#cb17-842" aria-hidden="true" tabindex="-1"></a><span class="in">```{r}</span></span>
<span id="cb17-843"><a href="#cb17-843" aria-hidden="true" tabindex="-1"></a><span class="co"># Time-series figure:revenue, cost, and profit</span></span>
<span id="cb17-844"><a href="#cb17-844" aria-hidden="true" tabindex="-1"></a>financial_plot <span class="ot">&lt;-</span> commercial_df <span class="sc">%&gt;%</span></span>
<span id="cb17-845"><a href="#cb17-845" aria-hidden="true" tabindex="-1"></a>  <span class="fu">pivot_longer</span>(<span class="at">cols =</span> <span class="fu">c</span>(revenue, cost, profit), <span class="at">names_to =</span> <span class="st">"Metric"</span>, <span class="at">values_to =</span> <span class="st">"Value"</span>) <span class="sc">%&gt;%</span></span>
<span id="cb17-846"><a href="#cb17-846" aria-hidden="true" tabindex="-1"></a>  <span class="fu">ggplot</span>(<span class="fu">aes</span>(<span class="at">x =</span> month, <span class="at">y =</span> Value, <span class="at">color =</span> Metric)) <span class="sc">+</span>  </span>
<span id="cb17-847"><a href="#cb17-847" aria-hidden="true" tabindex="-1"></a>  <span class="fu">geom_line</span>(<span class="at">linewidth =</span> <span class="fl">1.5</span>) <span class="sc">+</span></span>
<span id="cb17-848"><a href="#cb17-848" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_color_manual</span>(<span class="at">values =</span> <span class="fu">c</span>(<span class="st">"revenue"</span> <span class="ot">=</span> <span class="st">"#4A0072"</span>, <span class="st">"cost"</span> <span class="ot">=</span> <span class="st">"#9A4EAE"</span>, <span class="st">"profit"</span> <span class="ot">=</span> <span class="st">"purple"</span>)) <span class="sc">+</span></span>
<span id="cb17-849"><a href="#cb17-849" aria-hidden="true" tabindex="-1"></a>  <span class="fu">scale_y_continuous</span>(<span class="at">labels =</span> comma) <span class="sc">+</span>  <span class="co"># format with commas</span></span>
<span id="cb17-850"><a href="#cb17-850" aria-hidden="true" tabindex="-1"></a>  <span class="fu">labs</span>(</span>
<span id="cb17-851"><a href="#cb17-851" aria-hidden="true" tabindex="-1"></a>    <span class="at">title =</span> <span class="st">"Revenue, Cost, and Profit Over Time"</span>,</span>
<span id="cb17-852"><a href="#cb17-852" aria-hidden="true" tabindex="-1"></a>    <span class="at">x =</span> <span class="st">"Month"</span>,</span>
<span id="cb17-853"><a href="#cb17-853" aria-hidden="true" tabindex="-1"></a>    <span class="at">y =</span> <span class="st">"USD ($)"</span>,</span>
<span id="cb17-854"><a href="#cb17-854" aria-hidden="true" tabindex="-1"></a>    <span class="at">color =</span> <span class="st">"Metric"</span></span>
<span id="cb17-855"><a href="#cb17-855" aria-hidden="true" tabindex="-1"></a>  ) <span class="sc">+</span></span>
<span id="cb17-856"><a href="#cb17-856" aria-hidden="true" tabindex="-1"></a>  <span class="fu">theme_minimal</span>(<span class="at">base_size =</span> <span class="dv">14</span>)</span>
<span id="cb17-857"><a href="#cb17-857" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-858"><a href="#cb17-858" aria-hidden="true" tabindex="-1"></a>financial_plot</span>
<span id="cb17-859"><a href="#cb17-859" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-860"><a href="#cb17-860" aria-hidden="true" tabindex="-1"></a><span class="in">```</span></span>
<span id="cb17-861"><a href="#cb17-861" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-862"><a href="#cb17-862" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-863"><a href="#cb17-863" aria-hidden="true" tabindex="-1"></a><span class="fu">### Conclusion</span></span>
<span id="cb17-864"><a href="#cb17-864" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-865"><a href="#cb17-865" aria-hidden="true" tabindex="-1"></a>The Phase 2 simulations clearly demonstrate that earlier identification of high-risk patients through improved screening, combined with timely initiation of OsteoGuard therapy, can meaningfully prevent fractures and slow the progression of osteoporosis. In our simulated cohort, patients receiving treatment showed up to a **5.4% increase in lumbar spine BMD over 24 months**, compared with a **1.6% gain or slight decline in low-adherence and control groups**, respectively. Even partial adherence or early discontinuation conferred measurable benefit, highlighting the clinical value of targeting treatment to the right population.</span>
<span id="cb17-866"><a href="#cb17-866" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-867"><a href="#cb17-867" aria-hidden="true" tabindex="-1"></a>From a commercial perspective, this represents a **substantial market opportunity**. By expanding screening and driving uptake among eligible patients, OsteoGuard could capture a growing share of the addressable population, generating significant revenue and profit per patient while delivering tangible health benefits. Running an aggressive early-screening campaign, including physician outreach, patient education, and targeted risk-assessment programs, could accelerate identification of missed high-risk adults and maximize therapy adoption. Such initiatives would help reach the untapped portion of the market, ensuring that high-risk individuals who would otherwise remain undetected have the opportunity to benefit from treatment. The simulations underscore that therapies with preventative potential—when combined with strategic patient identification and proactive outreach—can both improve outcomes and unlock meaningful commercial value, establishing a compelling case for investment in screening programs, adherence support, and market rollout strategies.</span>
<span id="cb17-868"><a href="#cb17-868" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-869"><a href="#cb17-869" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-870"><a href="#cb17-870" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-871"><a href="#cb17-871" aria-hidden="true" tabindex="-1"></a><span class="fu">### References</span></span>
<span id="cb17-872"><a href="#cb17-872" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-873"><a href="#cb17-873" aria-hidden="true" tabindex="-1"></a>Alendronate Prices, Coupons, Copay &amp; Patient Assistance. Drugs.com, www.drugs.com/price-guide/alendronate.</span>
<span id="cb17-874"><a href="#cb17-874" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-875"><a href="#cb17-875" aria-hidden="true" tabindex="-1"></a>“Bisphosphonates <span class="sc">\|</span> International Osteoporosis Foundation.” www.osteoporosis.foundation, www.osteoporosis.foundation/health-professionals/treatment/bisphosphonates.</span>
<span id="cb17-876"><a href="#cb17-876" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-877"><a href="#cb17-877" aria-hidden="true" tabindex="-1"></a>Fatoye, F., Smith, P., Gebrye, T., &amp; Yeowell, G. (2019). Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open, 9(4), e027049. https://doi.org/10.1136/bmjopen-2018-027049</span>
<span id="cb17-878"><a href="#cb17-878" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-879"><a href="#cb17-879" aria-hidden="true" tabindex="-1"></a>Haderslev, K. V., Tjellesen, L., Sorensen, H. A., &amp; Staun, M. (2000). Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology, 119(3), 639–646. https://doi.org/10.1053/gast.2000.16518</span>
<span id="cb17-880"><a href="#cb17-880" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-881"><a href="#cb17-881" aria-hidden="true" tabindex="-1"></a>Hui, R. L., Adams, A. L., Niu, F., Ettinger, B., Yi, D. K., Chandra, M., &amp; Lo, J. C. (2017). Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. Journal of Managed Care &amp; Specialty Pharmacy, 23(4), 503–512. https://doi.org/10.18553/jmcp.2017.23.4.503</span>
<span id="cb17-882"><a href="#cb17-882" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-883"><a href="#cb17-883" aria-hidden="true" tabindex="-1"></a>Karpf, D. B., Shapiro, D. R., Seeman, E., Ensrud, K. E., Johnston, C. C., Jr, Adami, S., Harris, S. T., Santora, A. C., 2nd, Hirsch, L. J., Oppenheimer, L., &amp; Thompson, D. (1997). Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA, 277(14), 1159–1164.</span>
<span id="cb17-884"><a href="#cb17-884" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-885"><a href="#cb17-885" aria-hidden="true" tabindex="-1"></a>Pharmaceutical drug prices and trends for ALENDRONATE SODIUM. (2026). Deep Knowledge on Small-Molecule Drugs and the Global Patents Covering Them. https://www.drugpatentwatch.com/p/drug-price/drugname/ALENDRONATE%2BSODIUM)</span>
<span id="cb17-886"><a href="#cb17-886" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-887"><a href="#cb17-887" aria-hidden="true" tabindex="-1"></a>“Popular Bisphosphonates List, Drug Prices and Medication Information.” GoodRx, 2024, www.goodrx.com/classes/bisphosphonates.</span>
<span id="cb17-888"><a href="#cb17-888" aria-hidden="true" tabindex="-1"></a></span>
</code></pre></div><button title="Copy to Clipboard" class="code-copy-button" data-in-quarto-modal=""><i class="bi"></i></button></div>
</div></div></div></div></div>
</div> <!-- /content -->




</body></html>